WO2020225779A1 - Rig-i agonists for cancer treatment and immunotherapy - Google Patents
Rig-i agonists for cancer treatment and immunotherapy Download PDFInfo
- Publication number
- WO2020225779A1 WO2020225779A1 PCT/IB2020/054361 IB2020054361W WO2020225779A1 WO 2020225779 A1 WO2020225779 A1 WO 2020225779A1 IB 2020054361 W IB2020054361 W IB 2020054361W WO 2020225779 A1 WO2020225779 A1 WO 2020225779A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- cells
- seq
- subject
- tumor
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 253
- 201000011510 cancer Diseases 0.000 title claims abstract description 129
- 238000011282 treatment Methods 0.000 title abstract description 45
- 229940044606 RIG-I agonist Drugs 0.000 title description 46
- 238000009169 immunotherapy Methods 0.000 title description 12
- 238000000034 method Methods 0.000 claims abstract description 125
- 239000000203 mixture Substances 0.000 claims abstract description 98
- 239000000427 antigen Substances 0.000 claims abstract description 73
- 108091007433 antigens Proteins 0.000 claims abstract description 72
- 102000036639 antigens Human genes 0.000 claims abstract description 72
- 108091027075 5S-rRNA precursor Proteins 0.000 claims abstract description 69
- 229940022399 cancer vaccine Drugs 0.000 claims abstract description 38
- 238000009566 cancer vaccine Methods 0.000 claims abstract description 38
- 230000028993 immune response Effects 0.000 claims abstract description 22
- 230000004936 stimulating effect Effects 0.000 claims abstract description 8
- 230000003053 immunization Effects 0.000 claims abstract description 7
- 238000002649 immunization Methods 0.000 claims abstract description 7
- 210000004027 cell Anatomy 0.000 claims description 269
- 230000014509 gene expression Effects 0.000 claims description 64
- 230000030833 cell death Effects 0.000 claims description 59
- 210000004443 dendritic cell Anatomy 0.000 claims description 57
- 239000002671 adjuvant Substances 0.000 claims description 41
- 210000004881 tumor cell Anatomy 0.000 claims description 36
- 230000006698 induction Effects 0.000 claims description 33
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 27
- 230000001419 dependent effect Effects 0.000 claims description 27
- 230000037396 body weight Effects 0.000 claims description 26
- 108090000623 proteins and genes Proteins 0.000 claims description 26
- -1 CD86 Proteins 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 102100037907 High mobility group protein B1 Human genes 0.000 claims description 20
- 239000002246 antineoplastic agent Substances 0.000 claims description 20
- 230000003213 activating effect Effects 0.000 claims description 19
- 230000034994 death Effects 0.000 claims description 19
- 230000001939 inductive effect Effects 0.000 claims description 18
- 239000003446 ligand Substances 0.000 claims description 16
- 201000001441 melanoma Diseases 0.000 claims description 16
- 125000002264 triphosphate group Chemical group [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 claims description 16
- 101100339431 Arabidopsis thaliana HMGB2 gene Proteins 0.000 claims description 15
- 108700010013 HMGB1 Proteins 0.000 claims description 15
- 101150021904 HMGB1 gene Proteins 0.000 claims description 15
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 claims description 14
- 108091034117 Oligonucleotide Proteins 0.000 claims description 14
- 206010060862 Prostate cancer Diseases 0.000 claims description 14
- 230000030741 antigen processing and presentation Effects 0.000 claims description 14
- 239000000839 emulsion Substances 0.000 claims description 14
- 230000007420 reactivation Effects 0.000 claims description 14
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 claims description 13
- 239000013592 cell lysate Substances 0.000 claims description 13
- 102000004082 Calreticulin Human genes 0.000 claims description 12
- 108090000549 Calreticulin Proteins 0.000 claims description 12
- 206010009944 Colon cancer Diseases 0.000 claims description 12
- 230000028327 secretion Effects 0.000 claims description 12
- 208000026310 Breast neoplasm Diseases 0.000 claims description 11
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 11
- 238000009472 formulation Methods 0.000 claims description 11
- 239000003550 marker Substances 0.000 claims description 11
- 206010006187 Breast cancer Diseases 0.000 claims description 10
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 10
- 208000009956 adenocarcinoma Diseases 0.000 claims description 10
- 239000002158 endotoxin Substances 0.000 claims description 10
- 230000002401 inhibitory effect Effects 0.000 claims description 10
- 229920006008 lipopolysaccharide Polymers 0.000 claims description 10
- 201000005202 lung cancer Diseases 0.000 claims description 10
- 208000020816 lung neoplasm Diseases 0.000 claims description 10
- 102100034221 Growth-regulated alpha protein Human genes 0.000 claims description 9
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 claims description 9
- 229940035032 monophosphoryl lipid a Drugs 0.000 claims description 9
- 102000006354 HLA-DR Antigens Human genes 0.000 claims description 8
- 108010058597 HLA-DR Antigens Proteins 0.000 claims description 8
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 8
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 8
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 8
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 8
- 239000002480 mineral oil Substances 0.000 claims description 8
- 235000010446 mineral oil Nutrition 0.000 claims description 8
- 201000009030 Carcinoma Diseases 0.000 claims description 7
- 102000013462 Interleukin-12 Human genes 0.000 claims description 7
- 108010065805 Interleukin-12 Proteins 0.000 claims description 7
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 7
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 7
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 7
- 201000002528 pancreatic cancer Diseases 0.000 claims description 7
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 7
- 108700013048 CCL2 Proteins 0.000 claims description 6
- 102000000018 Chemokine CCL2 Human genes 0.000 claims description 6
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 6
- 208000029742 colonic neoplasm Diseases 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 6
- 230000001394 metastastic effect Effects 0.000 claims description 6
- 239000002105 nanoparticle Substances 0.000 claims description 6
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims description 5
- 102000003952 Caspase 3 Human genes 0.000 claims description 5
- 108090000397 Caspase 3 Proteins 0.000 claims description 5
- 108010040721 Flagellin Proteins 0.000 claims description 5
- 101001025337 Homo sapiens High mobility group protein B1 Proteins 0.000 claims description 5
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims description 5
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims description 5
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 5
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims description 5
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 5
- 238000002624 low-dose chemotherapy Methods 0.000 claims description 5
- 201000000849 skin cancer Diseases 0.000 claims description 5
- 229940031439 squalene Drugs 0.000 claims description 5
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims description 5
- 239000000277 virosome Substances 0.000 claims description 5
- 231100000699 Bacterial toxin Toxicity 0.000 claims description 4
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 claims description 4
- 244000052616 bacterial pathogen Species 0.000 claims description 4
- 239000000688 bacterial toxin Substances 0.000 claims description 4
- 208000037819 metastatic cancer Diseases 0.000 claims description 4
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims description 4
- 239000003161 ribonuclease inhibitor Substances 0.000 claims description 4
- 230000003442 weekly effect Effects 0.000 claims description 4
- 102000002227 Interferon Type I Human genes 0.000 claims description 3
- 108010014726 Interferon Type I Proteins 0.000 claims description 3
- 101710127675 Antiviral innate immune response receptor RIG-I Proteins 0.000 abstract description 53
- 102100037435 Antiviral innate immune response receptor RIG-I Human genes 0.000 abstract description 52
- 239000000556 agonist Substances 0.000 abstract description 12
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 50
- 125000003729 nucleotide group Chemical group 0.000 description 38
- 150000001875 compounds Chemical class 0.000 description 36
- 230000000694 effects Effects 0.000 description 35
- 239000002773 nucleotide Substances 0.000 description 35
- 230000001225 therapeutic effect Effects 0.000 description 35
- 230000004913 activation Effects 0.000 description 31
- 229960005486 vaccine Drugs 0.000 description 25
- 230000037449 immunogenic cell death Effects 0.000 description 22
- 239000006228 supernatant Substances 0.000 description 18
- 206010027476 Metastases Diseases 0.000 description 17
- 239000003795 chemical substances by application Substances 0.000 description 17
- 239000000463 material Substances 0.000 description 17
- 210000000822 natural killer cell Anatomy 0.000 description 17
- 230000009401 metastasis Effects 0.000 description 16
- 238000001890 transfection Methods 0.000 description 16
- 210000001744 T-lymphocyte Anatomy 0.000 description 15
- 230000037361 pathway Effects 0.000 description 15
- 230000011664 signaling Effects 0.000 description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 14
- 238000000684 flow cytometry Methods 0.000 description 14
- 239000007788 liquid Substances 0.000 description 14
- 208000024891 symptom Diseases 0.000 description 14
- 238000012384 transportation and delivery Methods 0.000 description 14
- 101000852870 Homo sapiens Interferon alpha/beta receptor 1 Proteins 0.000 description 13
- 102100036714 Interferon alpha/beta receptor 1 Human genes 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 13
- 230000015572 biosynthetic process Effects 0.000 description 13
- 230000001965 increasing effect Effects 0.000 description 13
- 150000007523 nucleic acids Chemical class 0.000 description 13
- 230000009385 viral infection Effects 0.000 description 13
- 238000002619 cancer immunotherapy Methods 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 238000003786 synthesis reaction Methods 0.000 description 12
- 208000036142 Viral infection Diseases 0.000 description 11
- 230000006907 apoptotic process Effects 0.000 description 11
- 230000000903 blocking effect Effects 0.000 description 11
- 230000002163 immunogen Effects 0.000 description 11
- 239000002502 liposome Substances 0.000 description 11
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 11
- 102000014150 Interferons Human genes 0.000 description 10
- 108010050904 Interferons Proteins 0.000 description 10
- 239000000872 buffer Substances 0.000 description 10
- 239000012636 effector Substances 0.000 description 10
- 210000000987 immune system Anatomy 0.000 description 10
- 230000036039 immunity Effects 0.000 description 10
- 229940079322 interferon Drugs 0.000 description 10
- 230000001404 mediated effect Effects 0.000 description 10
- 102000039446 nucleic acids Human genes 0.000 description 10
- 108020004707 nucleic acids Proteins 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 230000035899 viability Effects 0.000 description 10
- 206010057249 Phagocytosis Diseases 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 230000001506 immunosuppresive effect Effects 0.000 description 9
- 230000015788 innate immune response Effects 0.000 description 9
- 230000007246 mechanism Effects 0.000 description 9
- 230000004048 modification Effects 0.000 description 9
- 238000012986 modification Methods 0.000 description 9
- 231100001143 noxa Toxicity 0.000 description 9
- 230000008782 phagocytosis Effects 0.000 description 9
- 239000008194 pharmaceutical composition Substances 0.000 description 9
- 239000013641 positive control Substances 0.000 description 9
- 238000002255 vaccination Methods 0.000 description 9
- YXHLJMWYDTXDHS-IRFLANFNSA-N 7-aminoactinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=C(N)C=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 YXHLJMWYDTXDHS-IRFLANFNSA-N 0.000 description 8
- 108700012813 7-aminoactinomycin D Proteins 0.000 description 8
- 101000733743 Homo sapiens Phorbol-12-myristate-13-acetate-induced protein 1 Proteins 0.000 description 8
- 230000001093 anti-cancer Effects 0.000 description 8
- 230000000840 anti-viral effect Effects 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 210000004985 myeloid-derived suppressor cell Anatomy 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 8
- 229920001223 polyethylene glycol Polymers 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- RZCJYMOBWVJQGV-UHFFFAOYSA-N 2-naphthyloxyacetic acid Chemical compound C1=CC=CC2=CC(OCC(=O)O)=CC=C21 RZCJYMOBWVJQGV-UHFFFAOYSA-N 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 102100023727 Mitochondrial antiviral-signaling protein Human genes 0.000 description 7
- 101710142315 Mitochondrial antiviral-signaling protein Proteins 0.000 description 7
- 101100338491 Oryza sativa subsp. japonica HCT1 gene Proteins 0.000 description 7
- 102100033716 Phorbol-12-myristate-13-acetate-induced protein 1 Human genes 0.000 description 7
- 239000004698 Polyethylene Substances 0.000 description 7
- 101100495309 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CDH1 gene Proteins 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 230000000692 anti-sense effect Effects 0.000 description 7
- 230000000259 anti-tumor effect Effects 0.000 description 7
- 238000013459 approach Methods 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 229960001156 mitoxantrone Drugs 0.000 description 7
- 102000007863 pattern recognition receptors Human genes 0.000 description 7
- 108010089193 pattern recognition receptors Proteins 0.000 description 7
- 150000003904 phospholipids Chemical class 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 230000003612 virological effect Effects 0.000 description 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 101000971203 Homo sapiens Bcl-2-binding component 3, isoforms 1/2 Proteins 0.000 description 6
- 101000971209 Homo sapiens Bcl-2-binding component 3, isoforms 3/4 Proteins 0.000 description 6
- 108010032038 Interferon Regulatory Factor-3 Proteins 0.000 description 6
- 102100029843 Interferon regulatory factor 3 Human genes 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 102100038192 Serine/threonine-protein kinase TBK1 Human genes 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 230000005934 immune activation Effects 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 125000005647 linker group Chemical group 0.000 description 6
- 210000002540 macrophage Anatomy 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 238000011321 prophylaxis Methods 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 210000003289 regulatory T cell Anatomy 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 239000004094 surface-active agent Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 235000011178 triphosphate Nutrition 0.000 description 6
- 239000001226 triphosphate Substances 0.000 description 6
- 230000004614 tumor growth Effects 0.000 description 6
- 208000035657 Abasia Diseases 0.000 description 5
- 102000019034 Chemokines Human genes 0.000 description 5
- 108010012236 Chemokines Proteins 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 108020004459 Small interfering RNA Proteins 0.000 description 5
- 241000711975 Vesicular stomatitis virus Species 0.000 description 5
- 108020000999 Viral RNA Proteins 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 230000001086 cytosolic effect Effects 0.000 description 5
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 5
- 230000005860 defense response to virus Effects 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 230000009977 dual effect Effects 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 230000002519 immonomodulatory effect Effects 0.000 description 5
- 210000002865 immune cell Anatomy 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 230000034727 intrinsic apoptotic signaling pathway Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 208000021039 metastatic melanoma Diseases 0.000 description 5
- 239000004530 micro-emulsion Substances 0.000 description 5
- 239000002674 ointment Substances 0.000 description 5
- 230000003389 potentiating effect Effects 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 230000000770 proinflammatory effect Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 102100021573 Bcl-2-binding component 3, isoforms 3/4 Human genes 0.000 description 4
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 4
- 108010076667 Caspases Proteins 0.000 description 4
- 102000011727 Caspases Human genes 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 4
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 4
- 102000001398 Granzyme Human genes 0.000 description 4
- 108060005986 Granzyme Proteins 0.000 description 4
- 101000665442 Homo sapiens Serine/threonine-protein kinase TBK1 Proteins 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 4
- 102100028082 Tapasin Human genes 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000001640 apoptogenic effect Effects 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 238000007385 chemical modification Methods 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 230000007717 exclusion Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 230000003308 immunostimulating effect Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 230000003278 mimic effect Effects 0.000 description 4
- 210000001616 monocyte Anatomy 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000003961 penetration enhancing agent Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 102000040430 polynucleotide Human genes 0.000 description 4
- 108091033319 polynucleotide Proteins 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 4
- 230000000861 pro-apoptotic effect Effects 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 210000000130 stem cell Anatomy 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 4
- 239000012646 vaccine adjuvant Substances 0.000 description 4
- 229940124931 vaccine adjuvant Drugs 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- TXUWMXQFNYDOEZ-UHFFFAOYSA-N 5-(1H-indol-3-ylmethyl)-3-methyl-2-sulfanylidene-4-imidazolidinone Chemical compound O=C1N(C)C(=S)NC1CC1=CNC2=CC=CC=C12 TXUWMXQFNYDOEZ-UHFFFAOYSA-N 0.000 description 3
- 102000008096 B7-H1 Antigen Human genes 0.000 description 3
- 108010074708 B7-H1 Antigen Proteins 0.000 description 3
- 101150003242 Bbc3 gene Proteins 0.000 description 3
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 3
- 229930091371 Fructose Natural products 0.000 description 3
- 239000005715 Fructose Substances 0.000 description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 101000897480 Homo sapiens C-C motif chemokine 2 Proteins 0.000 description 3
- 108090000978 Interleukin-4 Proteins 0.000 description 3
- 229920000161 Locust bean gum Polymers 0.000 description 3
- 108060001084 Luciferase Proteins 0.000 description 3
- 239000005089 Luciferase Substances 0.000 description 3
- 102000003945 NF-kappa B Human genes 0.000 description 3
- 108010057466 NF-kappa B Proteins 0.000 description 3
- 108700020796 Oncogene Proteins 0.000 description 3
- 108091007960 PI3Ks Proteins 0.000 description 3
- 101150074164 PMAIP1 gene Proteins 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 3
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 230000003044 adaptive effect Effects 0.000 description 3
- 230000033289 adaptive immune response Effects 0.000 description 3
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 3
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 3
- 229940037003 alum Drugs 0.000 description 3
- 230000005975 antitumor immune response Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 125000002091 cationic group Chemical group 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000006721 cell death pathway Effects 0.000 description 3
- 230000022534 cell killing Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 230000000139 costimulatory effect Effects 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical class NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 3
- 238000002784 cytotoxicity assay Methods 0.000 description 3
- 231100000263 cytotoxicity test Toxicity 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical class O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 3
- 210000002443 helper t lymphocyte Anatomy 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 206010022000 influenza Diseases 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 239000007951 isotonicity adjuster Substances 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 235000010420 locust bean gum Nutrition 0.000 description 3
- 239000000711 locust bean gum Substances 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 230000002101 lytic effect Effects 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 3
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 3
- 230000002438 mitochondrial effect Effects 0.000 description 3
- 210000000581 natural killer T-cell Anatomy 0.000 description 3
- 230000021597 necroptosis Effects 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 3
- 201000001514 prostate carcinoma Diseases 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 150000005846 sugar alcohols Chemical class 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 239000012049 topical pharmaceutical composition Substances 0.000 description 3
- 229960001727 tretinoin Drugs 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
- AOMXMOCNKJTRQP-UHFFFAOYSA-N 1-[4-[1-[(2,6-difluorophenyl)methyl]-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxothieno[2,3-d]pyrimidin-6-yl]phenyl]-3-methoxyurea Chemical compound C1=CC(NC(=O)NOC)=CC=C1C1=C(CN(C)C)C(C(=O)N(C=2N=NC(OC)=CC=2)C(=O)N2CC=3C(=CC=CC=3F)F)=C2S1 AOMXMOCNKJTRQP-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- ATVJXMYDOSMEPO-UHFFFAOYSA-N 3-prop-2-enoxyprop-1-ene Chemical compound C=CCOCC=C ATVJXMYDOSMEPO-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 2
- 108090000672 Annexin A5 Proteins 0.000 description 2
- 102000004121 Annexin A5 Human genes 0.000 description 2
- 102100030346 Antigen peptide transporter 1 Human genes 0.000 description 2
- 102100030343 Antigen peptide transporter 2 Human genes 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 206010003571 Astrocytoma Diseases 0.000 description 2
- 208000005440 Basal Cell Neoplasms Diseases 0.000 description 2
- 206010004146 Basal cell carcinoma Diseases 0.000 description 2
- 206010004593 Bile duct cancer Diseases 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 241000167854 Bourreria succulenta Species 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 206010010144 Completed suicide Diseases 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- HEAUOKZIVMZVQL-VWLOTQADSA-N Elagolix Chemical compound COC1=CC=CC(C=2C(N(C[C@H](NCCCC(O)=O)C=3C=CC=CC=3)C(=O)N(CC=3C(=CC=CC=3F)C(F)(F)F)C=2C)=O)=C1F HEAUOKZIVMZVQL-VWLOTQADSA-N 0.000 description 2
- 102100031351 Galectin-9 Human genes 0.000 description 2
- 101710121810 Galectin-9 Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 2
- 108010069236 Goserelin Proteins 0.000 description 2
- 229920002907 Guar gum Polymers 0.000 description 2
- 102000005623 HSP27 Heat-Shock Proteins Human genes 0.000 description 2
- 108010045100 HSP27 Heat-Shock Proteins Proteins 0.000 description 2
- 101710113864 Heat shock protein 90 Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 2
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 2
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 2
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 2
- 101001124792 Homo sapiens Proteasome subunit beta type-10 Proteins 0.000 description 2
- 101001136986 Homo sapiens Proteasome subunit beta type-8 Proteins 0.000 description 2
- 101001136981 Homo sapiens Proteasome subunit beta type-9 Proteins 0.000 description 2
- 101000649068 Homo sapiens Tapasin Proteins 0.000 description 2
- 101150106931 IFNG gene Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000003814 Interleukin-10 Human genes 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- 102100033467 L-selectin Human genes 0.000 description 2
- 239000012098 Lipofectamine RNAiMAX Substances 0.000 description 2
- 102000043129 MHC class I family Human genes 0.000 description 2
- 108091054437 MHC class I family Proteins 0.000 description 2
- 239000004907 Macro-emulsion Substances 0.000 description 2
- 108010023335 Member 2 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 2
- 108010006519 Molecular Chaperones Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 102100029081 Proteasome subunit beta type-10 Human genes 0.000 description 2
- 102100035760 Proteasome subunit beta type-8 Human genes 0.000 description 2
- 102100035764 Proteasome subunit beta type-9 Human genes 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 108091028664 Ribonucleotide Proteins 0.000 description 2
- 108091081021 Sense strand Proteins 0.000 description 2
- 101710106944 Serine/threonine-protein kinase TBK1 Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- 101800000849 Tachykinin-associated peptide 2 Proteins 0.000 description 2
- 102000002689 Toll-like receptor Human genes 0.000 description 2
- 108020000411 Toll-like receptor Proteins 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 208000014070 Vestibular schwannoma Diseases 0.000 description 2
- MIFGOLAMNLSLGH-QOKNQOGYSA-N Z-Val-Ala-Asp(OMe)-CH2F Chemical compound COC(=O)C[C@@H](C(=O)CF)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)OCC1=CC=CC=C1 MIFGOLAMNLSLGH-QOKNQOGYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- UVIQSJCZCSLXRZ-UBUQANBQSA-N abiraterone acetate Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CC[C@@H](CC4=CC[C@H]31)OC(=O)C)C=C2C1=CC=CN=C1 UVIQSJCZCSLXRZ-UBUQANBQSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 208000004064 acoustic neuroma Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000004721 adaptive immunity Effects 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229940061720 alpha hydroxy acid Drugs 0.000 description 2
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 2
- 230000003466 anti-cipated effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 150000001277 beta hydroxy acids Chemical class 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 208000026900 bile duct neoplasm Diseases 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 201000007455 central nervous system cancer Diseases 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000019693 cherries Nutrition 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 230000002074 deregulated effect Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000003467 diminishing effect Effects 0.000 description 2
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 2
- 239000002612 dispersion medium Substances 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000008029 eradication Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 150000002224 folic acids Chemical class 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 230000030279 gene silencing Effects 0.000 description 2
- 150000002334 glycols Chemical class 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 235000010417 guar gum Nutrition 0.000 description 2
- 239000000665 guar gum Substances 0.000 description 2
- 229960002154 guar gum Drugs 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 229920001477 hydrophilic polymer Polymers 0.000 description 2
- 230000008073 immune recognition Effects 0.000 description 2
- 230000037451 immune surveillance Effects 0.000 description 2
- 230000006058 immune tolerance Effects 0.000 description 2
- 210000005008 immunosuppressive cell Anatomy 0.000 description 2
- 230000001024 immunotherapeutic effect Effects 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 230000013795 induction of necroptosis Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 108010027775 interleukin-1beta-converting enzyme inhibitor Proteins 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 201000005249 lung adenocarcinoma Diseases 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000015654 memory Effects 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000027829 mitochondrial depolarization Effects 0.000 description 2
- 238000001565 modulated differential scanning calorimetry Methods 0.000 description 2
- 230000009826 neoplastic cell growth Effects 0.000 description 2
- 230000000242 pagocytic effect Effects 0.000 description 2
- 229940127255 pan-caspase inhibitor Drugs 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- AQIXEPGDORPWBJ-UHFFFAOYSA-N pentan-3-ol Chemical compound CCC(O)CC AQIXEPGDORPWBJ-UHFFFAOYSA-N 0.000 description 2
- 229960003742 phenol Drugs 0.000 description 2
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 230000010287 polarization Effects 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- 230000030786 positive chemotaxis Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000006010 pyroptosis Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 229950004238 relugolix Drugs 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 229930002330 retinoic acid Natural products 0.000 description 2
- 239000002336 ribonucleotide Substances 0.000 description 2
- 125000002652 ribonucleotide group Chemical group 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 108010059434 tapasin Proteins 0.000 description 2
- 150000003505 terpenes Chemical class 0.000 description 2
- 235000007586 terpenes Nutrition 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- ZBRAJOQFSNYJMF-SFHVURJKSA-N (1s)-1-[6,7-bis(difluoromethoxy)naphthalen-2-yl]-2-methyl-1-(2h-triazol-4-yl)propan-1-ol Chemical compound C1([C@](O)(C(C)C)C=2C=C3C=C(OC(F)F)C(OC(F)F)=CC3=CC=2)=CNN=N1 ZBRAJOQFSNYJMF-SFHVURJKSA-N 0.000 description 1
- GRZXWCHAXNAUHY-NSISKUIASA-N (2S)-2-(4-chlorophenyl)-1-[4-[(5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl]-1-piperazinyl]-3-(propan-2-ylamino)-1-propanone Chemical compound C1([C@H](C(=O)N2CCN(CC2)C=2C=3[C@H](C)C[C@@H](O)C=3N=CN=2)CNC(C)C)=CC=C(Cl)C=C1 GRZXWCHAXNAUHY-NSISKUIASA-N 0.000 description 1
- STUWGJZDJHPWGZ-LBPRGKRZSA-N (2S)-N1-[4-methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)-4-pyridinyl]-2-thiazolyl]pyrrolidine-1,2-dicarboxamide Chemical compound S1C(C=2C=C(N=CC=2)C(C)(C)C(F)(F)F)=C(C)N=C1NC(=O)N1CCC[C@H]1C(N)=O STUWGJZDJHPWGZ-LBPRGKRZSA-N 0.000 description 1
- OMDQUFIYNPYJFM-XKDAHURESA-N (2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-[[(2r,3s,4r,5s,6r)-4,5,6-trihydroxy-3-[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@H](O)[C@H](O)O1 OMDQUFIYNPYJFM-XKDAHURESA-N 0.000 description 1
- KATZUZNTRINHDT-HALMFYTRSA-N (2s)-1-[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]-methylamino]-3-(4-hydroxyphenyl)propanoyl]amino Chemical compound C([C@@H](C(=O)N[C@H](CCCCNC(N)=O)C(=O)N[C@@H](CCCC)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 KATZUZNTRINHDT-HALMFYTRSA-N 0.000 description 1
- YOVVNQKCSKSHKT-HNNXBMFYSA-N (2s)-1-[4-[[2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]piperazin-1-yl]-2-hydroxypropan-1-one Chemical compound C1CN(C(=O)[C@@H](O)C)CCN1CC1=C(C)C2=NC(C=3C=NC(N)=NC=3)=NC(N3CCOCC3)=C2S1 YOVVNQKCSKSHKT-HNNXBMFYSA-N 0.000 description 1
- UOUBHJRCKHLGFB-DGJUNBOTSA-N (3s)-3-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-5-chloro-4-oxopentanoic acid Chemical compound OC(=O)C[C@@H](C(=O)CCl)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(C)=O)CC1=CC=C(O)C=C1 UOUBHJRCKHLGFB-DGJUNBOTSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- FGODUFHTWYYOOB-UHFFFAOYSA-N 1,3-diaminopropan-2-yl dihydrogen phosphate Chemical compound NCC(CN)OP(O)(O)=O FGODUFHTWYYOOB-UHFFFAOYSA-N 0.000 description 1
- 150000005208 1,4-dihydroxybenzenes Chemical class 0.000 description 1
- MPCAJMNYNOGXPB-UHFFFAOYSA-N 1,5-anhydrohexitol Chemical class OCC1OCC(O)C(O)C1O MPCAJMNYNOGXPB-UHFFFAOYSA-N 0.000 description 1
- QLHHRYZMBGPBJG-UHFFFAOYSA-N 1-[4-[1-(1,4-dioxaspiro[4.5]decan-8-yl)-4-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-6-pyrazolo[3,4-d]pyrimidinyl]phenyl]-3-methylurea Chemical compound C1=CC(NC(=O)NC)=CC=C1C1=NC(N2CC3CCC(O3)C2)=C(C=NN2C3CCC4(CC3)OCCO4)C2=N1 QLHHRYZMBGPBJG-UHFFFAOYSA-N 0.000 description 1
- NZJXADCEESMBPW-UHFFFAOYSA-N 1-methylsulfinyldecane Chemical compound CCCCCCCCCCS(C)=O NZJXADCEESMBPW-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- RLOQBKJCOAXOLR-UHFFFAOYSA-N 1h-pyrrole-2-carboxamide Chemical class NC(=O)C1=CC=CN1 RLOQBKJCOAXOLR-UHFFFAOYSA-N 0.000 description 1
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- SBASXUCJHJRPEV-UHFFFAOYSA-N 2-(2-methoxyethoxy)ethanol Chemical compound COCCOCCO SBASXUCJHJRPEV-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 1
- XDLYKKIQACFMJG-UHFFFAOYSA-N 2-amino-8-[4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound C1=NC(OC)=CC=C1C(C1=O)=CC2=C(C)N=C(N)N=C2N1C1CCC(OCCO)CC1 XDLYKKIQACFMJG-UHFFFAOYSA-N 0.000 description 1
- RGHYDLZMTYDBDT-UHFFFAOYSA-N 2-amino-8-ethyl-4-methyl-6-(1H-pyrazol-5-yl)-7-pyrido[2,3-d]pyrimidinone Chemical compound O=C1N(CC)C2=NC(N)=NC(C)=C2C=C1C=1C=CNN=1 RGHYDLZMTYDBDT-UHFFFAOYSA-N 0.000 description 1
- QINPEPAQOBZPOF-UHFFFAOYSA-N 2-amino-n-[3-[[3-(2-chloro-5-methoxyanilino)quinoxalin-2-yl]sulfamoyl]phenyl]-2-methylpropanamide Chemical compound COC1=CC=C(Cl)C(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=C(NC(=O)C(C)(C)N)C=CC=2)=C1 QINPEPAQOBZPOF-UHFFFAOYSA-N 0.000 description 1
- XTKLTGBKIDQGQL-UHFFFAOYSA-N 2-methyl-1-[[2-methyl-3-(trifluoromethyl)phenyl]methyl]-6-morpholin-4-ylbenzimidazole-4-carboxylic acid Chemical compound CC1=NC2=C(C(O)=O)C=C(N3CCOCC3)C=C2N1CC1=CC=CC(C(F)(F)F)=C1C XTKLTGBKIDQGQL-UHFFFAOYSA-N 0.000 description 1
- BEUQXVWXFDOSAQ-UHFFFAOYSA-N 2-methyl-2-[4-[2-(5-methyl-2-propan-2-yl-1,2,4-triazol-3-yl)-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl]pyrazol-1-yl]propanamide Chemical compound CC(C)N1N=C(C)N=C1C1=CN(CCOC=2C3=CC=C(C=2)C2=CN(N=C2)C(C)(C)C(N)=O)C3=N1 BEUQXVWXFDOSAQ-UHFFFAOYSA-N 0.000 description 1
- FTBBGQKRYUTLMP-UHFFFAOYSA-N 2-nitro-1h-pyrrole Chemical class [O-][N+](=O)C1=CC=CN1 FTBBGQKRYUTLMP-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- BMAAMIIYNNPHAB-UHFFFAOYSA-N 3-[5-[(2,3-difluoro-6-methoxyphenyl)methoxy]-2-fluoro-4-methoxyphenyl]-2,4-dioxo-1h-thieno[3,4-d]pyrimidine-5-carboxylic acid Chemical compound COC1=CC(F)=C(N2C(C3=C(C(O)=O)SC=C3NC2=O)=O)C=C1OCC1=C(OC)C=CC(F)=C1F BMAAMIIYNNPHAB-UHFFFAOYSA-N 0.000 description 1
- HYCSHFLKPSMPGO-UHFFFAOYSA-N 3-hydroxypropyl dihydrogen phosphate Chemical compound OCCCOP(O)(O)=O HYCSHFLKPSMPGO-UHFFFAOYSA-N 0.000 description 1
- LOJNBPNACKZWAI-UHFFFAOYSA-N 3-nitro-1h-pyrrole Chemical compound [O-][N+](=O)C=1C=CNC=1 LOJNBPNACKZWAI-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- LZINOQJQXIEBNN-UHFFFAOYSA-N 4-hydroxybutyl dihydrogen phosphate Chemical compound OCCCCOP(O)(O)=O LZINOQJQXIEBNN-UHFFFAOYSA-N 0.000 description 1
- LAVZKLJDKGRZJG-UHFFFAOYSA-N 4-nitro-1h-indole Chemical compound [O-][N+](=O)C1=CC=CC2=C1C=CN2 LAVZKLJDKGRZJG-UHFFFAOYSA-N 0.000 description 1
- OZFPSOBLQZPIAV-UHFFFAOYSA-N 5-nitro-1h-indole Chemical compound [O-][N+](=O)C1=CC=C2NC=CC2=C1 OZFPSOBLQZPIAV-UHFFFAOYSA-N 0.000 description 1
- OZPFIJIOIVJZMN-UHFFFAOYSA-N 6-(7-hydroxy-5,6-dihydropyrrolo[1,2-c]imidazol-7-yl)-N-methyl-2-naphthalenecarboxamide Chemical compound C1=CC2=CC(C(=O)NC)=CC=C2C=C1C1(O)C2=CN=CN2CC1 OZPFIJIOIVJZMN-UHFFFAOYSA-N 0.000 description 1
- XYVLZAYJHCECPN-UHFFFAOYSA-N 6-aminohexyl phosphate Chemical compound NCCCCCCOP(O)(O)=O XYVLZAYJHCECPN-UHFFFAOYSA-N 0.000 description 1
- XYVLZAYJHCECPN-UHFFFAOYSA-L 6-aminohexyl phosphate Chemical compound NCCCCCCOP([O-])([O-])=O XYVLZAYJHCECPN-UHFFFAOYSA-L 0.000 description 1
- PSWCIARYGITEOY-UHFFFAOYSA-N 6-nitro-1h-indole Chemical compound [O-][N+](=O)C1=CC=C2C=CNC2=C1 PSWCIARYGITEOY-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 229960005531 AMG 319 Drugs 0.000 description 1
- 231100000582 ATP assay Toxicity 0.000 description 1
- KVLFRAWTRWDEDF-IRXDYDNUSA-N AZD-8055 Chemical compound C1=C(CO)C(OC)=CC=C1C1=CC=C(C(=NC(=N2)N3[C@H](COCC3)C)N3[C@H](COCC3)C)C2=N1 KVLFRAWTRWDEDF-IRXDYDNUSA-N 0.000 description 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 description 1
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- YUXMAKUNSXIEKN-BTJKTKAUSA-N BGT226 Chemical compound OC(=O)\C=C/C(O)=O.C1=NC(OC)=CC=C1C1=CC=C(N=CC2=C3N(C=4C=C(C(N5CCNCC5)=CC=4)C(F)(F)F)C(=O)N2C)C3=C1 YUXMAKUNSXIEKN-BTJKTKAUSA-N 0.000 description 1
- CWHUFRVAEUJCEF-UHFFFAOYSA-N BKM120 Chemical compound C1=NC(N)=CC(C(F)(F)F)=C1C1=CC(N2CCOCC2)=NC(N2CCOCC2)=N1 CWHUFRVAEUJCEF-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241001598984 Bromius obscurus Species 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- UFKLYTOEMRFKAD-SHTZXODSSA-N C1C[C@@H](OC)CC[C@@H]1N1C2=NC(C=3C=NC(=CC=3)C(C)(C)O)=CN=C2NCC1=O Chemical compound C1C[C@@H](OC)CC[C@@H]1N1C2=NC(C=3C=NC(=CC=3)C(C)(C)O)=CN=C2NCC1=O UFKLYTOEMRFKAD-SHTZXODSSA-N 0.000 description 1
- 102000002164 CARD domains Human genes 0.000 description 1
- 108050009503 CARD domains Proteins 0.000 description 1
- 101150077124 CXCL10 gene Proteins 0.000 description 1
- 101000715943 Caenorhabditis elegans Cyclin-dependent kinase 4 homolog Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical group NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- UGTJLJZQQFGTJD-UHFFFAOYSA-N Carbonylcyanide-3-chlorophenylhydrazone Chemical compound ClC1=CC=CC(NN=C(C#N)C#N)=C1 UGTJLJZQQFGTJD-UHFFFAOYSA-N 0.000 description 1
- 102000021350 Caspase recruitment domains Human genes 0.000 description 1
- 108091011189 Caspase recruitment domains Proteins 0.000 description 1
- 102100035904 Caspase-1 Human genes 0.000 description 1
- 108090000426 Caspase-1 Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- 108010008978 Chemokine CXCL10 Proteins 0.000 description 1
- 102000006579 Chemokine CXCL10 Human genes 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 241000206575 Chondrus crispus Species 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 108020004394 Complementary RNA Proteins 0.000 description 1
- 208000009798 Craniopharyngioma Diseases 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 229940124766 Cyp17 inhibitor Drugs 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- HEBKCHPVOIAQTA-QWWZWVQMSA-N D-arabinitol Chemical compound OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108091008794 FGF receptors Proteins 0.000 description 1
- 108010040476 FITC-annexin A5 Proteins 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 229920000926 Galactomannan Polymers 0.000 description 1
- PAFKTGFSEFKSQG-PAASFTFBSA-N Galeterone Chemical compound C1=NC2=CC=CC=C2N1C1=CC[C@H]2[C@H](CC=C3[C@@]4(CC[C@H](O)C3)C)[C@@H]4CC[C@@]21C PAFKTGFSEFKSQG-PAASFTFBSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical group NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
- 229920000569 Gum karaya Polymers 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101001023379 Homo sapiens Lysosome-associated membrane glycoprotein 1 Proteins 0.000 description 1
- 101000991061 Homo sapiens MHC class I polypeptide-related sequence B Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 101000586618 Homo sapiens Poliovirus receptor Proteins 0.000 description 1
- 101001109145 Homo sapiens Receptor-interacting serine/threonine-protein kinase 1 Proteins 0.000 description 1
- 101000607306 Homo sapiens UL16-binding protein 1 Proteins 0.000 description 1
- 101000607318 Homo sapiens UL16-binding protein 3 Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- 102100030698 Interleukin-12 subunit alpha Human genes 0.000 description 1
- 101710194995 Interleukin-12 subunit alpha Proteins 0.000 description 1
- 102100024319 Intestinal-type alkaline phosphatase Human genes 0.000 description 1
- 101710184243 Intestinal-type alkaline phosphatase Proteins 0.000 description 1
- 108020003285 Isocitrate lyase Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 description 1
- 102100030301 MHC class I polypeptide-related sequence A Human genes 0.000 description 1
- 102100030300 MHC class I polypeptide-related sequence B Human genes 0.000 description 1
- 229940124640 MK-2206 Drugs 0.000 description 1
- ULDXWLCXEDXJGE-UHFFFAOYSA-N MK-2206 Chemical compound C=1C=C(C=2C(=CC=3C=4N(C(NN=4)=O)C=CC=3N=2)C=2C=CC=CC=2)C=CC=1C1(N)CCC1 ULDXWLCXEDXJGE-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000009018 Medullary thyroid cancer Diseases 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- RJUFJBKOKNCXHH-UHFFFAOYSA-N Methyl propionate Chemical compound CCC(=O)OC RJUFJBKOKNCXHH-UHFFFAOYSA-N 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 description 1
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000238367 Mya arenaria Species 0.000 description 1
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
- 108060005251 Nectin Proteins 0.000 description 1
- 102100035488 Nectin-2 Human genes 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- XVZUMQAMCYSUMS-SIUGBPQLSA-N OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 XVZUMQAMCYSUMS-SIUGBPQLSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 239000012270 PD-1 inhibitor Substances 0.000 description 1
- 239000012668 PD-1-inhibitor Substances 0.000 description 1
- 229940032310 PROSTVAC vaccine Drugs 0.000 description 1
- QIUASFSNWYMDFS-NILGECQDSA-N PX-866 Chemical compound CC(=O)O[C@@H]1C[C@]2(C)C(=O)CC[C@H]2C2=C1[C@@]1(C)[C@@H](COC)OC(=O)\C(=C\N(CC=C)CC=C)C1=C(O)C2=O QIUASFSNWYMDFS-NILGECQDSA-N 0.000 description 1
- 206010033701 Papillary thyroid cancer Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108091093037 Peptide nucleic acid Proteins 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 102100029740 Poliovirus receptor Human genes 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 208000033766 Prolymphocytic Leukemia Diseases 0.000 description 1
- 108091008611 Protein Kinase B Proteins 0.000 description 1
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 1
- 108090000944 RNA Helicases Proteins 0.000 description 1
- 102000004409 RNA Helicases Human genes 0.000 description 1
- 102100022501 Receptor-interacting serine/threonine-protein kinase 1 Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 102000001332 SRC Human genes 0.000 description 1
- 108060006706 SRC Proteins 0.000 description 1
- 101000744436 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Trans-acting factor D Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 241001479493 Sousa Species 0.000 description 1
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000934878 Sterculia Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 206010051259 Therapy naive Diseases 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 229940122429 Tubulin inhibitor Drugs 0.000 description 1
- 238000010162 Tukey test Methods 0.000 description 1
- 102100040012 UL16-binding protein 1 Human genes 0.000 description 1
- 102100040011 UL16-binding protein 3 Human genes 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- HGVNLRPZOWWDKD-UHFFFAOYSA-N ZSTK-474 Chemical compound FC(F)C1=NC2=CC=CC=C2N1C(N=1)=NC(N2CCOCC2)=NC=1N1CCOCC1 HGVNLRPZOWWDKD-UHFFFAOYSA-N 0.000 description 1
- 102100025093 Zinc fingers and homeoboxes protein 2 Human genes 0.000 description 1
- 229960004103 abiraterone acetate Drugs 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 108010052004 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000005250 alkyl acrylate group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000005103 alkyl silyl group Chemical group 0.000 description 1
- 229950010482 alpelisib Drugs 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 229940059260 amidate Drugs 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000000420 anogeissus latifolia wall. gum Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 230000002622 anti-tumorigenesis Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000007416 antiviral immune response Effects 0.000 description 1
- 230000005775 apoptotic pathway Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- 229960001716 benzalkonium Drugs 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- HUTDDBSSHVOYJR-UHFFFAOYSA-H bis[(2-oxo-1,3,2$l^{5},4$l^{2}-dioxaphosphaplumbetan-2-yl)oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O HUTDDBSSHVOYJR-UHFFFAOYSA-H 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 229950003628 buparlisib Drugs 0.000 description 1
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000004611 cancer cell death Effects 0.000 description 1
- 230000005880 cancer cell killing Effects 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000005859 cell recognition Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- JROFGZPOBKIAEW-HAQNSBGRSA-N chembl3120215 Chemical compound N1C=2C(OC)=CC=CC=2C=C1C(=C1C(N)=NC=NN11)N=C1[C@H]1CC[C@H](C(O)=O)CC1 JROFGZPOBKIAEW-HAQNSBGRSA-N 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 230000014564 chemokine production Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000007958 cherry flavor Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 229950006418 dactolisib Drugs 0.000 description 1
- JOGKUKXHTYWRGZ-UHFFFAOYSA-N dactolisib Chemical compound O=C1N(C)C2=CN=C3C=CC(C=4C=C5C=CC=CC5=NC=4)=CC3=C2N1C1=CC=C(C(C)(C)C#N)C=C1 JOGKUKXHTYWRGZ-UHFFFAOYSA-N 0.000 description 1
- 229960002272 degarelix Drugs 0.000 description 1
- MEUCPCLKGZSHTA-XYAYPHGZSA-N degarelix Chemical compound C([C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CC=1C=CC(NC(=O)[C@H]2NC(=O)NC(=O)C2)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(NC(N)=O)C=C1 MEUCPCLKGZSHTA-XYAYPHGZSA-N 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 229950004823 elagolix Drugs 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- NPUKDXXFDDZOKR-LLVKDONJSA-N etomidate Chemical compound CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1 NPUKDXXFDDZOKR-LLVKDONJSA-N 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 230000034725 extrinsic apoptotic signaling pathway Effects 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 229950003400 galeterone Drugs 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229950008209 gedatolisib Drugs 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000000451 gelidium spp. gum Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 125000005908 glyceryl ester group Chemical group 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- XDDAORKBJWWYJS-UHFFFAOYSA-N glyphosate Chemical compound OC(=O)CNCP(O)(O)=O XDDAORKBJWWYJS-UHFFFAOYSA-N 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 235000019314 gum ghatti Nutrition 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 201000002222 hemangioblastoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- PHNWGDTYCJFUGZ-UHFFFAOYSA-L hexyl phosphate Chemical compound CCCCCCOP([O-])([O-])=O PHNWGDTYCJFUGZ-UHFFFAOYSA-L 0.000 description 1
- 238000010842 high-capacity cDNA reverse transcription kit Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- UUADYKVKJIMIPA-UHFFFAOYSA-N hydron;3-(1-methylindol-3-yl)-4-[1-[1-(pyridin-2-ylmethyl)piperidin-4-yl]indol-3-yl]pyrrole-2,5-dione;chloride Chemical compound Cl.C12=CC=CC=C2N(C)C=C1C(C(NC1=O)=O)=C1C(C1=CC=CC=C11)=CN1C(CC1)CCN1CC1=CC=CC=N1 UUADYKVKJIMIPA-UHFFFAOYSA-N 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 230000000899 immune system response Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000010185 immunofluorescence analysis Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000006054 immunological memory Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000011293 immunotherapeutic strategy Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000010921 in-depth analysis Methods 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 230000010468 interferon response Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 229940074928 isopropyl myristate Drugs 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 229940075495 isopropyl palmitate Drugs 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 235000010494 karaya gum Nutrition 0.000 description 1
- 239000000231 karaya gum Substances 0.000 description 1
- 229940039371 karaya gum Drugs 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229940087857 lupron Drugs 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000000838 magnetophoresis Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 229940100630 metacresol Drugs 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 235000006109 methionine Nutrition 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 229940017219 methyl propionate Drugs 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000004001 molecular interaction Effects 0.000 description 1
- 238000009126 molecular therapy Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 108091005763 multidomain proteins Proteins 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 208000001611 myxosarcoma Diseases 0.000 description 1
- KWRYMZHCQIOOEB-LBPRGKRZSA-N n-[(1s)-1-(7-fluoro-2-pyridin-2-ylquinolin-3-yl)ethyl]-7h-purin-6-amine Chemical compound C1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)=CC2=CC=C(F)C=C2N=C1C1=CC=CC=N1 KWRYMZHCQIOOEB-LBPRGKRZSA-N 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- GDCJHDUWWAKBIW-UHFFFAOYSA-N n-[4-[4-[2-(difluoromethyl)-4-methoxybenzimidazol-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl]phenyl]-2-(dimethylamino)ethanesulfonamide Chemical compound FC(F)C1=NC=2C(OC)=CC=CC=2N1C(N=1)=NC(N2CCOCC2)=NC=1C1=CC=C(NS(=O)(=O)CCN(C)C)C=C1 GDCJHDUWWAKBIW-UHFFFAOYSA-N 0.000 description 1
- JOWXJLIFIIOYMS-UHFFFAOYSA-N n-hydroxy-2-[[2-(6-methoxypyridin-3-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]pyrimidine-5-carboxamide Chemical compound C1=NC(OC)=CC=C1C1=NC(N2CCOCC2)=C(SC(CN(C)C=2N=CC(=CN=2)C(=O)NO)=C2)C2=N1 JOWXJLIFIIOYMS-UHFFFAOYSA-N 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- CGBJSGAELGCMKE-UHFFFAOYSA-N omipalisib Chemical compound COC1=NC=C(C=2C=C3C(C=4C=NN=CC=4)=CC=NC3=CC=2)C=C1NS(=O)(=O)C1=CC=C(F)C=C1F CGBJSGAELGCMKE-UHFFFAOYSA-N 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 238000012379 oncolytic virotherapy Methods 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000000577 osteoprotective effect Effects 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 229950008505 ozarelix Drugs 0.000 description 1
- 108010011957 ozarelix Proteins 0.000 description 1
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 208000004019 papillary adenocarcinoma Diseases 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229940121655 pd-1 inhibitor Drugs 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 1
- 231100000435 percutaneous penetration Toxicity 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000012660 pharmacological inhibitor Substances 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- LHNIIDJUOCFXAP-UHFFFAOYSA-N pictrelisib Chemical compound C1CN(S(=O)(=O)C)CCN1CC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 LHNIIDJUOCFXAP-UHFFFAOYSA-N 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000003405 preventing effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 229940021993 prophylactic vaccine Drugs 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 1
- 210000005267 prostate cell Anatomy 0.000 description 1
- 229940034080 provenge Drugs 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 150000003902 salicylic acid esters Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 208000018964 sebaceous gland cancer Diseases 0.000 description 1
- 208000011581 secondary neoplasm Diseases 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229950001043 seviteronel Drugs 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 108091069025 single-strand RNA Proteins 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- BTURAGWYSMTVOW-UHFFFAOYSA-M sodium dodecanoate Chemical compound [Na+].CCCCCCCCCCCC([O-])=O BTURAGWYSMTVOW-UHFFFAOYSA-M 0.000 description 1
- 229940082004 sodium laurate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- YEENEYXBHNNNGV-XEHWZWQGSA-M sodium;3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoate;(2r,3r,4s,5s,6r)-2-[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound [Na+].CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I.O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 YEENEYXBHNNNGV-XEHWZWQGSA-M 0.000 description 1
- 239000007892 solid unit dosage form Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 208000017572 squamous cell neoplasm Diseases 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- SFVFIFLLYFPGHH-UHFFFAOYSA-M stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 229960002385 streptomycin sulfate Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000008362 succinate buffer Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 201000008759 sweat gland cancer Diseases 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229950001269 taselisib Drugs 0.000 description 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229940022511 therapeutic cancer vaccine Drugs 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 239000005451 thionucleotide Substances 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 239000008181 tonicity modifier Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical class CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 230000004222 uncontrolled growth Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 230000005924 vaccine-induced immune response Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000009637 wintergreen oil Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 229940033942 zoladex Drugs 0.000 description 1
- 229940051084 zytiga Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46449—Melanoma antigens
- A61K39/464491—Melan-A/MART
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46449—Melanoma antigens
- A61K39/464492—Glycoprotein 100 [Gp100]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/57—Skin; melanoma
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
Definitions
- the field is RNA-based therapeutic molecules. More specifically, the field is 5'- triphosphate oligoribonucleotide immune system agonists, pharmaceutical compositions comprising the same, and methods of use of the compositions.
- the innate immune system has evolved numerous molecular sensors and signaling pathways to detect, contain and clear viral infections (Takeuchi & Akira, Immunol Rev 227:75-86, 2009; Yoneyama & Fujita, Rev Med Virol 20:4-22, 2010; Wilkins & Gale, Curr Opin Immunol 22:41 -47, 2010; Brennan & Bowie, Curr Opin Microbiol 13:503-507, 2010).
- Viruses are sensed by a subset of pattern recognition receptors (PRRs) that recognize evolutionarily conserved structures known as pathogen- associated molecular patterns (PAMPs).
- PRRs pattern recognition receptors
- PAMPs pathogen- associated molecular patterns
- RNA structures within the cytoplasm are recognized by members of the retinoic acid-inducible gene-l (RIG-l)-like receptors (RLRs) family, including the three DExD/H box RNA helicases RIG-I, Mda5 and LGP-2 (Kumar et al., Int Rev Immunol 30:16-34, 2011 ; Loo & Gale, Immunity 34:680-692, 2011 ; Belgnaoui et al., Curr Opin Immunol 23:564-572, 2011 ; Beutler, Blood 1 13:1399-1407, 2009; Kawai & Akira, Immunity 34, 637-650, 201 1 ).
- RIG-l retinoic acid-inducible gene-l
- Mda5 retinoic acid-inducible gene-l
- LGP-2 three DExD/H box RNA helicases
- tumors adopt multiple strategies to escape immune surveillance and to generate an immunosuppressive and pro-tumorigenic microenvironment (Schreiber et al., Science 331 :1565-1570, 201 1 ).
- cancer cells become less visible to cells of the immune system by: 1 ) downregulation of HLA-ABC, co-stimulatory molecules and NK ligands; 2) expression or secretion of immunosuppressing molecules (such as PD-L1 , Galectin 9, ID01 ); and/or 3) chemoattraction of immunosuppressive cells such as regulatory T cells, myeloid derived suppressor cells or tumor activated macrophage cells (Treg, MDSC and TAM, respectively) (Mittal et al., Curr Opin Immunol 27:16-25, 2014).
- the retinoic acid inducible gene-l is a cytosolic PRR for short 5' triphosphate double strand RNA, that has a crucial role in activating immune response against viral infection (Hornung et al., Science 314:994-997, 2006).
- RIG-I is a cytosolic multidomain protein that detects viral RNA through its helicase domain (Jiang et al., Nature 479:423-427, 2011 ; Yoneyama & Fujita, J Biol Chem 282, 15315-15318, 2007).
- RIG-I In addition to its RNA sensing domain, RIG-I also possesses an effector caspase activation and recruitment domain (CARD) that interacts with the mitochondrial adaptor MAVS, also known as VISA, I PS-1 , and Cardif (Kawai et al., Nat Immunol 6:981 -988, 2005; Meylan et al., Nature 437:1 167-1172, 2005).
- CARD effector caspase activation and recruitment domain
- RIG-I Upon recognition of viral RNA, RIG-I activates through CARD- mediated interactions the adaptor mitochondrial antiviral signaling protein (MAVS), which in turn activates TANK-binding kinase 1 (TBK1 ) and the IKB kinase (IKK) complex (Kawai et al., Nat Immunol 6:981-988, 2005).
- MAVS adaptor mitochondrial antiviral signaling protein
- TK1 TANK-binding kinase 1
- IKK IKB kinase
- IRF3 interferon regulatory factor 3
- NF-KB nuclear factor kappa B
- RIG-I signaling can also trigger suicide of infected cells as an ultimate mechanism of protection to limit viral spread through at least three different mechanisms: IRF3-dependent induction of apoptotic genes (Heylbroeck et al., J Virol 74:3781-92, 2000); IRF3- mediated induction of BAX-dependent mitochondrial apoptosis (Chattopadhyay et al., Immunity 44:1 151-1161 , 2016); and, direct RIG-I induction of necroptosis (Schock et al., Cell Death Differ 24:615-625, 2017).
- RIG- I agonists can induce cell death in different tumor types and activate both innate and adaptive immunity against tumors in mouse models (Poeck et al., Nat Med 14:1256-1263, 2008; Besch et al., J Clin Invest 119:2399-241 1 , 2009; Glas et al., Stem Cells 31 :1064-1074, 2013; Ellermeier et al., Cancer Res 73:1709-1720, 2013; Duewell et al., Cell Death Differ 21 :1825-1837, 2014).
- RNA carrying an exposed 5' terminal triphosphate (5'ppp) moiety was identified as a RIG-1 agonist (Hornung et ai, Science 314:994-997, 2006; Pichlmair et ai, Science 314:997-1001 , 2006; and Kim et ai, Nat Biotechol 22:321 -325, 2004).
- the 5'ppp moiety is added to the end of all viral and eukaryotic RNA molecules generated by RNA polymerization.
- RNA processing in the nucleus cleaves the 5'ppp end and the RNA is capped prior to release into the cytoplasm.
- the eukaryotic immune system evolved the ability to distinguish viral‘non-self 5'ppp RNA from cellular ‘self RNA through RIG-I (Fujita, Immunity 31 :4-5, 2009). Further characterization of RIG-I ligand structure indicated that blunt base pairing at the 5' end of the RNA and a minimum double strand (ds) length of 20 nucleotides were also important for RIG-I signaling (Schlee & Hartmann, Molecular Therapy 18:1254-1262, 2010).
- RNA extracted from virally infected cells was also shown to activate RIG-I (Baum et ai., Proc Natl Acad Sci USA 107:16303- 16308, 2010; Rehwinkel & Sousa, Science 327:284-286, 2010; Rehwinkel et ai., Cell 140:397-408, 2010).
- RIG-I Rehwinkel & Sousa, Science 327:284-286, 2010
- UTRs highly conserved 5' and 3' untranslated regions
- VSV Vesicular Stomatitis Virus
- M8 potently blocked a variety of viral infections in vitro and in vivo, in part due to the activation of an innate immune response with great breadth and intensity. Furthermore, M8 acted as a potent vaccine adjuvant against influenza, leading to high antibody titers and Th1 -shift in immune responses (Beljanski et ai, J Virol 89:10612-10624, 2015).
- oligoribonucleotide RIG-I agonist that is at least 41 nucleotides in length and that can form a hairpin structure comprising at least 17 base pairs.
- the synthetic oligoribonucleotide further includes a triphosphate group at its 5' end.
- the oligoribonucleotide can also be of at least 99 nucleotides in length and can form a hairpin structure of at least 48 base pairs. In such an oligoribonucleotide, the hairpin structure can comprise at least 26 consecutive U-A base pairs.
- the therapeutic oligoribonucleotides include sequences such as any one of SEQ ID NOs: 10-17.
- One embodiment is a method of treating cancer in a subject in need thereof including administering a therapeutically effective amount of a synthetic oligoribonucleotide including a 5' end triphosphate group and including (or having only) the sequence shown in M8 (SEQ ID NO: 13) or M5 (SEQ ID NO: 10) to the subject, thereby treating the cancer in the subject.
- the cancer includes melanoma, adenocarcinoma, carcinoma, or a metastatic cancer.
- the cancer includes lung cancer, colon cancer, or prostate cancer.
- Another provided embodiment is a method of inducing death of cancerous cells in a subject, the method including administering a therapeutically effective amount of a synthetic oligoribonucleotide including a 5' end triphosphate group and including (or having only) the sequence shown in M8 (SEQ ID NO: 13) or M5 (SEQ ID NO: 10) to the subject, thereby inducing death of cancerous cells in the subject.
- the cancerous cells include melanoma cells, adenocarcinoma cells, carcinoma cells, or metastatic cells.
- the cancerous cells arise from melanoma, adenocarcinoma, carcinoma, or a metastatic cancer.
- the cancerous cells arise from lung, colon, or prostate cancer.
- the cell death is dependent on caspase 3. In examples of the methods of inducing cell death of cancerous cells in a subject, the cell death is dependent on type I interferon (IFN-I).
- IFN-I type I interferon
- death of cancerous cells includes: an increase in expression of chemokines CCL2, CXCL1 , CXCL10, and/or IFNp in the cancerous cells; an increase in surface exposure of calreticulin on the cancerous cells; an increase in secretion of High Mobility Group Box 1 (HMGB1 ) from the cancerous cells; and/or an increase in release of ATP from the cancerous cells, as compared to the corresponding parameter in cancerous cells from the subject prior to the administering.
- chemokines CCL2, CXCL1 , CXCL10, and/or IFNp in the cancerous cells
- an increase in surface exposure of calreticulin on the cancerous cells an increase in secretion of High Mobility Group Box 1 (HMGB1 ) from the cancerous cells
- HMGB1 High Mobility Group Box 1
- the immune reactivation comprises: an increase in natural killer (NK) activating ligands on the cancerous cells; induction of expression of an NK inhibiting marker on the cancerous cells; induction of antigen processing machinery (APM) genes in the cancerous cells; an increase in expression of CD80, CD86, and/or HLA-DR on dendritic cells from the subject; and/or an increase in IL-12 expression in dendritic cells from the subject, as compared to the corresponding parameter in cancerous cells or dendritic cells from the subject prior to the administering.
- NK natural killer
- APM antigen processing machinery
- the method further involves administering at least one second anti-cancer agent.
- the therapeutically effective amount includes at least 0.2 milligrams to at least 5 milligrams of the synthetic oligoribonucleotide per kilogram of the subject's body weight per week (0.2-5 mg/kg/wk).
- the therapeutically effective amount includes at least 0.5 milligrams to at least 2.5 milligrams of the synthetic oligoribonucleotide per kilogram of the subject's body weight per week (0.5-2.5 mg/kg/wk).
- the synthetic oligoribonucleotide is administered to the subject for at least 1 -52 weeks; and/or administered to the subject 1 -6 times per week; and / or administered 1 -6 times during the first week and 1 time each subsequent week.
- the provided methods involve the synthetic oligoribonucleotide being administered in a total weekly dose of any of 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, 125 mg, 150 mg, 175 mg, 200 mg, 225 mg, 250 mg, 275 mg, 300 mg, 325 mg, 350 mg, 375 mg, 400 mg, 425 mg, 450 mg, 475 mg, 500 mg, 525 mg, 550 mg, 575 mg, 600 mg, 625 mg, 650 mg, 675 mg, 700 mg, 725 mg, or 750 mg.
- Further examples of the methods include the effective amount of the synthetic oligoribonucleotide being administered at a rate of 5 n M/kg to 100 nM/kg of the synthetic oligoribonucleotide per kilogram of the subject's body.
- the therapeutically effective amount includes 15.5 nM/kg to 77.5 nM/kg of the synthetic oligoribonucleotide per kilogram of the subject's body.
- Another provided embodiment is a vaccine composition including: a tumor antigen; an adjuvant; and a pharmaceutically acceptable carrier, wherein the adjuvant comprises at least one synthetic oligoribonucleotide RIG-I agonist described herein.
- the adjuvant comprises at least one synthetic oligoribonucleotide RIG-I agonist described herein.
- the oligoribonucleotides suitable for an adjuvant include sequences such as any one of SEQ ID NOs: 10-17.
- the synthetic oligoribonucleotide has a sequence set forth in SEQ ID NO: 10 (M5) or SEQ ID NO: 13 (M8).
- Examples of the vaccine composition include a tumor antigen derived from tumors found in melanoma, skin cancer, prostate cancer, lung cancer, pancreatic cancer, or breast cancer. Further examples of the vaccine composition include a tumor antigen that is part of a tumor cell lysate. Yet another example of the vaccine composition includes a tumor antigen that is part of an inactivated cancer cell population. Further examples of the vaccine composition include a tumor antigen that is part of an antigen presenting cell (APC) population. In particular embodiments, the APC population includes dendritic cells.
- APC antigen presenting cell
- the adjuvant further includes mineral oil, bacterial toxins, aluminum salts, squalene, virosomes, mineral oil in water emulsions, CpG, lipopolysaccharide (LPS), monophosphoryl lipid A (MPLA), QS21 or AS02, flagellin, peptidoglycans, inactivated bacterial pathogens, and/or RNAse inhibitors.
- the synthetic oligoribonucleotide is in a nanoparticle formulation.
- the tumor antigen and the adjuvant are formulated together. In particular embodiments, the tumor antigen and the adjuvant are not formulated together.
- Another provided embodiment is a method for stimulating an immune response against a tumor antigen in a subject at risk of having or having a cancer including the tumor antigen, including administering to the subject a therapeutically effective amount of the vaccine composition.
- these methods for stimulating an immune response against a tumor antigen further include administering at least one second anti-cancer agent.
- the second anti cancer agent is low dose chemotherapy.
- the second anti-cancer agent is an immune checkpoint inhibitor that blocks programmed cell death protein 1 (PD-1 ).
- Another provided embodiment is a method of activating antigen presenting cells (APC) ex vivo including contacting the APC with the vaccine composition.
- these methods of activating APC ex vivo further include administering the contacted APC to a subject at risk of having or having a cancer comprising the tumor antigen.
- Another provided embodiment is an immunization kit including a vaccine composition described herein.
- FIG. 1A-1 G RIG-I agonist M8 induces cell death in cancer cells.
- FIG. 1 A Viability of Mel1007 cells transfected with different doses of M8 (1 -500 ng/ml) for 48 hours assessed by 7-AAD exclusion by flow cytometry.
- FIG. 1 B LDH based cytotoxicity was measured on supernatant of Mel1007 cells transfected with different doses of M8 (1 -500 ng/ml) for 48 hours, the % was calculated as the ratio of spontaneous-normalized LDH activity over normalized maximum control following manufactured instructions.
- FIG. 1 C
- FIG. 1 D Viability of Mel1007 cells pretreated for 24 h with siRNA specific for RIG-I gene and then transfected with M8 (500 ng/ml) for 48 h.
- FIG. 1 E Viability of Mel1007 cells transfected with the indicated RIG-I agonists (500 ng/ml), untreated, or transfected only with lipofectamine for 48 hours.
- FIG. 1 F Viability of Mel1007 cells transfected with the indicated RIG-I agonists (500 ng/ml), untreated, or transfected only with lipofectamine for 48 hours.
- FIG. 1 G Viability of PBMC transfected with different doses of M8 (1 -500 ng/ml) for 48 hours assessed by 7-AAD exclusion by flow cytometry. * P ⁇ 0.05; ** P ⁇ 0.01 ; *** P ⁇ 0.001
- FIG. 2A-2F M8 activates intrinsic apoptosis driven by PUMA and NOXA.
- FIG. 2A (parts 1 and 2). Flow Cytometry evaluation of Annexin V/7-AAD positivity of Mel1007 cells transfected with M8 (500 ng/ml) assessed at 10, 16, 24, 32 and 48 h.
- FIG. 2B Viability of Mel1007 cell transfected for 48 h with M8 and treated with pan-caspase inhibitor ZVAD-FMK (100 pM), caspase 1 inhibitor YVAD- FMK (50 pg/ml), and necroptosis inhibitor necrostatin 1 (100 pM).
- FIG. 2C Viability of Mel1007 cell transfected for 48 h with M8 and treated with pan-caspase inhibitor ZVAD-FMK (100 pM), caspase 1 inhibitor YVAD- FMK (50 pg/ml), and necroptosis inhibitor necrostatin 1 (100 pM).
- FIG. 2D Analysis of % of Mel1007 24 h after transfection showing monomeric JC-1 , an indicator of mitochondria depolarization. CCCP was used as a positive control and added 30’ before the analysis.
- FIG. 2E Expression levels of NOXA gene in Mel1007 cells 24 h after transfection with the indicated doses of M8.
- FIG. 2F Expression levels of PUMA gene in Mel1007 cells 24 h after transfection with the indicated doses of M8. * P ⁇ 0.05; ** P ⁇ 0.01 ; *** P ⁇ 0.001
- FIG. 3A-3C M8 induced apoptosis relies on IFN-I signaling.
- FIG. 3A Viability of Mel1007 cells transfected with M8 (500 ng/ml) and treated with IFNAR1 blocking Ab for 48h (1 pg/ml).
- FIG. 3B and FIG. 3C Expression levels of NOXA and PUMA genes, respectively in Mel1007 cells 24 h after transfection with M8 500 ng/ml treated with IFNAR1 blocking Ab for 48h (1 pg/ml). Fold changes were calculated over untreated Mel1007 cells. ** P ⁇ 0.01
- FIG. 4A-4C M8 induces immunogenic cell death in cancer cells.
- FIG. 4A and FIG. 4B Expression levels of IFNp and CXCL10 gene, respectively, in Mel1007 cells 24 h after transfection with different doses of M8 (1 -500 ng/ml) and IFNAR1 blocking Ab (1 pg/ml) over control cells.
- FIG. 4C Analysis by Magnetic Luminex assay from R&D systems (see Material and Methods for details) of the chemokines CCL2, CXCL1 , CXCL10, and IFNp on supernatants of Mel1007 cells stimulated for 24 hours with M8 (10, 100, and 500 ng/ml). Untransfected (Un) and lipofectamine RNAiMax transfected (lipo) Mel1007 were used as negative controls.
- FIG. 5A-5E Cancer cells exposed to M8 exhibit the hallmarks of ICD.
- FIG. 5A Calreticulin expression levels as assessed by % of positive cells in Mel1007 30 h after transfection with M8 (500 ng/ml); mitoxantrone (1 pM) was used as positive control;
- FIG. 5B Calreticulin expression levels as assessed by % of positive cells in HCT1 16 cells (left) and PC3 cells (right) 24 or 18 h, respectively, after transfection with M8 (500 ng/ml), mitoxantrone (1 pM) was used as positive control;
- FIG. 5C Calreticulin expression levels as assessed by % of positive cells in HCT1 16 cells (left) and PC3 cells (right) 24 or 18 h, respectively, after transfection with M8 (500 ng/ml), mitoxantrone (1 pM) was used as positive control;
- FIG. 5C Calreticulin expression levels as assessed by % of positive cells in HCT1 16 cells
- FIG. 6A-6E M8 triggering of RIG-I represses NK cell-mediated cancer cell killing and activates antigen processing machinery.
- FIG. 6A Relative expression levels of NK activating ligands on Mel1007 transfected with M8 (10-100 ng/ml) for 48 h.
- FIG. 6B Degranulation of NK from healthy donors co-cultured with Mel1007 cells transfected with M8 (10-100 ng/ml) for 48 h.
- FIG. 6C Cytotoxicity assay of NKL cell line against Mel1007 cells transfected with M8 (10-100 ng/ml) for 48 h. Both in FIG. 6B and FIG.
- FIG. 6C K562 were used as positive control of NK activation.
- FIG. 6D MFI of HLA-ABC expression levels of Mel1007 transfected for 24 h with different doses of M8 (1 -500 ng/ml) and IFNAR1 blocking Ab (1 pg/ml) over control cells;
- FIG. 6E Expression levels of the indicated APM genes in Mel1007 cells 24 h after transfection with different doses of M8 (1 -500 ng/ml) and IFNAR1 blocking Ab (1 pg/ml) over control cells.
- FIG. 7A-7E M8 treatment in cancer cells induces phagocytosis and pro-inflammatory phenotype in DC.
- FIG. 7A and FIG. 7B Mel1007 cells were stained with CTFR and then transfected with M8 (500 ng/ml). After 48 h, Mo-DC were added to the cell culture at a 1 :1 ratio. After 4 h phagocytosis of DC was analyzed by flow cytometry analyzing the % of DC (gated on CD209 expression) that incorporated CTFR.
- FIG. 7A Representative plots of phagocytosis assay.
- FIG. 7B Percentage of DC phagocytosis as in FIG. 7A.
- FIGs. 7C-7E Percentage of DC phagocytosis as in FIG. 7A.
- FIG. 7C Cell surface expression levels expressed as relative MFI of costimulatory markers CD80 and CD86 and HLA-DR in DC treated for 24 h with supernatants of Mel1007 transfected with different doses of M8.
- FIG. 7D and FIG. 7E Expression levels of IL-12A, IL-10 and CXCL10 genes at in DC treated as in c). * P ⁇ 0.05; ** P ⁇ 0.01 ; *** P ⁇ 0.001 .
- FIG. 8 is a drawing of the secondary structure of WT (SEQ ID NO: 5), M5 (SEQ ID NO: 10), and M8 (SEQ ID NO: 13) 5'pppRNA oligonucleotides.
- FIG. 9 is a schematic representation of 5'pppRNA sequences that include variations of the wild type (WT; SEQ ID NO: 5) VSV-derived 5’pppRNA (M1 -M8; SEQ ID NOs: 6-13).
- FIG. 10 is a schematic representation of modifications to the M8 5'pppRNA (SEQ ID NO: 13). Sequence changes were made to the poly AU base-pair stretch (M8A, SEQ ID NO: 14; M8C, SEQ ID NO: 15), the WT-derived blunt-end (M8D, SEQ ID NO: 16), and the entire sequence (M8B, SEQ ID NO: 17) while keeping the structure intact.
- nucleic acid sequences described herein are shown using standard letter abbreviations for nucleotide bases, as defined in 37 C.F.R. ⁇ 1 .822. Only one strand of each nucleic acid sequence is shown, but the complementary strand is understood as included in embodiments where it would be appropriate.
- a computer readable text file entitled“l081 -0003PCT_ST25.txt” created on or about May 7, 2020, with a file size of ⁇ 16 KB, contains the sequence listing for this application and is hereby incorporated by reference in its entirety. [0040] Table 1 : Sequences in Sequence Listing
- the oligoribonucleotide includes: a first polynucleotide having the sequence shown in SEQ ID NO: 1 , a second polynucleotide having the sequence shown in SEQ ID NO: 2 and a third polynucleotide having the sequence shown in SEQ ID NO: 3 with SEQ ID NO: 3 located between SEQ ID NO: 1 and SEQ ID NO: 2.
- SEQ ID NO: 1 can be 5' of SEQ ID NO: 2 or SEQ ID NO: 1 can be 3' of SEQ ID NO: 2.
- the oligoribonucleotides can comprise any additional sequence.
- the RIG-I agonist oligoribonucleotides include the structure:
- n is any integer greater than 1.
- n can equal 2, 3, 6, 1 1 , 16, 26, or more than 26 repeats of the nucleotide indicated in parentheses.
- the oligoribonucleotides can also include the structure:
- x and y are any integer greater than 2.
- the tripeptide in parentheses is repeated a number of times equal to x or y.
- x and y can be different numbers.
- x can equal 10 while y can equal 8.
- the oligoribonucleotides can have the structure:
- n is an integer greater than 1 .
- the therapeutic synthetic oligoribonucleotide can be an oligoribonucleotide of at least 59 nucleotides in length that can form a hairpin structure comprising at least 29 base pairs, the synthetic oligonucleotide further comprising a triphosphate group at the 5' end of the oligoribonucleotide.
- the oligoribonucleotides are at least 99 nucleotides in length that can form a hairpin structure comprising at least 49 base pairs.
- the synthetic oligoribonucleotides described herein can be expressed from a DNA plasmid.
- a DNA plasmid comprises the DNA sequence that encodes the described oligoribonucleotides.
- the oligoribonucleotides can be transcribed as an RNA molecule that automatically folds into duplexes with hairpin loops.
- a transcriptional unit or cassette will contain an RNA transcript promoter sequence, such as a T7 promoter operably linked to the sequence encoding the oligoribonucleotide.
- the synthetic oligoribonucleotides described herein comprise a 5'-triphosphate group. These may collectively be referred to as 5'pppRNA or individually as 5'ppp-SEQ ID NO: XX herein. Alternatively, individual compounds may be referred to herein by names such as WT, M5, or M8 as indicated in the Sequence Listing (including, for instance, SEQ ID NOs: 5-17). See also FIGs. 7, 8, and 9, as well as U.S. Patent Publication No. 2017-0268007 and U.S. Patent No. 10,167,476.
- An oligoribonucleotide can also be chemically synthesized. Synthesis of the single- stranded nucleic acid makes use of common nucleic acid protecting and coupling groups, such as dimethoxytrityl at the 5'-end and phosphoramidites at the 3'-end. As a non-limiting example, small scale syntheses can be conducted on an Applied Biosystems synthesizer using a 0.2 micromolar scale protocol with a 2.5 min coupling step for 2'-0-methylated nucleotides. Alternatively, syntheses at the 0.2 micromolar scale can be performed on a 96-well plate synthesizer from Protogene.
- a larger or smaller scale of synthesis is encompassed by the invention, including any method of synthesis now known or yet to be disclosed.
- Suitable reagents for synthesis of the single-stranded oligonucleotides, methods of RNA deprotection, methods of RNA purification, and methods of adding phosphate groups to an oligoribonucleotide are known to those of skill in the art.
- An oligoribonucleotide can be synthesized via a tandem synthesis technique, wherein both strands are synthesized as a single continuous fragment or strand separated by a linker that is subsequently cleaved to provide separate fragments or strands that hybridize to form an RNA duplex.
- the linker can be any linker, including a polynucleotide linker or a non-nucleotide linker.
- the linker can comprise any sequence of one or more ribonucleotides.
- the tandem synthesis of RNA can be readily adapted to both multiwell/multiplate synthesis platforms as well as large scale synthesis platforms employing batch reactors, synthesis columns, and the like.
- the oligoribonucleotide can be assembled from two distinct single-stranded molecules, wherein one strand includes the sense strand and the other includes the antisense strand of the RNA.
- each strand can be synthesized separately and joined together by hybridization or ligation following synthesis and/or deprotection.
- Either the sense or the antisense strand can contain additional nucleotides that are not complementary to one another and do not form a double stranded RNA molecule.
- the oligoribonucleotide can be synthesized as a single continuous fragment, where the self- complementary sense and antisense regions hybridize to form an RNA duplex having a hairpin or panhandle secondary structure.
- An oligoribonucleotide can comprise a duplex having two complementary strands that form a double-stranded region with least one modified nucleotide in the double-stranded region.
- the modified nucleotide may be on one strand or both. If the modified nucleotide is present on both strands, it may be in the same or different positions on each strand.
- modified nucleotides suitable for use in the present invention include, but are not limited to, ribonucleotides having a 2'-0-methyl (2'OMe), 2'-deoxy-2'-fluoro (2'F), 2'-deoxy, 5-C-methyl, 2'-0-(2-methoxyethyl) (MOE), 4'-thio, 2'-amino, or 2'-C-allyl group.
- Modified nucleotides having a conformation such as those described in, for example in Sanger ( Principles of Nucleic Acid Structure, Springer-Verlag Ed., 1984), are also suitable for use in oligoribonucleotides.
- LNA nucleotides include, without limitation: locked nucleic acid (LNA) nucleotides, G-clamp nucleotides, or nucleotide base analogs.
- LNA nucleotides include but need not be limited to 2'-0, 4'-C-methylene-(D-ribofuranosyl)nucleotides), 2'-0-(2-methoxyethyl) (MOE) nucleotides, 2'-methyl-thio-ethyl nucleotides, 2'-deoxy-2'-fluoro (2'F) nucleotides, 2'-deoxy-2'- chloro (20) nucleotides, and 2'-azido nucleotides.
- MOE 2-methoxyethyl
- a G-clamp nucleotide refers to a modified cytosine analog wherein the modifications confer the ability to hydrogen bond both Watson-Crick and Hoogsteen faces of a complementary guanine nucleotide within a duplex (Lin et ai, J Am Chem Soc, 120:8531 -8532, 1998).
- Nucleotide base analogs include for example, C-phenyl, C- naphthyl, other aromatic derivatives, inosine, azole carboxamides, and nitroazole derivatives such as 3-nitropyrrole, 4-nitroindole, 5-nitroindole, and 6-nitroindole (Loakes, Nucl Acids Res, 29:2437-2447, 2001 ).
- An oligoribonucleotide can comprise one or more chemical modifications such as terminal cap moieties, phosphate backbone modifications, and the like.
- classes of terminal cap moieties include, without limitation, inverted deoxy abasic residues, glyceryl modifications, 4', 5'- methylene nucleotides, l -(P-D-erythrofuranosyl) nucleotides, 4'-thio nucleotides, carbocyclic nucleotides, 1 ,5-anhydrohexitol nucleotides, L-nucleotides, a- nucleotides, modified base nucleotides, threo pentofuranosyl nucleotides, acyclic 3',4'-seco nucleotides, acyclic 3,4-dihydroxybutyl nucleotides, acyclic 3,5-dihydroxypentyl nucleotides, 3'- 3'-
- Non-limiting examples of phosphate backbone modifications include phosphorothioate, phosphorodithioate, methylphosphonate, phosphotriester, morpholino, amidate, carbamate, carboxymethyl, acetamidate, polyamide, sulfonate, sulfonamide, sulfamate, formacetal, thioformacetal, and alkylsilyl substitutions (see, e.g., Hunziker et at., Modern Synthetic Methods, VCH, 331 -417, 1995; Mesmaeker et al., Antisense Research, ACS, 24-39, 1994). Such chemical modifications can occur at the 5'-end and/or 3'-end of the sense strand, antisense strand, or both strands of the oligoribonu
- the sense and/or antisense strand of an oligoribonucleotide may comprise a 3'-terminal overhang having 1 to 4 or more 2'-deoxyribonucleotides and/or any combination of modified and unmodified nucleotides. Additional examples of modified nucleotides and types of chemical modifications that can be introduced into the modified oligoribonucleotides of the present invention are described, e.g., in Patent No. GB 2,397,818 B and U.S. Patent Publications No. 2004/0192626 and 2005/0282188.
- An oligoribonucleotide may comprise one or more non-nucleotides in one or both strands of the siRNA.
- a non-nucleotide can be any subunit, functional group, or other molecular entity capable of being incorporated into a nucleic acid chain in the place of one or more nucleotide units that is not or does not comprise a commonly recognized nucleotide base such as adenosine, guanine, cytosine, uracil, or thymine, such as a sugar or phosphate.
- Chemical modification of the disclosed oligoribonucleotides may also comprise attaching a conjugate to the oligoribonucleotide molecule.
- the conjugate can be attached at the 5'- and/or the 3'- end of the sense and/or the antisense strand of the oligoribonucleotide via a covalent attachment such as a nucleic acid or non-nucleic acid linker.
- the conjugate can also be attached to the oligoribonucleotide through a carbamate group or other linking group (see, e.g., U.S. Patent Publications No. 2005/0074771 , 2005/0043219, and 2005/0158727).
- a conjugate may be added to the oligoribonucleotide for any of a number of purposes.
- the conjugate may be a molecular entity that facilitates the delivery of the oligoribonucleotide into a cell or the conjugate a molecule that comprises a drug or label.
- conjugate molecules suitable for attachment to the disclosed oligoribonucleotides include, without limitation, steroids such as cholesterol, glycols such as polyethylene glycol (PEG), human serum albumin (FISA), fatty acids, carotenoids, terpenes, bile acids, folates (e.g., folic acid, folate analogs and derivatives thereof), sugars ⁇ e.g., galactose, galactosamine, N-acetyl galactosamine, glucose, mannose, fructose, fucose, etc.), phospholipids, peptides, ligands for cellular receptors capable of mediating cellular uptake, and combinations thereof (see, e.g., U.S.
- Other examples include the lipophilic moiety, vitamin, polymer, peptide, protein, nucleic acid, small molecule, oligosaccharide, carbohydrate cluster, intercalator, minor groove binder, cleaving agent, and cross- linking agent conjugate molecules described in U.S. Patent Publication Nos. 200501 19470 and 20050107325.
- conjugate molecules include the 2'-0-alkyl amine, 2'-0-alkoxyalkyl amine, polyamine, C5- cationic modified pyrimidine, cationic peptide, guanidinium group, amidininium group, cationic amino acid conjugate molecules described in U.S. Patent Publication No. 2005/0153337. Additional examples of conjugate molecules include a hydrophobic group, a membrane active compound, a cell penetrating compound, a cell targeting signal, an interaction modifier, or a steric stabilizer as described in U.S. Patent Publication No. 2004/0167090. Further examples include the conjugate molecules described in U.S. Patent Publication No. 2005/0239739.
- the type of conjugate used and the extent of conjugation to the disclosed oligoribonucleotides can be evaluated for improved pharmacokinetic profiles, bioavailability, and/or stability of the oligoribonucleotide while retaining activity.
- one skilled in the art can screen oligoribonucleotides having various conjugates attached thereto to identify oligonucleotide conjugates having improved properties using any of a variety of well-known in vitro cell culture or in vivo animal models.
- the therapeutic compounds provided herein can be formulated as pharmaceutical compositions and administered to a mammalian host, such as a human patient in a variety of forms adapted to the chosen route of administration, i.e., orally or parenterally, by intravenous, intramuscular, topical or subcutaneous routes.
- the therapeutic compounds provided herein can be formulated as an adjuvant in a cancer vaccine composition.
- a cancer vaccine is a biological preparation that improves immunity to a particular cancerous disease.
- Vaccine compositions can affect the course of a cancerous disease by causing an effect on cells of the adaptive immune response, namely, B cells and/or T cells.
- the effect of vaccines can include, for example, induction of cell-mediated immunity or alteration of the response of a T cell to its antigen.
- a vaccine typically contains an agent (e.g., immunogen) that stimulates the body's immune system to recognize the agent as foreign, destroy it, and“remember” it, so that the immune system can more easily recognize and destroy the agent at subsequent encounters.
- a successful immune response is characterized by, e.g., eradication of pathogens, tissue repair, eradication of tumors, and/or short and long term immune memory.
- the agent can include molecules derived from a cancerous disease-causing pathogen or can be inactivated cancer cells, tumor cell lysates, or tumor-specific antigens.
- Vaccines can be prophylactic or therapeutic.
- a tumor (i.e. cancer) antigen is presented on the surface of cancer cells and may be specific, associated, or over-expressed on such cancer cells.
- Tumor antigens can be obtained by conventional techniques, such as by preparation of tumor cell lysates by repeatedly freezing and thawing tumor cells/tissues obtained from either fresh tumor biopsy tissues or from tumor cells generated in vitro by tissue culture.
- the tumor lysate can be obtained by centrifugation and harvesting the supernatant fluid.
- the tumor cell lysates can be used immediately or frozen and stored until ready for use.
- the tumor antigen can be used in a purified form or in partially purified or unpurified form as cell lysate.
- the tumor antigen may be expressed by recombinant DNA techniques in any of a wide variety of expression systems.
- a tumor antigen is derived from tumors found in melanoma, skin cancer, prostate cancer, lung cancer, pancreatic cancer, or breast cancer.
- a tumor antigen includes a tumor cell lysate.
- the tumor antigen is included in a population of cells including antigen presenting cells (APC).
- APC include cells that express MHC Class I and/or Class II molecules that present antigens to T cells. Examples of APCs include, e.g., professional or non-professional antigen processing and presenting cells.
- APC examples include dendritic cells, B cells, spleen cells, lymph node cells, bone-marrow derived cells, monocytes, macrophages, or non-fractionated peripheral blood mononuclear cells (PMBC).
- PMBC peripheral blood mononuclear cells
- hematopoietic APC examples include dendritic cells, B cells, and macrophages.
- a vaccine often contains, or is administered with, an adjuvant.
- a vaccine adjuvant is an agent that stimulates the immune system and increases the immune system's response to a vaccine.
- RIG-1 agonists of the disclosure can increase immunogenicity of a vaccine for an infectious disease or cancer.
- RIG-1 agonists can activate interferon- Y (IFN-g) producing type 1 T helper cells (Th1 ) and cytotoxic T lymphocytes (CTLs).
- the vaccine is a cancer vaccine.
- the cancer vaccine can include a tumor antigen against which an immune response is desired and a RIG-I agonist of the present disclosure.
- the tumor antigen and the adjuvant are formulated together. In particular embodiments, the tumor antigen and the adjuvant are not formulated together.
- a RIG-I agonist functioning as an adjuvant may be formulated with buffers, carriers, preservatives, and/or excipients as described below.
- a RIG-I agonist may also be delivered with other PAMPs such as CpG, lipopolysaccharide (LPS), flagellin, or monophosphoryl lipid A (MPLA).
- PAMPs such as CpG, lipopolysaccharide (LPS), flagellin, or monophosphoryl lipid A (MPLA).
- An adjuvant including a RIG-I agonist can also include a pharmaceutically acceptable excipient, and optionally other adjuvant ingredients.
- the adjuvant may include mineral oil, certain bacterial toxins, aluminum salts such as aluminum hydroxide and aluminum phosphate, squalene, virosomes, mineral oil in water emulsions (e.g., MF59, AS3, and montanide), CpG, LPS, MPLA, QS21 or AS02, flagellin, peptidoglycans, and/or whole killed or otherwise inactivated bacterial pathogens.
- An adjuvant may also include agents that help stabilize the antigen and/or the RNA component, e.g., RNAse inhibitors.
- An oligoribonucleotide may be incorporated into a composition including a pharmaceutically acceptable carrier or transfection reagent, including the oligoribonucleotides described herein.
- the carrier system may be a lipid-based carrier system such as a stabilized nucleic acid-lipid particle (e.g., SNALP or SPLP), cationic lipid or liposome nucleic acid complexes (i.e., lipoplexes), a liposome, a micelle, a virosome, or a mixture thereof.
- the carrier system is a polymer-based carrier system such as a cationic polymer-nucleic acid complex (i.e., polyplex).
- the carrier system is a cyclodextrin-based carrier system such as a cyclodextrin polymer-nucleic acid complex (see US Patent Publication 2007/0218122).
- the carrier system is a protein-based carrier system such as a cationic peptide-nucleic acid complex.
- An oligoribonucleotide molecule may also be delivered as naked RNA.
- a pharmaceutical composition can be any combination of active and/or inert materials that can be administered to a subject for the purpose of treating a disease.
- a pharmaceutically acceptable carrier/vehicle can be any material or molecular entity that facilitates the administration or other delivery of the pharmaceutical composition.
- the nature of the carrier will depend on the particular mode of administration being employed.
- parenteral formulations usually comprise injectable fluids that include pharmaceutically and physiologically acceptable fluids such as water, physiological saline, balanced salt solutions, aqueous dextrose, glycerol or the like as a vehicle.
- Exemplary generally used pharmaceutically acceptable carriers include any and all bulking agents or fillers, solvents or co-solvents, dispersion media, coatings, surfactants, antioxidants (e.g., ascorbic acid, methionine, vitamin E), preservatives, isotonic agents, absorption delaying agents, salts, stabilizers, buffering agents, gels, binders, disintegration agents, and/or lubricants.
- bulking agents or fillers include any and all bulking agents or fillers, solvents or co-solvents, dispersion media, coatings, surfactants, antioxidants (e.g., ascorbic acid, methionine, vitamin E), preservatives, isotonic agents, absorption delaying agents, salts, stabilizers, buffering agents, gels, binders, disintegration agents, and/or lubricants.
- Exemplary buffering agents include citrate buffers, succinate buffers, tartrate buffers, fumarate buffers, gluconate buffers, oxalate buffers, lactate buffers, acetate buffers, phosphate buffers, histidine buffers and trimethylamine salts.
- Exemplary preservatives include phenol, benzyl alcohol, meta-cresol, methyl paraben, propyl paraben, octadecyldimethylbenzyl ammonium chloride, benzalkonium halides, hexamethonium chloride, alkyl parabens such as methyl or propyl paraben, catechol, resorcinol, cyclohexanol and 3- pentanol.
- Exemplary isotonic agents include polyhydric sugar alcohols including trihydric or higher sugar alcohols, such as glycerin, erythritol, arabitol, xylitol, sorbitol and mannitol.
- compositions can be made as aqueous solutions, such as in buffers such as Flanks' solution, Ringer's solution, or physiological saline.
- the solutions can contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
- the composition can be in lyophilized and/or powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
- compositions can include liposomes.
- Liposomes are self assembling phospholipid bilayer structures that can be prepared from natural or synthetic phospholipid sources. These vesicles can encapsulate water soluble molecules in the aqueous volume while water insoluble molecules can be embedded in the hydrophobic region of the lipid bilayer.
- the simplest and the most widely used method for preparing liposomes is the thin lipid film hydration method introduced by Bangham et at. (J Mol Biol, 13:238, 1965).
- the constituents of a liposomal delivery system are the primary determinants of the preparation method to be employed.
- hydrophobic molecules can be included during the lipid film formation process (passive loading), whereas water soluble molecules can be introduced during the hydration step (passive loading) or incorporated later by active loading procedures using ion gradients.
- the phospholipid backbone of the liposomes includes saturated or unsaturated phospholipids with acyl chain length of 14 to 20 carbons.
- Surface modification by hydrophilic polymers is a commonly used method in liposomal delivery systems. The main goals of surface modification are prevention of particle aggregation and reduction of the capture of the liposomes by cells of the reticuloendothelial system.
- polyethylene ethylene glycol (PEG) molecules of various chain lengths can be used to provide a protective shield over the phospholipid bilayer.
- PEG is a linear polyether diol that has a chemically inert backbone and hydroxyl groups available for derivatization.
- PEG derivatives that are covalently bound to phospholipids, functional groups, proteins, and even fluorescent probes.
- the liposomes contain at least one metal ion donor, such as MnC and/or MgC ; for instance, specific liposome embodiments contain 1 mM MnC and/or 10 mM MgCh.
- the therapeutic compounds described herein may be systemically administered, e.g., orally, in combination with a pharmaceutically acceptable vehicle such as an inert diluent or an assimilable, edible carrier. They may be enclosed in hard or soft shell gelatin capsules, may be compressed into tablets, or may be incorporated directly with the food of the patient's diet.
- a pharmaceutically acceptable vehicle such as an inert diluent or an assimilable, edible carrier. They may be enclosed in hard or soft shell gelatin capsules, may be compressed into tablets, or may be incorporated directly with the food of the patient's diet.
- the active compound may be combined with one or more excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like.
- Such compositions and preparations should contain at least 0.1% of active compound.
- the percentage of the compositions and preparations may, of course, be varied and may conveniently be between
- the tablets, troches, pills, capsules, and the like may also contain the following: binders such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, fructose, lactose or aspartame or a flavoring agent such as peppermint, oil of wintergreen, or cherry flavoring may be added.
- a liquid carrier such as a vegetable oil or a polyethylene glycol.
- any material used in preparing any unit dosage form should be pharmaceutically acceptable and substantially non-toxic in the amounts employed.
- the active compound may be incorporated into sustained-release preparations and devices.
- the active compound may also be administered intravenously or intraperitoneally by infusion or injection.
- Solutions of the active compound or its salts can be prepared in water, optionally mixed with a nontoxic surfactant.
- Dispersions can also be prepared in glycerol, liquid polyethylene glycols, triacetin, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
- the pharmaceutical dosage forms suitable for injection or infusion can include sterile aqueous solutions or dispersions or sterile powders comprising the active ingredient which are adapted for the extemporaneous preparation of sterile injectable or infusible solutions or dispersions, optionally encapsulated in liposomes.
- the liquid carrier or vehicle can be a solvent or liquid dispersion medium comprising, for example, water, ethanol, a polyol (for example, glycerol, propylene glycol, liquid polyethylene glycols, and the like), vegetable oils, nontoxic glyceryl esters, and suitable mixtures thereof.
- the proper fluidity can be maintained, for example, by the formation of liposomes, by the maintenance of the required particle size in the case of dispersions or by the use of surfactants.
- the prevention of the action of (contaminating) microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, buffers or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.
- Sterile injectable solutions are prepared by incorporating the active compound in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filter sterilization.
- the preferred methods of preparation are vacuum drying and the freeze-drying techniques, which yield a powder of the active ingredient plus any additional desired ingredient present in the previously sterile-filtered solutions.
- the present compounds may be applied in pure form, i.e., when they are liquids. However, it will generally be desirable to administer them to the skin as compositions or formulations, in combination with a dermatologically acceptable carrier, which may be a solid or a liquid.
- Useful solid carriers include finely divided solids such as talc, clay, microcrystalline cellulose, silica, alumina and the like.
- Useful liquid carriers include water, alcohols or glycols or water- alcohol/glycol blends, in which the present compounds can be dissolved or dispersed at effective levels, optionally with the aid of non-toxic surfactants.
- Adjuvants such as fragrances and additional antimicrobial agents can be added to optimize the properties for a given use.
- the resultant liquid compositions can be applied from absorbent pads, used to impregnate bandages and other dressings, or sprayed onto the affected area using pump-type or aerosol sprayers.
- Thickeners such as synthetic polymers, fatty acids, fatty acid salts and esters, fatty alcohols, modified celluloses or modified mineral materials can also be employed with liquid carriers to form spreadable pastes, gels, ointments, soaps, and the like, for application directly to the skin of the user.
- the formulation can further include a penetration enhancer.
- the penetration enhancer can be a skin penetration enhancer.
- a skin penetration enhancer is a molecule that promotes the diffusion of polypeptides through the skin.
- a variety of compounds have been shown to be effective skin penetration enhancers. See, Percutaneous Penetration Enhancers (Smith et al., CRC Press, Inc., Boca Raton, F.L. 1995).
- Exemplary skin penetration enhancers include sulfoxides such as dimethylsulfoxide (DMSO) and decylmethylsulfoxide (CioMSO; DeMS); ethers such as diethylene glycol monoethyl ether and diethylene glycol monomethyl ether; surfactants such as sodium laurate, sodium lauryl sulfate, cetyltrimethylammonium bromide, benzalkonium chloride, Poloxamer (231 , 182, 184), Tween (20, 40, 60, 80), and lecithin; the 1 - substituted azacycloheptan-2-ones, particularly l-n-dodecylcyclazacycloheptan-2-one; alcohols such as ethanol, propanol, octanol, benzyl alcohol, etc.; fatty acids such as lauric acid, oleic acid and valeric acid; fatty acid esters such as isopropyl myristate, isopropyl
- galactomannan gums such as guar gum or locust bean gum
- polysaccharide gum such as agar gum, alginate, carob gum, carrageen gum, ghatti gum, guar gum, karaya gum, kadaya gum, locust bean gum, rhamsan gum, xanthan gum, or a mixture thereof
- cellulose derivatives such as ethyl cellulose, methyl cellulose, hyrdoxypropyl cellulose, and mixtures thereof.
- the compositions can be in the form of, e.g., gels, ointments, pastes, lotions, creams, sprays, foams, liquids, aerosol, suspension, emulsion, hydrogels, or powders. It is particularly contemplated that the compositions may be formulated as shampoos, soaps, body washes, and the like.
- a gel is a substantially dilute cross-linked system, which exhibits no flow when in the steady-state. Most gels are liquid; however, they behave more like solids due to the three- dimensional cross-linked network within the liquid. Gels can have properties ranging from soft and weak to hard and tough.
- An ointment is a homogeneous, viscous, semi-solid preparation, most commonly a greasy, thick oil (oil 80% - water 20%) with a high viscosity.
- Ointments have a water number, which is the maximum quantity of water that 100 g of a base can contain at 20°C.
- a paste includes three agents - oil, water, and powder, one of which includes a therapeutic agent. Pastes can be an ointment in which a powder is suspended.
- a lotion also includes oil, water, and powder, but can have additional components (e.g., alcohol to hold the emulsion together) and often has a lower viscosity than a paste.
- a cream is an emulsion of oil and water in equal proportions. Creams are thicker than lotions and maintain their shape when removed from a container.
- Topical formulations disclosed herein can include components, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc, titanium oxide, and zinc oxide, or mixtures thereof.
- topical formulations may include thickening agents, surfactants, organic solvents, and/or tonicity modifiers.
- the topical formulations include one or more of retinol, tretinoin, vitamin A, vitamin C, hydroquinones, alpha hydroxy acids (AHAs), and/or beta hydroxy acids (BHAs).
- Examples of useful dermatological compositions which can be used to deliver the therapeutic compounds provided herein to the skin are known to the art; for example, see Jacquet et al. (U.S. Pat. No. 4,608,392), Geria (U.S. Pat. No. 4,992,478), Smith et al. (U.S. Pat. No. 4,559,157) and Wortzman (U.S. Pat. No. 4,820,508).
- the compositions may be in the form of emulsions.
- An emulsion is a dispersed system containing at least two immiscible liquid phases, one of which is dispersed in the form of small droplets throughout the other, and an emulsifying agent in order to improve the stability of the system.
- Microemulsions are stable systems having droplets which are significantly smaller, being 500 nm or smaller in diameter on the average.
- microemulsions are translucent, and routinely transparent, in appearance.
- Microemulsions are an extraordinary type of emulsion that form spontaneously. Products having these systems are valued for their stability and small particle size, thus affording microemulsions a special consideration in the marketplace.
- compositions can also be depot preparations. Such long acting compositions may be administered by, for example, implantation (for example, subcutaneously).
- compounds can be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as sparingly soluble salts.
- suitable polymeric or hydrophobic materials for example as an emulsion in an acceptable oil
- ion exchange resins for example as sparingly soluble derivatives, for example, as sparingly soluble salts.
- such preparations may include one or more injectable fillers.
- compositions can be delivered using sustained-release systems, such as semipermeable matrices of solid polymers containing at least one compound disclosed herein.
- sustained-release systems such as semipermeable matrices of solid polymers containing at least one compound disclosed herein.
- sustained-release materials have been established and are well known by those of ordinary skill in the art.
- Sustained-release capsules may, depending on their chemical nature, release the compound following administration for a few weeks up to over 100 days.
- Useful dosages of the therapeutic compounds provided herein can be determined by comparing their in vitro activity, and in vivo activity in animal models. Methods for the extrapolation of effective dosages in mice, and other animals, to humans are known to the art; for example, see U.S. Pat. No. 4,938,949.
- the amount of the compound useful or required for use in treatment will vary not only with the particular compound selected but also with the route of administration, the nature of the condition being treated and the age and condition of the patient and will be ultimately at the discretion of the attendant physician or clinician.
- the desired dose may conveniently be presented in a single dose or as divided doses administered at appropriate intervals, for example, as two, three, four or more sub-doses per day.
- the sub-dose itself may be further divided, e.g., into a number of discrete loosely spaced administrations.
- Methods disclosed herein include treating subjects (humans, veterinary animals (dogs, cats, reptiles, birds, etc.) livestock (horses, cattle, goats, pigs, chickens, etc.) and research animals (monkeys, rats, mice, fish, etc.) with one or more therapeutic compositions disclosed herein. Treating subjects includes delivering one or more therapeutically effective amount(s). Therapeutically effective amounts include those that provide effective amounts, prophylactic treatments and/or therapeutic treatments.
- compositions to which the pharmaceutical composition may be properly administered include subjects known to have cancer or any neoplastic disease (identified through, for example, a molecular diagnostic test or clinical diagnosis), subjects having a predisposition to developing cancer, or subjects displaying one or more symptoms of cancer.
- Cancer is characterized by deregulated cell growth and cell division.
- cancers include acoustic neuroma, adenocarcinoma, astrocytoma, basal cell cancer, bile duct cancer, bladder cancer, brain cancer, breast cancer, bronchogenic cancer, central nervous system cancer, cervical cancer, colon cancer, lung cancer, prostate cancer, ovarian cancer, pancreatic cancer, thyroid cancer, and leukemia.
- cancers include acoustic neuroma, adenocarcinoma, astrocytoma, basal cell cancer, bile duct cancer, bladder cancer, brain cancer, breast cancer, bronchogenic cancer, central nervous system cancer, cervical cancer, chondrosarcoma, choriocarcinoma, chronic lymphocytic leukemia, colon cancer, craniopharyngioma, ependymoma, Ewing's tumor, fibrosarcoma, glandular cancer, glioma, hairy cell leukemia, hemangioblastoma, hepatocellular carcinoma, hepatoma, kidney cancer, leiomyosarcoma, liver cancer, liposarcoma, lung cancer, melanoma, medulloblastoma, medullary cancer, medullary thyroid cancer, menangioma, mesothelioma, multiple myeloma (MM), myxosarcoma, neuroblastom
- certain types of cancers may be less susceptible to the therapeutic treatments described herein.
- RIG-1 agonist mediated cancer cell death is mediated in part by IFN release
- cells that have a poor IFN response may be more resistant to cell death induction.
- the other (IFN-independent) mechanisms described herein would nevertheless become activated to kill these cells.
- some tumor cells may be resistant to uptake of the therapeutic RNA oligonucleotide (e.g., M8), such that the amount delivered to the cells might be limited, which would then limit cell death.
- This issue can be corrected by delivering the therapeutic RIG-1 agonist RNA as a formulation, such as a nanoparticle that 'protects' the RNA.
- tumor cells that are rich in RNAase activity could destroy the therapeutic RNA oligonucleotide before it has an opportunity to bind RIG-1 and activate the cell death cascade.
- Cancer (sometimes referred to medically as malignant neoplasm) refers to a class of diseases in which a group of cells display uncontrolled growth (division beyond the normal limits), invasion (intrusion on and destruction of adjacent tissues), and sometimes metastasis.“Metastasis” refers to the spread of cancer cells from their original site of proliferation to another part of the body.
- metastasis refers to the spread of cancer cells from their original site of proliferation to another part of the body.
- metastasis is a very complex process and depends on detachment of malignant cells from the primary tumor, invasion of the extracellular matrix, penetration of the endothelial basement membranes to enter the body cavity and vessels, and then, after being transported by the blood or lymph, infiltration of target organs.
- the growth of a new tumor i.e. a secondary tumor or metastatic tumor, at the target site depends on angiogenesis. Tumor metastasis often occurs even after the removal of the primary tumor because tumor cells or components may remain and develop metastatic potential.
- Treating subjects includes delivering therapeutically effective amounts.
- Therapeutically effective amounts include those that provide effective amounts, prophylactic treatments and/or therapeutic treatments.
- an“effective amount” is the amount of active agent(s) or composition(s) necessary to result in a desired physiological change in vivoor in vitro. Effective amounts are often administered for research purposes. In particular embodiments, effective amounts disclosed herein can cause a statistically- significant effect in an animal model or in vitro assay relevant to the assessment of: number of cancer cells; number of tumors, size of tumors and/or total tumor burden; level or speed of metastasis; frequency of or time to onset of cancer; and risk of death (hazard ratios) and/or increase in survival in subjects exposed to a cancer-causing agent.
- A“prophylactic treatment” includes a treatment administered to a subject who does not display signs or symptoms of cancer, cancer relapse, or metastasis or displays only early signs or symptoms of cancer, cancer relapse, or metastasis such that treatment is administered for the purpose of diminishing, preventing, or decreasing the risk of developing cancer relapse or metastasis further.
- a prophylactic treatment functions as a preventative treatment against cancer, cancer relapse, or metastasis.
- prophylactic treatments prevent, reduce, or delay cancer, cancer relapse, or metastasis from a primary tumor site from occurring.
- a “therapeutic treatment” includes a treatment administered to a subject who displays symptoms or signs of cancer (initial, relapsed, or metastasis) and is administered to the subject for the purpose of diminishing or eliminating further signs or symptoms of cancer or metastasis.
- the therapeutic treatment can reduce, control, or eliminate the presence or activity of cancer or metastasis and/or reduce control or eliminate side effects of cancer or metastasis.
- therapeutic treatments prevent, reduce, or delay further cancer or metastasis from occurring.
- therapeutically effective amounts provide an anti-cancer effect, through providing an effective amount, a prophylactic treatment and/or a therapeutic treatment.
- an anti-cancer effect refers to a biological effect, which can be manifested by a decrease in tumor volume, a decrease in the number of cancer cells, a decrease in the number of metastases, an increase in life expectancy, and/or a decrease of various physiological symptoms associated with the cancerous condition.
- An anti-cancer effect can also be manifested by a decrease in recurrence or an increase in the time before recurrence.
- an anti-cancer effect includes death of cancerous cells in a subject in need thereof administered a RIG-I agonist of the present disclosure. Death of the cancerous cells can be indicated or measured in a number of ways. In particular embodiments, death of the cancerous cells is associated with an increase in expression of chemokines CCL2, CXCL1 , CXCL10, and/or IFNp in the cancerous cells. In particular embodiments, chemokines CCL2, CXCL1 , CXCL10, and/or IFNp in the cancerous cells increase by 2 fold, 3 fold, 4 fold, 5 fold, or more, as compared to the corresponding chemokine expression in cancerous cells in the subject prior to the administering.
- death of the cancerous cells is associated with an increase in surface exposure of calreticulin on the cancerous cells.
- the percentage of cancerous cells that express calreticulin increases 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, or more as compared to the percentage of cancerous cells that express calreticulin in the subject prior to the administering.
- death of the cancerous cells is associated with an increase in secretion of High Mobility Group Box 1 (HMGB1 ) from the cancerous cells.
- HMGB1 High Mobility Group Box 1
- HMGB1 secretion from the cancerous cells is increased 1.5 fold, 2 fold, 3 fold, 4 fold, 5 fold, or more, as compared to secretion of HMGB1 from cancerous cells in the subject prior to the administering.
- death of the cancerous cells is associated with an increase in release of ATP.
- ATP release from the cancerous cells increases 5 fold, 10 fold, 20 fold, 50 fold, 100 fold, 1000 fold, or more, as compared to ATP release from cancerous cells in the subject prior to the administering.
- an anti-cancer effect includes immune reactivation in a subject in need thereof administered a RIG-I agonist of the present disclosure.
- Immune reactivation can be indicated or measured in a number of ways.
- immune reactivation is associated with an increase in NK activating ligands on the cancerous cells.
- the NK activating ligands include MICA, MICB, ULBP1 , ULBP3, Nectin-2, PVR, and/or B7-H6.
- the amount of NK activating ligands on the cancerous cells increase 1 .1 fold, 1.2 fold, 1 .3 fold, 1 .4 fold, 1 .5 fold, 1 .6 fold, 1 .7 fold, 1.8 fold, 1 .9 fold, 2 fold, or more as compared to the amount of corresponding NK activating ligands on cancerous cells in the subject prior to the administering.
- immune reactivation is associated with induction of expression of an NK inhibiting marker on the cancerous cells.
- the NK inhibiting marker is HLA-ABC.
- NK inhibiting marker expression is induced 2 fold, 3 fold, 4 fold, 5 fold, 6 fold, or more, as compared to NK inhibiting marker expression in cancerous cells in the subject prior to the administering.
- immune reactivation is associated with induction of antigen processing machinery (APM) genes in the cancerous cells.
- APM antigen processing machinery
- the APM genes include: immunoproteasome subunits PSMB8, PSMB9, and PSMB10; transporters associated with antigen processing TAP1 and TAP2; and the endoplasmic reticulum chaperone Tapasin (TAPBP).
- APM genes are induced 15 fold, 20 fold, 30 fold, 40 fold, 50 fold, 60 fold, 70 fold, 80 fold, 90 fold, 100 fold, 200 fold, 300 fold, 400 fold, 500 fold, or more, as compared to the corresponding APM gene levels in cancerous cells in the subject prior to the administering.
- immune reactivation is associated with an increase in expression of CD80, CD86, and/or HLA-DR on dendritic cells from the subject.
- expression of CD80, CD86, and/or HLA-DR on dendritic cells increase 2 fold, 3 fold, 4 fold, 5 fold, or more, as compared to the corresponding markers on dendritic cells from the subject prior to the administering.
- immune reactivation is associated with an increase in IL-12 expression in dendritic cells from the subject.
- IL-12 expression increases 5 fold, 10 fold, 15 fold, 20 fold, or more, as compared to IL- 12 expression in dendritic cells from the subject prior to the administering.
- methods of the disclosure include using a RIG-I agonist of the disclosure as an adjuvant for a cancer vaccine to stimulate an immune response against a tumor antigen in a subject at risk of having or having a cancer comprising the tumor antigen.
- Effectiveness of a RIG-I agonist as an adjuvant can be measured by a number of parameters including: tumor growth; early and late apoptosis of tumor cells by T cells using annexin V-FITC and propidium idodide, respectively; effector function of T cells isolated from tumors can be assessed for activation, proliferation, and lytic function by examining the levels of ICOS, Ki-67, and Granzyme B, respectively; tumor infiltrating cells can be identified and quantified by flow cytometry as follows: 1 ) cells of the innate immune compartment including NK cells (NK1 1 hi , CD3 NK1 1 hi , or CD3 DX5+) and NKT cells (NK1 .1 hi (or DX5 + )CD3e hi CD1 d hi CD60 hi ), and 2) cells of the adaptive compartment including CD8+ T cells, CD8+ subpopulations (IFNg + Th1 , IL4 + Th2, IL-17 + , Th17), CD4+ T cells,
- methods to stimulate an immune response against a tumor antigen in a subject at risk of having or having a cancer comprising the tumor antigen can further include administering a second anti-cancer agent to the subject.
- the second anti cancer agent is low dose chemotherapy.
- the second anti-cancer agent is an immune checkpoint inhibitor drug that blocks an immune checkpoint protein selected from programmed cell death protein 1 (PD-1 ), programmed death-ligand 1 (PD-L1 ), and cytotoxic T- lymphocyte-associated protein 4 (CTLA-4).
- A“tumor” is a swelling or lesion formed by an abnormal growth of cells (called neoplastic cells or tumor cells).
- A“tumor cell” is an abnormal cell that divides by a rapid, uncontrolled cellular proliferation and continues to divide after the stimuli that initiated the new division cease. Tumors show partial or complete lack of structural organization and functional coordination with the normal tissue, and usually form a distinct mass of tissue, which may be either benign, pre-malignant or malignant.
- therapeutically effective amounts can be initially estimated based on results from in vitro assays and/or animal model studies.
- the actual dose amount administered to a particular subject can be determined by a physician, veterinarian or researcher taking into account parameters such as physical and physiological factors including target, body weight, severity of cancer, type of cancer, stage of cancer, previous or concurrent therapeutic interventions, idiopathy of the subject and route of administration.
- a therapeutically effective amount or concentration of a compound such as the disclosed oligoribonucleotides may be any amount of a composition that alone, or together with one or more additional therapeutic agents (such as another anti-cancer agent), is sufficient to achieve a desired effect in a subject.
- the effective amount of the agent will be dependent on several factors, including, but not limited to, the subject being treated and the manner of administration of the therapeutic composition.
- a therapeutically effective amount or concentration is one that is sufficient to prevent advancement, delay progression, or to cause regression of a disease, or which is capable of reducing symptoms caused by any disease, including cancer or any neoplasia.
- a desired effect is to reduce or inhibit one or more symptoms associated with cancer.
- the one or more symptoms do not have to be completely eliminated for the composition to be effective.
- a composition can decrease the sign or symptom by a desired amount, for example by at least 20%, at least 50%, at least 80%, at least 90%, at least 95%, at least 98%, or even at least 100%, as compared to the sign or symptom in the absence of the composition.
- a therapeutically effective amount of a pharmaceutical composition can be administered in a single dose, or in several doses, for example daily, during a course of treatment.
- the therapeutically effective amount can depend on the subject being treated, the severity and type of the condition being treated, and the manner of administration.
- a therapeutically effective amount of such agent can vary from about 100 pg -10 mg per kg body weight if administered intravenously.
- the actual dosages will vary according to factors such as the type of cancer to be treated and the particular status of the subject (for example, the subject’s age, size, fitness, extent of symptoms, susceptibility factors, and the like) time and route of administration, other drugs or treatments being administered concurrently, as well as the specific pharmacology of treatments for cancer for eliciting the desired activity or biological response in the subject. Dosage regimens can be adjusted to provide an optimum prophylactic or therapeutic response.
- Dosage can be varied by the attending clinician to maintain a desired concentration. Higher or lower concentrations can be selected based on the mode of delivery, for example, trans-epidermal, rectal, oral, pulmonary, intranasal delivery, intravenous or subcutaneous delivery.
- Suitable models in this regard include, for example, murine, rat, porcine, feline, non-human primate, and other accepted animal model subjects known in the art.
- effective dosages can be determined using in vitro models (for example, cell culture assays). Using such models, only ordinary calculations and adjustments are required to determine an appropriate concentration and dose to administer a therapeutically effective amount of the treatments for cancer treatment (for example, amounts that are effective to alleviate one or more symptoms of a cancer).
- a therapeutically effective amount is also one in which any toxic or detrimental side effects of the compound and/or other biologically active agent is outweighed in clinical terms by therapeutically beneficial effects.
- a non-limiting range for a therapeutically effective amount of treatments for cancer within the methods and formulations of the disclosure is about 0.0001 pg/kg body weight to about 10 mg/kg body weight per dose, such as about 0.0001 pg/kg body weight to about 0.001 pg/kg body weight per dose, about 0.001 pg/kg body weight to about 0.01 pg/kg body weight per dose, about 0.01 pg/kg body weight to about 0.1 pg/kg body weight per dose, about 0.1 pg/kg body weight to about 10 pg/kg body weight per dose, about 1 pg/kg body weight to about 100 pg/kg body weight per dose, about 100 pg/kg body weight to about 500 pg/kg body weight per dose, about 500 pg/kg body weight per dose to about 1000 pg/kg body
- the compound herein referred to as M8 was administered at a rate of 2-25 pg per mouse (the average weight of which was 0.01 kg). This is equivalent to 15.5 nM/kg - 77.5 nM/kg, which provides useful doses for treatment in other subjects, including human subjects.
- a dose can range from 0.1 to 5 pg or from 0.5 to 1 pg.
- a dose can include 1 pg, 5 pg, 10 pg, 15 pg, 20 pg, 25 pg, 30 pg, 35 pg, 40 pg, 45 pg, 50 pg, 55 pg, 60 pg, 65 pg, 70 pg, 75 pg, 80 pg, 85 pg, 90 pg, 95 pg, 100 pg, 150 pg, 200 pg, 250 pg, 350 pg, 400 pg, 450 pg, 500 pg, 550 pg, 600 pg, 650 pg, 700 pg, 750 pg, 800 pg, 850 pg, 900 pg, 950 pg, 1000 pg,
- a dose can include 1 mg, 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, 100 mg, 150 mg, 200 mg, 250 mg, 350 mg, 400 mg, 450 mg, 500 mg, 550 mg, 600 mg, 650 mg, 700 mg, 750 mg, 800 mg, 850 mg, 900 mg, 950 mg, 1000 mg, or more.
- doses can be administered QD or BID to a subject with, e.g., total daily doses of 1 .5 mg/kg, 3.0 mg/kg, or 4.0 mg/kg of a composition with up to 92-98% wt/v of the compounds disclosed herein.
- a therapeutic compound may be present from 0.1 wt. % to 10 wt. %, 0.1 wt. % to 9 wt. %, 0.1 wt. % to 8 wt. %, 0.1 wt. % to 7 wt. %, 0.1 wt. % to 6 wt. %, 0.1 wt. % to 5 wt. %, 0.1 wt. % to 4 wt. %, 0.1 wt. % to 3 wt. %, 0.1 wt. % to 2 wt. %, or 0.1 wt. % to 1 wt. %.
- weight percentages disclosed herein may be weight-to-weight or weight-to- volume percentages with respect to the total amount of the composition.
- Therapeutically effective amounts can be achieved by administering single or multiple doses during the course of a treatment regimen (e.g., hourly, every 2 hours, every 3 hours, every 4 hours, every 6 hours, every 9 hours, every 12 hours, every 18 hours, daily, every other day, every 3 days, every 4 days, every 5 days, every 6 days, weekly, every 2 weeks, every 3 weeks, or monthly).
- a treatment regimen e.g., hourly, every 2 hours, every 3 hours, every 4 hours, every 6 hours, every 9 hours, every 12 hours, every 18 hours, daily, every other day, every 3 days, every 4 days, every 5 days, every 6 days, weekly, every 2 weeks, every 3 weeks, or monthly.
- Administration of a pharmaceutical composition may be any method of providing or give a subject a pharmaceutical composition comprising the disclosed oligoribonucleotides, by any effective route.
- routes of administration include, but are not limited to, injection (such as subcutaneous, intramuscular, intradermal, intraperitoneal, and intravenous), oral, sublingual, rectal, transdermal, intranasal, vaginal and inhalation routes.
- administration of the therapeutic compound is by topical application, transdermal, percutaneous, or microneedle injection.
- Administration can also be, for example, parenteral, subcutaneous, intravenous, intramuscular, intraperitoneal, transdermal, oral, buccal, or ocular routes, or intravaginally, by inhalation, by depot injections, or by implants.
- therapeutic compositions are administered percutaneously, and the compound reaches epidermal and dermal layer through percutaneous absorption.
- the percutaneous application of the anhydrous composition does not result in systemic absorption.
- percutaneous delivery is aided by the use of ultrasound technology. The ultrasound energy is applied to percutaneous delivery composition over the tissue and assists the diffusion of the composition past the tissue. Also contemplated are delivery methods involving iontophoresis, electroporation, magnetophoresis, laser assisted peptide delivery, and so forth.
- compositions disclosed herein can be used in conjunction with other cancer treatments.
- the composition disclosed herein can be administered in combination with other active ingredients, for example, a gonadotropin-releasing hormone agonist or antagonist (e.g., Lupron, Zoladex (Goserelin), Degarelix, Ozarelix, ABT-620 (Elagolix), TAK-385 (Relugolix), EP-100 or KLH-2109); a phosphoinositide 3-kinase (PI3K) inhibitor, a TORC inhibitor, or a dual PI3K/TORC inhibitor (e.g., BEZ-235, BKM120, BGT226, BYL-719, GDC0068, GDC-0980, GDC0941 , GDC0032, MK-2206, OSI-027, CC-223, AZD8055, SAR245408, SAR245409, PF04691502, WYE125132, GSK2126458, GSK
- MET VEGFR, EGFR, MEK, SRC, AKT, RAF, FGFR, CDK4/6); Provenge, Prostvac, Ipilimumab, a PD-1 inhibitor; a taxane or tubulin inhibitor; an anti-STEAP-1 antibody; a heat shock protein 90 (HSP90) or heat shock protein 27 (HSP27) pathway modulator; an anti-androgen (e.g., bicalutamide); and/or immunotherapy.
- HSP90 heat shock protein 90
- HSP27 heat shock protein 27 pathway modulator
- an anti-androgen e.g., bicalutamide
- kits can include one or more containers including (containing) one or more or more compounds as described herein, optionally along with one or more agents for use in therapy. For instance, some kits will include an amount of at least one additional anti-cancer composition.
- a kit can include an immunization kit including a vaccine composition described herein (for instance, a cancer vaccine composition).
- a vaccine composition includes: a tumor antigen; and an adjuvant including at least one described RIG agonist of the disclosure.
- the tumor antigen and the adjuvant are in separate containers.
- the tumor antigen and the adjuvant are in the same container.
- any active component in a kit may be provided in premeasured dosages, though this is not required; and it is anticipated that certain kits will include more than one dose.
- Kits can also include a notice in the form prescribed by a governmental agency regulating the manufacture, use, or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use, or sale for human administration.
- the notice may state that the provided active ingredients can be administered to a subject.
- the kits can include further instructions for using the kit, for example, instructions regarding administration; proper disposal of related waste; and the like.
- the instructions can be in the form of printed instructions provided within the kit or the instructions can be printed on a portion of the kit itself. Instructions may be in the form of a sheet, pamphlet, brochure, CD-ROM, or computer-readable device, or can provide directions to instructions at a remote location, such as a website.
- kits can also include some or all of the necessary medical supplies needed to use the kit effectively, such as applicators, ampules, sponges, sterile adhesive strips, Chloraprep, gloves, and the like. Variations in contents of any of the kits described herein can be made.
- the instructions of the kit will direct use of the active ingredient(s) included in that kit to effectuate a clinical and/or therapeutic use described herein.
- a method of treating cancer in a subject in need thereof including: administering to the subject a therapeutically effective amount of a synthetic oligoribonucleotide including: a 5' end triphosphate group, and the sequence shown in M8 (SEQ ID NO: 13) or M5 (SEQ ID NO: 10), thereby treating the cancer in the subject.
- a method of treating cancer in a subject in need thereof including: administering to the subject a therapeutically effective amount of a synthetic oligoribonucleotide including: a 5' end triphosphate group, and the sequence shown in SEQ ID NO: 1 1 , SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, or SEQ ID NO: 17, thereby treating the cancer in the subject.
- a synthetic oligoribonucleotide including: a 5' end triphosphate group, and the sequence shown in SEQ ID NO: 1 1 , SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, or SEQ ID NO: 17, thereby treating the cancer in the subject.
- a method of inducing death of cancerous cells in a subject including: administering to the subject a therapeutically effective amount of a synthetic oligoribonucleotide including: a 5' end triphosphate group, and the sequence shown in M8 (SEQ ID NO: 13), r M5 (SEQ ID NO: 10), SEQ ID NO: 1 1 , SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, or SEQ ID NO: 17, thereby inducing death of cancerous cells in the subject.
- a synthetic oligoribonucleotide including: a 5' end triphosphate group, and the sequence shown in M8 (SEQ ID NO: 13), r M5 (SEQ ID NO: 10), SEQ ID NO: 1 1 , SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, or SEQ ID NO: 17, thereby inducing death of cancerous cells in the subject.
- cancerous cells include melanoma cells, adenocarcinoma cells, carcinoma cells, or metastatic cells.
- death of cancerous cells includes: an increase in expression of chemokines CCL2, CXCL1 , CXCL10, and/or IFNp in the cancerous cells; an increase in surface exposure of calreticulin on the cancerous cells; an increase in secretion of High Mobility Group Box 1 (HMGB1 ) from the cancerous cells; and/or an increase in release of ATP from the cancerous cells, as compared to the corresponding parameter in cancerous cells from the subject prior to the administering.
- chemokines CCL2, CXCL1 , CXCL10, and/or IFNp in the cancerous cells
- an increase in surface exposure of calreticulin on the cancerous cells an increase in secretion of High Mobility Group Box 1 (HMGB1 ) from the cancerous cells
- HMGB1 High Mobility Group Box 1
- the immune reactivation includes: an increase in NK activating ligands on the cancerous cells; induction of expression of an NK inhibiting marker on the cancerous cells; induction of antigen processing machinery (APM) genes in the cancerous cells; an increase in expression of CD80, CD86, and/or HLA-DR on dendritic cells from the subject; and/or an increase in IL-12 expression in dendritic cells from the subject, as compared to the corresponding parameter in cancerous cells or dendritic cells from the subject prior to the administering.
- APM antigen processing machinery
- the therapeutically effective amount includes at least 0.2 milligrams to at least 5 milligrams of the synthetic oligoribonucleotide per kilogram of the subject's body weight per week (0.2-5 mg/kg/wk).
- the therapeutically effective amount includes at least 0.5 milligrams to at least 2.5 milligrams of the synthetic oligoribonucleotide per kilogram of the subject's body weight per week (0.5-2.5 mg/kg/wk).
- a cancer vaccine composition including a tumor antigen; an adjuvant; and a pharmaceutically acceptable carrier,
- the adjuvant includes a synthetic oligoribonucleotide including: a 5' end triphosphate group, and the sequence shown in M8 (SEQ ID NO: 13), M5 (SEQ ID NO: 10), SEQ ID NO: 1 1 , SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, or SEQ ID NO: 17 25.
- the adjuvant further includes mineral oil, bacterial toxins, aluminum salts, squalene, virosomes, mineral oil in water emulsions, CpG, lipopolysaccharide (LPS), monophosphoryl lipid A (MPLA), QS21 or AS02, flagellin, peptidoglycans, inactivated bacterial pathogens, and/or RNAse inhibitors.
- a method for stimulating an immune response against a tumor antigen in a subject at risk of having or having a cancer including the tumor antigen including administering to the subject a therapeutically effective amount of the cancer vaccine composition of embodiment 24.
- a method of activating antigen presenting cells (APC) ex vivo including contacting the APC with the cancer vaccine composition of embodiment 24.
- Example 1 The following examples are illustrative of disclosed methods. In light of this disclosure, those of skill in the art will recognize that variations of these examples and other examples of the disclosed method would be possible without undue experimentation. At least some of the material described in Example 1 was published as Castiello et al. ⁇ Cancer Immunol. Immunother. 68(9) :1479-1492, August 28, 2019).
- Example 1 Sequence-optimized RIG-I agonist M8 induces immunogenic cell death of cancer cells and dendritic cell activation
- This Example demonstrates that activation of the cytosolic innate immune sensor RIG-I using a sequence-optimized RIG-I agonist M8 induces type-l-IFN/caspase 3-dependent cell death in cancer cells characterized by induction of multiple markers of immunogenic cell death (ICD). Also, M8 activates antigen processing machinery and mature dendritic cells to a pro-inflammatory phenotype.
- ICD immunogenic cell death
- RIG-I is a cytosolic RNA sensor that recognizes short 5' triphosphate RNA, commonly generated during virus infection. Upon activation, RIG-I initiates antiviral immunity, and in some circumstances, induces cell death. Because of this dual capacity, RIG-I has emerged as a promising target for cancer immunotherapy.
- M8 a sequence-optimized RIG-I agonist was identified for its ability to stimulate a robust innate immune response capable of blocking viral infection and functioning as an adjuvant in vaccination strategies of influenza antigens.
- M8 as an anti-cancer agent is further investigated by analyzing its ability to both induce cell death and activate the immune response.
- M8 treatment strongly activated caspase 3-dependent apoptosis.
- Apoptosis relied on an intrinsic NOXA and PUMA-driven pathway that was largely dependent on IFN- I signaling.
- cell death induced by M8 was characterized by the expression of the immunogenic cell death markers - calreticulin and HMGB1 - as well as high levels of CXCL10, a marker of inflammation.
- M8 cell death induced by M8 was characterized by the expression of the immunogenic cell death related DAMP (ICD-DAMP) - calreticulin, HMGB1 and ATP - as well as high levels of CCL2, CXCL1 , CXCL10, and IFNp, cytokine markers of ICD and inflammation.
- ICD-DAMP immunogenic cell death related DAMP
- M8 increased the levels of HLA-ABC expression on the tumor cell surface, as well as up-regulation of genes involved in antigen processing and presentation.
- M8 induction of the RIG-I pathway in cancer cells favored dendritic cell phagocytosis and induction of co-stimulatory molecules CD80 and CD86, together with increased expression of IL12 and CXCL10.
- cancer cells become less visible to cells of the immune system by: 1 ) downregulation of HLA-ABC, co-stimulatory molecules and NK ligands; 2) expression or secretion of immunosuppressing molecules (such as PD- L1 , Galectin 9, ID01 ); and/or 3) chemoattraction of immunosuppressive cells such as regulatory T cells, myeloid derived suppressor cells or tumor activated macrophage cells (Treg, MDSC and TAM, respectively) (Mittal et al., Curr Opin Immunol 27:16-25, 2014).
- immunosuppressive cells such as regulatory T cells, myeloid derived suppressor cells or tumor activated macrophage cells (Treg, MDSC and TAM, respectively) (Mittal et al., Curr Opin Immunol 27:16-25, 2014).
- the retinoic acid inducible gene-l is a cytosolic PRR for short 5' triphosphate double strand RNA, that has a crucial role in activating immune response against viral infection (Hornung et al., Science 314:994-997, 2006).
- RIG-I activates through caspase recruitment domain (CARD)-mediated interactions the adaptor mitochondrial antiviral signaling protein (MAVS), which in turn activates TANK-binding kinase 1 (TBK1 ) and the IKB kinase (IKK) complex (Kawai et al., Nat Immunol 6:981-988, 2005).
- IFN interferon
- TBK1 and IKK lead to the activation of IRF3 and NF-KB, respectively, thus inducing interferon (IFN), antiviral and inflammatory response
- IFN interferon
- antiviral and inflammatory response Goulet et al., PLoS Pathog 9:e1003298, 2013; Zevini et al., Trends Immunol. 38(3):194-205, 2017.
- RIG-I signaling can also trigger suicide of infected cells as an ultimate mechanism of protection to limit viral spread through at least three different mechanisms: IRF3-dependent induction of apoptotic genes (Heylbroeck et al., J Virol 74:3781-92, 2000); IRF3-mediated induction of BAX-dependent mitochondrial apoptosis (Chattopadhyay et al., Immunity 44:1 151-1161 , 2016); and, direct RIG-I induction of necroptosis (Schock et al., Cell Death Differ 24:615-625, 2017).
- RIG-I agonists can induce cell death in different tumor types and activate both innate and adaptive immunity against tumors in mouse models (Poeck et al., Nat Med 14:1256-1263, 2008; Besch et al., J Clin Invest 119:2399-41 1 , 2009; Glas et al., Stem Cells 31 :1064-1074, 2013; Ellermeier et al., Cancer Res 73:1709-1720, 2013; Duewell et al., Cell Death Differ 21 :1825-1837, 2014).
- VSV Vesicular Stomatitis Virus
- M8 potently blocked a variety of viral infections in vitro and in vivo, in part due to the activation of an innate immune response with great breadth and intensity. Furthermore, M8 acted as a potent vaccine adjuvant against influenza, leading to high antibody titers and Th1 -shift in immune responses (Beljanski et ai, J Virol 89:10612-24, 2015).
- M8 was tested for cancer therapeutic effects, by taking advantage of its dual ability to induce cell death and activate innate immunity.
- the results described herein demonstrate that stimulation of the RIG-I pathway by M8 induced an IFN-dependent intrinsic apoptosis in different cancer cells, characterized by many immunogenic cell death features and it was paired by increased antigen processing activity and strong activation of dendritic cells (DC).
- DC dendritic cells
- RIG-I agonists and transfection M8, RIG-I agonists #1 and #2 (RA#1 and RA#2) (Poeck et al., Nat Med. 14(1 1 ) :1256-1263, 2008; Duewell & Latz, Methods Mol Biol. 1040:19- 27, 2013) were synthesized using Megascript T7 Transcription Kit (Thermo Fisher Scientific) on synthetic oligonucleotides (Eurofins Genomics) and following manufacturer instruction. Templates used were:
- RNA was then purified using Nucleospin MiRNA Kit (Mackerey-Nagel) and concentration assessed using Nanodrop 2000 (Thermo Fisher Scientific).
- RNA/iMax (Thermo Fischer Scientific) was used following manufacturer instructions. The amount of lipofectamine was optimized for each cell type in order to reduce toxicity: 1.5 mI/ml were used for Mel 1007 cells, 2 mI/ml for HCT1 16, 3 mI/ml for PC3, Mel120 and A549. Both RNAiMAX and RA were diluted in Opti-Mem (Thermo Fisher Scientific). To remove the 5’ triphosphate group of M8, Calf Intestinal Alkaline Phosphatase (Thermo Fischer Scientific) was used following manufacturer instruction and RNA was then purified as before.
- Reagents LDH cytotoxicity assay (Thermo Fischer Scientific) was used following manufacturer instructions. For cell death inhibition Z-VAD-FMK (Santa Cruz Biotechnology) was used at a final concentration of 100 mM, Ac-YVAD-CMK (Sigma Aldrich) was used at a final concentration of 100 pg/ml (-180 mM), Necrostatin-1 (Cayman Chemical) was used at a final concentration of 50 mM; all the reagents were added to the culture immediately after transfection.
- PBMC and DC differentiation PBMC were isolated starting from healthy donor buffy coat by standard stratification with Ficoll® Paque PLUS density gradient (GE Healthcare) following manufacturer instructions and cultured in RPMI supplemented with 10% Certified FBS (Thermo Fisher Scientific) and 1 % of P/S.
- monocytes were isolated from fresh PBMC by magnetic selection using CD14 MicroBeads (Miltenyi Biotec) and cultured in RPMI supplemented with 10% Certified FBS (Thermo Fisher Scientific), 1 % of P/S, 50 ng/ml of GMCSF (Miltenyi) and 25 ng/ml of IL-4 (Miltenyi). After 5 days of culture, DC were used for phagocytosis assay or stimulated for 24 h with supernatants of transfected Mel1007 cells.
- NK CD107 degranulation and cytotoxicity assay As the source of effector cells, PBMCs were isolated from two healthy donors by Lymphoprep (Nycomed, Oslo, Norway) gradient centrifugation and co-cultured for 10d with the irradiated (30 Gy) EBV-transformed B cell line RPMI 8866 at 37°C in a humidified 5% CO2 atmosphere, as previously described (Zingoni et al., Eur J Immunol 30:644-651 , 2000). On day 10, the cell population was routinely >95% CD56 + CD16 + CD3-, as assessed by immunofluorescence and flow cytometry analysis.
- M8-transfected Mel1007 cells and K562 cells were then incubated with the effector cells at 37°C for 2 h. Thereafter, cells were washed and incubated for 45’ at 4°C with the lysosomal marker CD107a-APC and anti-CD3-APC-H7 and anti- CD56-PE to gate on NK cells. At the end of incubation cells were washed and analyzed by flow cytometry for percentage of CD107a+ cells among the gated CD3-/CD56+ cells.
- the effector NKL cells were labeled with CFSE and co-cultured for 4 h with target Mel 1007 transfected or not with M8 for 48 h or K562 cells at different Effector to Target ratios for 4 h at 37°C. Cells were then washed and cytotoxicity assessed at flow cytometer analyzing viable cells using 7- AAD among the CFSE- cells.
- Phagocytosis assay Mel 1007 cells were labeled with Cell Trace Far Red (CTFR) (Thermo Fischer Scientific) and transfected with M8 for 48 h. Cells were then cocultured at a 1 :1 ratio with DC for 4 h. Cells were then washed and labeled with anti-CD209-PE and 7-AAD, and analyzed by flow cytometer assessing CTFR + cells among live CD209 + cells.
- CTR Cell Trace Far Red
- Flow cytometry Viability was assessed by gating 7-AAD exclusion over FSC-A plots on FSC- A vs FSC-H gated single cell suspensions. To evaluate early and late apoptosis, cells were labeled with Annexin-V-APC (Biolegend) and 7-AAD in a solution of HEPES 0.01 M (Sigma Aldrich), NaCI 140 mM (Sigma Aldrich), CaC 2.5 mM (Sigma Aldrich) following manufacturer instructions.
- RNA were isolated by column separation using RNeasy Kit (Qiagen) and following manufacturer instructions and measured with Nanodrop 2000 (Thermo Fischer Scientific). 350 ng of RNA were used for cDNA synthesis using High-Capacity cDNA Reverse Transcription Kit (Thermo Fischer Scientific). Quantitative PCR was then performed using Taqman Fast Advanced MasterMix with Taqman probes or Universal ProbeLibrary Probes (Roche) with specific primers designed using Roche Lifescience Assay Design Center (available online at lifescience.roche.eom/en_it/brands/universal-probe-library.html#assay-design-center) on a StepOnePlus Real-Time PCR System (Thermo Fischer Scientific). Relative quantification method was used with GAPDH as housekeeper gene.
- Magnetic Luminex Assay Supernatants of M8-transfected Mel 1007 cells were analyzed on a 96-well plate for the presence of the following analytes: CCL2, CXCL1 , CXCL10, and IFNp. The fluorescence responses and concentrations of cytokines were obtained using a Human Premixed Multi-Analyte kit (R&D systems, Minneapolis, Minnesota, USA), and analyzed with a MAGPIX system and the accompanying xPONENT Software. All reagents were provided with the kit and were prepared according to the manufacturer’s recommendations: reconstituted standards were serially diluted 1 to 3 in calibrator diluent, which was used as background.
- Concentrated wash buffer was diluted in a 25- fold volume of deionized water.
- Microparticle cocktail, biotin-antibody cocktail, and Streptavidin-PE were diluted in their specific buffers immediately before the assay.
- the protocol outlined in the Luminex manual was followed exactly. Briefly, all supernatants were diluted 2-fold with calibrator diluent prior to data acquisition. 50 mI of samples and standards were incubated for 2 hours with 50 mI of microplate cocktail, then the plate was washed and 50 mI of biotin antibody cocktail was added.
- HMGB1 Elisa Supernatants of Mel1007, HCT1 16 and PC3 cells transfected or not with M8 for 48 h were analyzed for HMGB1 levels using HMGB1 Elisa kit (ST51001 , IBL international) following manufacturer instructions and absorbance measured with iMarkTM Microplate Absorbance Reader (Bio-Rad). As positive control, cells treated with Mitoxantrone 1 mM (Sigma Aldrich) were used.
- ATP release Extracellular ATP levels were measured by the luciferin-based ENLITEN ATP Assay (Promega, Madison, Wl, USA), following the manufacturer’s instructions, and light intensity was measured by Glomax luminometer. Briefly, 100 mI of not diluted supernatant were dispensed, in duplicate, in an opaque-walled 96 well plate; in each well an equal volume of rL/L reagent was added by an injection system and a 2-second delay time after injection, 10-second RLU signal integration time were used to record the light signals resulting from the luciferase reactions.
- M8 the capacity of M8 to induce cell death was compared to other RIG-I agonists previously shown to induce cell death in cancer cells (Poeck et al., Nat Med 14:1256-1263, 2008; Duewell et al., Cell Death Differ 21 :1825-1837, 2014).
- M8 proved to be the strongest inducer of cell death in Mel1007 (>58% vs 1 1 and 8%) (FIG. 1 E).
- M8 was effective in inducing cell death in a variety of cancer cell lines, including metastatic melanoma Mel120, lung adenocarcinoma A549, colon carcinoma HCT1 16, prostate carcinoma PC3 (FIG. 1 F) (40%, 75%, 45%, and 33%, respectively), indicating that cell death pathways activated by M8 were intact among several cancer cell types.
- M8 induced RIG-I-, IFN-I-, NOXA-dependent apoptotic pathway.
- apoptosis was analyzed at different times after M8 treatment by annexin V staining.
- FIG. 2A Mel1007 treated with M8 began showing apoptotic features as early as 16h post transfection with high percentages of early apoptotic cells between 24 and 30h, while by 48h most of the cells were already dead, thus indicating that the mechanisms leading to cell death start within the first 24h.
- Several pharmacological inhibitors of cell death pathways were used to explore the specificity of M8-mediated cell death.
- pan-caspase inhibitor Z-VAD significantly reduced M8-induced cell death (19% vs 44%), suggesting caspase involvement, whereas involvement of caspase 1 -dependent pyroptosis or necroptosis through the RIP1 kinase were ruled out, based on the use of the caspase 1 inhibitor YVAD or the necroptosis inhibitor necrostatin 1 (FIG. 2B).
- Cleavage of caspases 3 and 9 was detected by immunoblot 24h post M8 treatment (FIG. 2C), indicating that M8-induced cell death involved the intrinsic apoptotic pathway. This observation was further confirmed by analyzing mitochondria depolarization by JC1 staining at 24h post treatment; as shown in FIG. 2D, M8 treatment of mel1007 cells increased the percentage of cells exhibiting disrupted mitochondria.
- M8 induced ICD-DAMP. Given its ability to mimic virus infection, M8 induced a RIG-I- dependent innate response. IFNp transcriptional levels increased proportionally with the tested concentration of M8 (10, 100, 500 ng/ml), and the downstream chemokine CXCL10 underwent an even more dramatic induction that was significantly reduced by blocking IFNAR1 signaling (FIGs. 4A, B). Given that IFNp and CXCL10 are two critical factors required for ICD [19] the potential of M8 to induce the complete chemokine signature of ICD (i.e. CCL2, CXCL1 , CXCL10 and IFNP) was investigated next by a multiplex ELISA assay. All tested cytokines displayed an M8-dose-dependent, and statistically significant increase in chemokine production, as measured in the supernatant of MS- treated Mel1007 versus control (FIG. 4C).
- Apoptosis of cancer cells induced by M8 displayed several other features of ICD.
- flow cytometry it was found that M8 in Mel1007 cells induced surface exposure of calreticulin at levels comparable to the ICD inducer mitoxantrone (FIG. 5A). Similar results were also observed in other cell lines (FIG. 5B).
- HMGB1 High Mobility Group Box 1
- M8 triggering of RIG-I represses NK activity and upregulates antigen processing machinery (APM). Having observed the activation of many ICD markers in cancer cells stimulated by M8, whether pathways downstream of RIG-I activation also generated signals crucial for immune cell recognition was studied next.
- the induction of NK cell activating signals on Mel1007 was evaluated using mid-range doses of M8 to ensure strong RIG-I activation and minimize cell death. As shown in FIG. 6A, most activating NK ligands were increased on the Mel1007 cell surface after M8 treatment, although not to a statistically relevant level. However, when NK degranulation and cytotoxic activities were measured, a clear inhibition of NK activity was observed.
- APM genes immunoproteasome subunits PSMB8, PSMB9, and PSMB10, transporters associated with antigen processing TAP1 and TAP2, and the endoplasmic reticulum chaperone Tapasin (TAPBP) - displayed a dose dependent increase in M8-Mel1007 cells, peaking at a concentration of 100 ng/ml M8, with inductions ranging from 15-500 fold over untreated cells (FIG. 6E).
- Activation of monocyte-derived dendritic cells is skewed to a Th1 phenotype.
- the modulation of DC activity was next analyzed to determine whether the immunogenic signals induced by M8 enhanced DC phagocytosis of M8-Mel1007.
- Monocyte-derived DC (MoDC) co-cultured with labeled Mel1007 or M8-Mel1007 were evaluated for their ability to incorporate the membrane dye by phagocytosis.
- MoDC phagocyt ized more M8-Mel1007 cells compared to control Mel 1007, based on membrane dye inclusion (9.5% vs 2.2%) (FIGs. 7A, 7B).
- Immune mechanisms against viral infection rely on recognition of viral components (including for instance unusual RNA structures) to initiate a complex and multifaceted array of processes that includes the secretion of IFN-I and chemokines to mobilize immune effector cells, the activation of the APM for immune recognition of non-self antigens, and in the last instance, cell death. All these processes are critical for the development of an efficient cancer immunotherapy. Within this setting, tumor cells develop multiple strategies to escape immune recognition and thereby evade immune control.
- the sequence optimized RIG agonist M8 (Chiang et al., J Virol 89:8011-8025, 2015; Beljanski et al., J Virol 89:10612-10624, 2015) was assessed for its potential effectiveness in cancer immunotherapy and its capacity to induce immunogenic cell death in several cancer cell lines that rely on secretion of IFN-I and induction of intrinsic apoptotic pathways is described. Moreover, M8 boosted HLA-ABC and APM expression, and activated proinflammatory phagocytic DC, thus illustrating its potential to trigger many propitious anti-cancer effects by inducing death of tumor cells and eliciting immune reactivation.
- RA sequence optimized RA
- M8 sequence optimized RA
- M8 induced cell death in several cancer cell lines together with the expression of ICD markers and activated direct and indirect immune processes. Therefore, the results presented herein highlight M8 as a promising broad-acting RA for cancer immunotherapy against multiple tumor types. More detailed studies may be helpful to dissect settings in which RIG-I activation is most preferable.
- IFN-I play a critical role in tumor development and in response to therapy (Dunn et al., Nat Immunol 6:722-9, 2005; Katlinskaya et al., Cell Rep 15:171-180, 2016; Katlinski et al., Cancer Cell 31 :194-207, 2017; Castiello et al., Cancer Immunol Res 6:658-670, 2018; Rizza et al., Cytokine Growth Factor Rev 26:195-201 , 2015; Gajewski et al., Cancer Immunol Immunother 61 :1343-1347, 2012).
- IFN-I are the cornerstone for the development of anti-tumor response thanks to the activity on tumor cells and ICD (Galluzzi et al., Nat Rev Immunol 17:97-1 1 1 , 2017), and to the activation of anti-tumor immune cells (Snell et al., Trends Immunol 38:542-557, 2017).
- Tumor cells often develop resistance to IFN-I signaling by downregulating IFNAR1 or altering downstream factors (Katlinskaya et al., Cell Rep 15:171-180, 2016; Katlinski et al., Cancer Cell 31 :194-207, 2017; FluangFu et al., Oncogene 31 :161-172, 2012; Bhattacharya et al., Oncogene 32:4214-21 , 2013), even though some IFN-I signals are minimally affected by IFNAR1 levels (Levin et al., Mol Cell Biol 31 :3252-66, 201 1 ).
- Cell death pathway induced by M8 strongly relies on IFN-I; in fact, by blocking IFNAR1 activation, cell death strongly diminished and was reasonably due to an IFN- I dependent induction of the pro-apoptotic NOXA.
- NK cells exert a crucial role in controlling and modulating therapy response in several settings (Sanchez-Correa et al., Cancer Immunol Immunother 60:1 195-1205, 2011 ; Zingoni et al., Front Immunol 8 :1 194, 2017).
- RA-based immunotherapy Pieris et al., Nat Med 14:1256-1263, 2008; Glas et al., Stem Cells 31 :1064-1074, 2013; Ellermeier et al., Cancer Res 73:1709-1720, 2013; Barsoum et al., Cancer Immunol Res 5:B44-B44, 2017).
- DC Because of their ability in actively uptake and process tumor antigens, DC play a pivotal role in inducing and maintaining tumor- specific T cell responses (Zong et al., Cancer Immunol Immunother 65:821-833, 2016) and combination therapies directed towards increasing the pool of tumor antigens recognized by T cells are highly sought after strategies (Schumacher & Schreiber, Science 348:69-74, 2015).
- M8 treated cells are highly phagocytized by DC and that DC stimulated with supernatants of M8 treated cells increase the expression of HLA-DR and of costimulatory molecules, and switch towards a Th1 biasing cytokine production, strongly indicate that M8 immunotherapy could broaden the anti-tumor antigenic repertoire.
- the upregulation of the APM in cancer cells induced by M8 should increase the recognition of cancer cells by the tumor infiltrating lymphocytes and thus additionally favor a strong antigen-specific T cell mediated immune response.
- RIG-I activation in breast tumors increased tumor lymphocytes and decreased tumor growth and metastasis, thus illustrating the successful therapeutic delivery of a synthetic RIG-I agonist to induce breast tumor cell killing and to modulate the tumor microenvironment in vivo.
- Example 2 Triggering M8 Induced Cell Death using Natural Killer (NK) Cells
- This example describes translational studies that build upon mechanistic knowledge of RIG-I signaling described herein. These studies apply this knowledge to the discovery, evaluation, and development of potent immunotherapeutics based on RIG-I agonists. Use of multiple tumor models, including metastatic and poorly immunogenic models will define the therapeutic potential of RIG-I agonists in cancer immunotherapy.
- tumour antigens are usually self-proteins, and therefore poorly immunogenic; while on the other hand, tumours develop several escape mechanisms, including loss of MHC class I molecules and secretion of suppressive cytokines. Additionally, cancer patients are frequently immune suppressed because of treatments; therefore, a therapeutic cancer vaccine requires a strong adjuvant to increase its immunogenicity. An ideal cancer immunotherapy should induce such a strong immune activation that overcomes tumour escape strategies, with acceptable profiles of toxicity and safety.
- the desired immune response in cancer therapy involves the activation of interferon-y (IFN-g) producing type 1 T helper cells (Th1 ) and cytotoxic T lymphocytes (CTLs).
- IFN-g interferon-y
- Th1 type 1 T helper cells
- CTLs cytotoxic T lymphocytes
- an ideal adjuvant remains to be identified.
- Th2 type 2 helper T cells
- Th1 type 2 helper T cells
- Th1 type 2 helper T cells
- PRRs pathogen-recognition receptors
- immunostimulatory therapies can now be developed based on the provided first-in-class RNA molecules against a novel target with a well-understood mode of action.
- the translation of these approaches toward clinical use is an important end goal for which the proposed studies will provide the foundation. It is believed that stimulation of multiple innate antiviral and inflammatory pathways by RIG-I agonist M8 will enhance antiviral and protective immunity against infectious diseases and cancer.
- Nanoparticle formulated M8 will be incubated with 1 ) granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing cellular cancer vaccines, 2) tumor cell lysates, or 3) single tumor antigens.
- GM-CSF granulocyte-macrophage colony-stimulating factor
- Subcutaneously growing MC38 colon carcinoma, B16-F10 metastatic melanoma, and poorly immunogenic TC-2 prostate cells, KPC pancreatic adenocarcinoma, CT26 colon carcinoma cells, and breast carcinoma transgenic Neu +/_ mice will be used as tumor models.
- Tumor antigens will be derived from both matched and un-matched tumor cell lysates; unmatched lysates will be used for comparison.
- mice with subcutaneously growing B16 cells will be vaccinated subcutaneously with the above antitumor vaccines formulated with or without M8 and compared to standard adjuvants Alum and AddaVaxTM squalene-based oil-in-water adjuvant (InvivoGen). Subcutaneous tumor growth will be measured, and splenic cytotoxic T cell responses will be evaluated as described herein. In addition, T cell killing activity of B16 cells will be evaluated by flow cytometry. B16 cells will be labeled with PKH26 and then cocultured with T cells for 4 hours. Early and late apoptosis will be measured among PKFI26+ target cells by using Annexin-FITC and PI, respectively. Identical experiments will be performed with B16-F10 metastatic melanoma.
- M8 adjuvant in other aggressive and poorly immunogenic tumor settings T o confirm M8 adjuvant properties for cancer vaccines, M8 adjuvanted vaccines will be tested against other aggressive, poorly immunogenic and transgenic tumor models.
- Tumors will be digested to single cell levels and tumor infiltrating cells will be quantified as follows: 1 ) innate immune compartment, NK cells (NK1 .1 hi ) and NKT cells (NK1 1 hi CD3e hi CD1 d hi CD60 hi ), and 2) the adaptive compartment will include CD8+ and conventional CD4+ T cells. Effector function of T cells isolated from tumors will be assessed for activation, proliferation, and lytic function by examining the levels of ICOS, Ki-67, and Granzyme B, respectively. Immunosuppressive regulatory T cells (CD4 hi CD25 hi FoxP3 hi ) and myeloid-derived suppressor cells (CD1 1 b hi Gr1 hi ) will be also quantified upon treatments with flow cytometry.
- NK cells NK1 .1 hi
- NKT cells NK1 1 hi CD3e hi CD1 d hi CD60 hi
- CD8+ and conventional CD4+ T cells Effector function of T cells isolated from tumors will be assessed for activation, proliferation, and
- Unpulsed DC or DC pulsed with an unrelated protein will be used as negative control.
- Elucidation of immune cell/pathway contribution to M8-based immunotherapy To determine cell type(s) primarily affected upon M8 vaccination, in-depth analysis of tumor cell infiltrates will be performed.
- Tumors will be digested to single cell levels and tumor infiltrating cells will be quantified: 1 ) innate immune compartment, NK cells (CD3 NK1 .1 hi or CD3 DX5+ depending on mouse models) and NKT cells(NK1 1 hi (or DX5 + )CD3e hi CD1 d hi CD60 hi ), and 2) the adaptive compartment will include analysis of both CD4+ and CD8+ and their subpopulations (IFNg + Th1 , IL4 + Th2, IL-17 + Th17, and FoxP3 + CD127 CD25 hi Treg for CD4+ cells; CD8+ cells will be characterized for their memory status by CCR7/CD45RO/CD62L/CD45RA expression levels).
- mice will be depleted for CD4+, CD8+, or NK cells using appropriate depleting antibodies. Adequate cell depletion of each cell subset upon antibody treatment will be confirmed by flow cytometry of peripheral blood. Mice deficient for CD4, CD8 or NK cells will be injected with MC38, B16-F10, or TC-2 cells, vaccinated, and therapeutic effect of M8 will be assessed by examining long-term survival.
- RIG-I agonists possess many intrinsic advantages over currently approved antiviral and adjuvant therapies, with the capacity to transiently stimulate antiviral, inflammatory and immune modulatory gene networks that bridge innate and adaptive immune responses. Sequence dependent optimization of the RIG-I agonist, coupled with an advanced understanding of the activation pathways, provide a solid foundation for these challenging and increasingly analyses.
- the discoveries provided herein enable immunostimulatory therapies based on a first-in-class RNA motif targeted against a well-defined immunomodulatory pathway.
- the programs and research described herein provide antiviral and adjuvant immunotherapies with improved efficacy against different immunogenic and non-immunogenic tumors.
- RNA molecules combine simplicity, safety, and focused immunogenicity with favorable immunological properties: 1 ) an RNA adjuvant is molecularly defined and can target a specific pathway; and 2) RNA is rapidly degraded by ubiquitous RNases, leading to a precise‘hit & run’ stimulation of specific innate pathways and bypass of autoimmune responses that could result from repeated administration. Significant advances in RNA chemistry and delivery have ushered in a new era of RNA-based therapeutics, involving technologies that improve stability and delivery, including lipid-based nanovectors, polymer-mediated delivery systems, and oligonucleotide nanoparticles.
- each embodiment disclosed herein can comprise, consist essentially of or consist of its particular stated element, step, ingredient or component.
- the terms“include” or“including” should be interpreted to recite:“comprise, consist of, or consist essentially of.”
- the transition term“comprise” or“comprises” means includes, but is not limited to, and allows for the inclusion of unspecified elements, steps, ingredients, or components, even in major amounts.
- the transitional phrase“consisting of” excludes any element, step, ingredient or component not specified.
- the transition phrase“consisting essentially of” limits the scope of the embodiment to the specified elements, steps, ingredients or components and to those that do not materially affect the embodiment.
- a material effect, in this context results in a statistically relevant change in the effectiveness of the method of composition to treat cancer.
- the term“about” has the meaning reasonably ascribed to it by a person skilled in the art when used in conjunction with a stated numerical value or range, i.e. denoting somewhat more or somewhat less than the stated value or range, to within a range of ⁇ 20% of the stated value; ⁇ 19% of the stated value; ⁇ 18% of the stated value; ⁇ 17% of the stated value; ⁇ 16% of the stated value; ⁇ 15% of the stated value; ⁇ 14% of the stated value; ⁇ 13% of the stated value; ⁇ 12% of the stated value; ⁇ 1 1 % of the stated value; ⁇ 10% of the stated value; ⁇ 9% of the stated value; ⁇ 8% of the stated value; ⁇ 7% of the stated value; ⁇ 6% of the stated value; ⁇ 5% of the stated value; ⁇ 4% of the stated value; ⁇ 3% of the stated value; ⁇ 2% of the stated value; or ⁇ 1 % of the stated value.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Disclosed herein are compositions and methods for the treatment of cancer, particularly compositions including at least one oligoribonucleotide-based RIG-1 agonist and methods of use of such compositions. Methods for stimulating an immune response against a tumor antigen in a subject at risk of having or having a cancer comprising the tumor antigen, which involve administering at least one oligoribonucleotide-based RIG-1 agonist to the subject, are also described. Also provided are cancer vaccines and immunization kits.
Description
RIG-1 AGONISTS FOR CANCER TREATMENT AND IMMUNOTHERAPY
CROSS-REFERENCE TO RELATED APPLICATION
[0001] This application claims the priority of U.S. Provisional Application No. 62/845,783, titled“RIG-I AGONISTS FOR CANCER TREATMENT” and filed on May 9, 2019, which is incorporated by reference herein in its entirety.
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
[0002] This invention was made with government support under grants AM 08861 and 7R21 CA192185 awarded by the National Institutes of Health. The government has certain rights in the invention.
FIELD OF THE DISCLOSURE
[0003] Generally, the field is RNA-based therapeutic molecules. More specifically, the field is 5'- triphosphate oligoribonucleotide immune system agonists, pharmaceutical compositions comprising the same, and methods of use of the compositions.
BACKGROUND OF THE DISCLOSURE
[0004] The innate immune system has evolved numerous molecular sensors and signaling pathways to detect, contain and clear viral infections (Takeuchi & Akira, Immunol Rev 227:75-86, 2009; Yoneyama & Fujita, Rev Med Virol 20:4-22, 2010; Wilkins & Gale, Curr Opin Immunol 22:41 -47, 2010; Brennan & Bowie, Curr Opin Microbiol 13:503-507, 2010). Viruses are sensed by a subset of pattern recognition receptors (PRRs) that recognize evolutionarily conserved structures known as pathogen- associated molecular patterns (PAMPs). Classically, viral nucleic acids are the predominant PAMPs detected by these receptors during infection. These sensing steps contribute to the activation of signaling cascades that culminate in the early production of antiviral effector molecules, cytokines and chemokines responsible for the inhibition of viral replication and the induction of adaptive immune responses (Takeuchi & Akira, Cell 140:805-820, 2010; Liu et al., Curr Opin Immunol 23:57-64, 2011 ; Akira et al., Cell 124:783-801 , 2006). In addition to the nucleic acid sensing by a subset of endosome- associated Toll-like receptors (TLR), viral RNA structures within the cytoplasm are recognized by members of the retinoic acid-inducible gene-l (RIG-l)-like receptors (RLRs) family, including the three DExD/H box RNA helicases RIG-I, Mda5 and LGP-2 (Kumar et al., Int Rev Immunol 30:16-34, 2011 ; Loo & Gale, Immunity 34:680-692, 2011 ; Belgnaoui et al., Curr Opin Immunol 23:564-572, 2011 ; Beutler, Blood 1 13:1399-1407, 2009; Kawai & Akira, Immunity 34, 637-650, 201 1 ).
[0005] Upon progression, tumors adopt multiple strategies to escape immune surveillance and to generate an immunosuppressive and pro-tumorigenic microenvironment (Schreiber et al., Science 331 :1565-1570, 201 1 ). During this“immunoediting escape phase”, cancer cells become less visible
to cells of the immune system by: 1 ) downregulation of HLA-ABC, co-stimulatory molecules and NK ligands; 2) expression or secretion of immunosuppressing molecules (such as PD-L1 , Galectin 9, ID01 ); and/or 3) chemoattraction of immunosuppressive cells such as regulatory T cells, myeloid derived suppressor cells or tumor activated macrophage cells (Treg, MDSC and TAM, respectively) (Mittal et al., Curr Opin Immunol 27:16-25, 2014). Several strategies are currently being investigated to overcome the limitations of the immunosuppressive microenvironment and induce tumor cell death. Among these approaches, the use of compounds that mimic viral infection represent a promising strategy to pair cell death signals with immune activation events (lurescia et al., Front Immunol 9:711 , 2018).
[0006] The retinoic acid inducible gene-l (RIG-I) is a cytosolic PRR for short 5' triphosphate double strand RNA, that has a crucial role in activating immune response against viral infection (Hornung et al., Science 314:994-997, 2006). RIG-I is a cytosolic multidomain protein that detects viral RNA through its helicase domain (Jiang et al., Nature 479:423-427, 2011 ; Yoneyama & Fujita, J Biol Chem 282, 15315-15318, 2007). In addition to its RNA sensing domain, RIG-I also possesses an effector caspase activation and recruitment domain (CARD) that interacts with the mitochondrial adaptor MAVS, also known as VISA, I PS-1 , and Cardif (Kawai et al., Nat Immunol 6:981 -988, 2005; Meylan et al., Nature 437:1 167-1172, 2005). Upon recognition of viral RNA, RIG-I activates through CARD- mediated interactions the adaptor mitochondrial antiviral signaling protein (MAVS), which in turn activates TANK-binding kinase 1 (TBK1 ) and the IKB kinase (IKK) complex (Kawai et al., Nat Immunol 6:981-988, 2005). TBK1 and IKK, then, lead to the activation of interferon regulatory factor 3 (IRF3) and nuclear factor kappa B (NF-KB), respectively, thus inducing interferon (IFN), antiviral and inflammatory response (Goulet et al., PLoS Pathog 9 :e 1003298, 2013; Zevini et al., Trends Immunol. 38(3):194-205, 2017). Additionally, RIG-I signaling can also trigger suicide of infected cells as an ultimate mechanism of protection to limit viral spread through at least three different mechanisms: IRF3-dependent induction of apoptotic genes (Heylbroeck et al., J Virol 74:3781-92, 2000); IRF3- mediated induction of BAX-dependent mitochondrial apoptosis (Chattopadhyay et al., Immunity 44:1 151-1161 , 2016); and, direct RIG-I induction of necroptosis (Schock et al., Cell Death Differ 24:615-625, 2017). Such dual effects (i.e., induction of cell death and immune activation) render RIG- I agonists as a promising therapeutic approach for cancer treatment. Indeed, preliminary results have already shown that RIG-I agonists can induce cell death in different tumor types and activate both innate and adaptive immunity against tumors in mouse models (Poeck et al., Nat Med 14:1256-1263, 2008; Besch et al., J Clin Invest 119:2399-241 1 , 2009; Glas et al., Stem Cells 31 :1064-1074, 2013; Ellermeier et al., Cancer Res 73:1709-1720, 2013; Duewell et al., Cell Death Differ 21 :1825-1837, 2014).
[0007] The nature of the ligand recognized by RIG-I has been the subject of intense study given that PAMPs are the initial triggers of the antiviral immune response. In vitro synthesized RNA carrying an
exposed 5' terminal triphosphate (5'ppp) moiety was identified as a RIG-1 agonist (Hornung et ai, Science 314:994-997, 2006; Pichlmair et ai, Science 314:997-1001 , 2006; and Kim et ai, Nat Biotechol 22:321 -325, 2004). The 5'ppp moiety is added to the end of all viral and eukaryotic RNA molecules generated by RNA polymerization. However, in eukaryotic cells, RNA processing in the nucleus cleaves the 5'ppp end and the RNA is capped prior to release into the cytoplasm. The eukaryotic immune system evolved the ability to distinguish viral‘non-self 5'ppp RNA from cellular ‘self RNA through RIG-I (Fujita, Immunity 31 :4-5, 2009). Further characterization of RIG-I ligand structure indicated that blunt base pairing at the 5' end of the RNA and a minimum double strand (ds) length of 20 nucleotides were also important for RIG-I signaling (Schlee & Hartmann, Molecular Therapy 18:1254-1262, 2010). Further studies indicated that a dsRNA length of less than 300 base pairs led to RIG-I activation but a dsRNA length of more than 2000 bp lacking a 5'ppp (as is the case with poly l:C) failed to activate RIG-I (Kato et ai, J Exp Med 205: 1601 - 1610, 2008).
[0008] RNA extracted from virally infected cells, specifically viral RNA genomes or viral replicative intermediates, was also shown to activate RIG-I (Baum et ai., Proc Natl Acad Sci USA 107:16303- 16308, 2010; Rehwinkel & Sousa, Science 327:284-286, 2010; Rehwinkel et ai., Cell 140:397-408, 2010). Interestingly, the highly conserved 5' and 3' untranslated regions (UTRs) of negative single strand RNA virus genomes display high base pair complementarity and the panhandle structure theoretically formed by the viral genome meets the requirements for RIG-I recognition. The elucidation of the crystal structure of RIG-I highlighted the molecular interactions between RIG-I and 5'ppp-dsRNA (Cui et ai, Molecular Cell 29:169-179, 2008), providing a structural basis for the conformational changes involved in exposing the CARD domain for effective downstream signaling.
[0009] By modifying the length, structure and sequence of the 5’ end of Vesicular Stomatitis Virus (VSV) RNA, a RIG-I agonist (named M8) was developed that was 10-100 fold more potent in stimulating an antiviral response compared to other agonists (Chiang et ai, J Virol 89:8011-8025, 2015; U.S. Patents No. 9,790,509 and No. 10,167,476). M8 potently blocked a variety of viral infections in vitro and in vivo, in part due to the activation of an innate immune response with great breadth and intensity. Furthermore, M8 acted as a potent vaccine adjuvant against influenza, leading to high antibody titers and Th1 -shift in immune responses (Beljanski et ai, J Virol 89:10612-10624, 2015).
[0010] U.S. Patent Publications No. US 2014/0287023 (published September 25, 2014), is incorporated herein by reference.
SUMMARY OF THE DISCLOSURE
[0011] Disclosed herein are methods of treating cancer, which methods involve administering to a subject at least one synthetic oligoribonucleotide RIG-I agonist that is at least 41 nucleotides in length and that can form a hairpin structure comprising at least 17 base pairs. The synthetic oligoribonucleotide further includes a triphosphate group at its 5' end. The oligoribonucleotide can also
be of at least 99 nucleotides in length and can form a hairpin structure of at least 48 base pairs. In such an oligoribonucleotide, the hairpin structure can comprise at least 26 consecutive U-A base pairs. Examples of the therapeutic oligoribonucleotides include sequences such as any one of SEQ ID NOs: 10-17.
[0012] One embodiment is a method of treating cancer in a subject in need thereof including administering a therapeutically effective amount of a synthetic oligoribonucleotide including a 5' end triphosphate group and including (or having only) the sequence shown in M8 (SEQ ID NO: 13) or M5 (SEQ ID NO: 10) to the subject, thereby treating the cancer in the subject. In examples of this embodiment, the cancer includes melanoma, adenocarcinoma, carcinoma, or a metastatic cancer. In other examples, the cancer includes lung cancer, colon cancer, or prostate cancer.
[0013] Another provided embodiment is a method of inducing death of cancerous cells in a subject, the method including administering a therapeutically effective amount of a synthetic oligoribonucleotide including a 5' end triphosphate group and including (or having only) the sequence shown in M8 (SEQ ID NO: 13) or M5 (SEQ ID NO: 10) to the subject, thereby inducing death of cancerous cells in the subject. By way of example, in such methods the cancerous cells include melanoma cells, adenocarcinoma cells, carcinoma cells, or metastatic cells. In other examples of this embodiment, the cancerous cells arise from melanoma, adenocarcinoma, carcinoma, or a metastatic cancer. In other examples, the cancerous cells arise from lung, colon, or prostate cancer.
[0014] In examples of the methods of inducing cell death of cancerous cells in a subject, the cell death is dependent on caspase 3. In examples of the methods of inducing cell death of cancerous cells in a subject, the cell death is dependent on type I interferon (IFN-I). In particular embodiments, death of cancerous cells includes: an increase in expression of chemokines CCL2, CXCL1 , CXCL10, and/or IFNp in the cancerous cells; an increase in surface exposure of calreticulin on the cancerous cells; an increase in secretion of High Mobility Group Box 1 (HMGB1 ) from the cancerous cells; and/or an increase in release of ATP from the cancerous cells, as compared to the corresponding parameter in cancerous cells from the subject prior to the administering.
[0015] In yet further examples of these methods administering further elicits immune reactivation in the subject. In particular embodiments, the immune reactivation comprises: an increase in natural killer (NK) activating ligands on the cancerous cells; induction of expression of an NK inhibiting marker on the cancerous cells; induction of antigen processing machinery (APM) genes in the cancerous cells; an increase in expression of CD80, CD86, and/or HLA-DR on dendritic cells from the subject; and/or an increase in IL-12 expression in dendritic cells from the subject, as compared to the corresponding parameter in cancerous cells or dendritic cells from the subject prior to the administering.
[0016] Optionally, in any of these methods of treating cancer or inducing cell death of cancerous cells in a subject, the method further involves administering at least one second anti-cancer agent.
[0017] In representative examples of any of the provided methods, the therapeutically effective amount includes at least 0.2 milligrams to at least 5 milligrams of the synthetic oligoribonucleotide per kilogram of the subject's body weight per week (0.2-5 mg/kg/wk).
[0018] In additional representative examples of any of the provided methods, the therapeutically effective amount includes at least 0.5 milligrams to at least 2.5 milligrams of the synthetic oligoribonucleotide per kilogram of the subject's body weight per week (0.5-2.5 mg/kg/wk).
[0019] In yet more representative examples of any of the provided methods, the synthetic oligoribonucleotide is administered to the subject for at least 1 -52 weeks; and/or administered to the subject 1 -6 times per week; and / or administered 1 -6 times during the first week and 1 time each subsequent week.
[0020] Further examples, the provided methods involve the synthetic oligoribonucleotide being administered in a total weekly dose of any of 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, 125 mg, 150 mg, 175 mg, 200 mg, 225 mg, 250 mg, 275 mg, 300 mg, 325 mg, 350 mg, 375 mg, 400 mg, 425 mg, 450 mg, 475 mg, 500 mg, 525 mg, 550 mg, 575 mg, 600 mg, 625 mg, 650 mg, 675 mg, 700 mg, 725 mg, or 750 mg.
[0021] Further examples of the methods include the effective amount of the synthetic oligoribonucleotide being administered at a rate of 5 n M/kg to 100 nM/kg of the synthetic oligoribonucleotide per kilogram of the subject's body. By way of specific example, the therapeutically effective amount includes 15.5 nM/kg to 77.5 nM/kg of the synthetic oligoribonucleotide per kilogram of the subject's body.
[0022] Another provided embodiment is a vaccine composition including: a tumor antigen; an adjuvant; and a pharmaceutically acceptable carrier, wherein the adjuvant comprises at least one synthetic oligoribonucleotide RIG-I agonist described herein. Examples of the oligoribonucleotides suitable for an adjuvant include sequences such as any one of SEQ ID NOs: 10-17. In particular embodiments, the synthetic oligoribonucleotide has a sequence set forth in SEQ ID NO: 10 (M5) or SEQ ID NO: 13 (M8).
[0023] Examples of the vaccine composition include a tumor antigen derived from tumors found in melanoma, skin cancer, prostate cancer, lung cancer, pancreatic cancer, or breast cancer. Further examples of the vaccine composition include a tumor antigen that is part of a tumor cell lysate. Yet another example of the vaccine composition includes a tumor antigen that is part of an inactivated cancer cell population. Further examples of the vaccine composition include a tumor antigen that is part of an antigen presenting cell (APC) population. In particular embodiments, the APC population includes dendritic cells.
[0024] In yet other examples of the vaccine composition, the adjuvant further includes mineral oil, bacterial toxins, aluminum salts, squalene, virosomes, mineral oil in water emulsions, CpG, lipopolysaccharide (LPS), monophosphoryl lipid A (MPLA), QS21 or AS02, flagellin, peptidoglycans,
inactivated bacterial pathogens, and/or RNAse inhibitors. In further examples of the vaccine composition, the synthetic oligoribonucleotide is in a nanoparticle formulation. In particular embodiments, the tumor antigen and the adjuvant are formulated together. In particular embodiments, the tumor antigen and the adjuvant are not formulated together.
[0025] Another provided embodiment is a method for stimulating an immune response against a tumor antigen in a subject at risk of having or having a cancer including the tumor antigen, including administering to the subject a therapeutically effective amount of the vaccine composition. In further examples, these methods for stimulating an immune response against a tumor antigen further include administering at least one second anti-cancer agent. In particular embodiments, the second anti cancer agent is low dose chemotherapy. In particular embodiments, the second anti-cancer agent is an immune checkpoint inhibitor that blocks programmed cell death protein 1 (PD-1 ).
[0026] Another provided embodiment is a method of activating antigen presenting cells (APC) ex vivo including contacting the APC with the vaccine composition. In further examples, these methods of activating APC ex vivo further include administering the contacted APC to a subject at risk of having or having a cancer comprising the tumor antigen.
[0027] Another provided embodiment is an immunization kit including a vaccine composition described herein.
BRIEF DESCRIPTION OF THE DRAWINGS
[0028] FIG. 1A-1 G. RIG-I agonist M8 induces cell death in cancer cells. FIG. 1 A. Viability of Mel1007 cells transfected with different doses of M8 (1 -500 ng/ml) for 48 hours assessed by 7-AAD exclusion by flow cytometry. FIG. 1 B. LDH based cytotoxicity was measured on supernatant of Mel1007 cells transfected with different doses of M8 (1 -500 ng/ml) for 48 hours, the % was calculated as the ratio of spontaneous-normalized LDH activity over normalized maximum control following manufactured instructions. FIG. 1 C. Viability of Mel1007 cells transfected with M8 or 5’ dephosphorylated M8 (CIAP-M8) (500 ng/ml) for 48 h assessed by 7-AAD exclusion by flow cytometry. FIG. 1 D. Viability of Mel1007 cells pretreated for 24 h with siRNA specific for RIG-I gene and then transfected with M8 (500 ng/ml) for 48 h. FIG. 1 E. Viability of Mel1007 cells transfected with the indicated RIG-I agonists (500 ng/ml), untreated, or transfected only with lipofectamine for 48 hours. FIG. 1 F. Viability of metastatic melanoma Me120, lung adenocarcinoma A549, colon carcinoma HCT 116, and prostate carcinoma PC3 transfected with 500 ng/ml of M8 for 48 hours. FIG. 1 G. Viability of PBMC transfected with different doses of M8 (1 -500 ng/ml) for 48 hours assessed by 7-AAD exclusion by flow cytometry. * P < 0.05; ** P < 0.01 ; *** P < 0.001
[0029] FIG. 2A-2F. M8 activates intrinsic apoptosis driven by PUMA and NOXA. FIG. 2A (parts 1 and 2). Flow Cytometry evaluation of Annexin V/7-AAD positivity of Mel1007 cells transfected with M8 (500 ng/ml) assessed at 10, 16, 24, 32 and 48 h. FIG. 2B. Viability of Mel1007 cell transfected for 48
h with M8 and treated with pan-caspase inhibitor ZVAD-FMK (100 pM), caspase 1 inhibitor YVAD- FMK (50 pg/ml), and necroptosis inhibitor necrostatin 1 (100 pM). FIG. 2C. Western blot of Mel1007 cells transfected for 24 or 48 h with different doses of M8. FIG. 2D. Analysis of % of Mel1007 24 h after transfection showing monomeric JC-1 , an indicator of mitochondria depolarization. CCCP was used as a positive control and added 30’ before the analysis. FIG. 2E. Expression levels of NOXA gene in Mel1007 cells 24 h after transfection with the indicated doses of M8. FIG. 2F. Expression levels of PUMA gene in Mel1007 cells 24 h after transfection with the indicated doses of M8. * P < 0.05; ** P < 0.01 ; *** P < 0.001
[0030] FIG. 3A-3C. M8 induced apoptosis relies on IFN-I signaling. FIG. 3A. Viability of Mel1007 cells transfected with M8 (500 ng/ml) and treated with IFNAR1 blocking Ab for 48h (1 pg/ml). FIG. 3B and FIG. 3C. Expression levels of NOXA and PUMA genes, respectively in Mel1007 cells 24 h after transfection with M8 500 ng/ml treated with IFNAR1 blocking Ab for 48h (1 pg/ml). Fold changes were calculated over untreated Mel1007 cells. ** P < 0.01
[0031] FIG. 4A-4C. M8 induces immunogenic cell death in cancer cells. FIG. 4A and FIG. 4B. Expression levels of IFNp and CXCL10 gene, respectively, in Mel1007 cells 24 h after transfection with different doses of M8 (1 -500 ng/ml) and IFNAR1 blocking Ab (1 pg/ml) over control cells. FIG. 4C. Analysis by Magnetic Luminex assay from R&D systems (see Material and Methods for details) of the chemokines CCL2, CXCL1 , CXCL10, and IFNp on supernatants of Mel1007 cells stimulated for 24 hours with M8 (10, 100, and 500 ng/ml). Untransfected (Un) and lipofectamine RNAiMax transfected (lipo) Mel1007 were used as negative controls. * P < 0.05; ** P < 0.01 ; *** P < 0.001
[0032] FIG. 5A-5E. Cancer cells exposed to M8 exhibit the hallmarks of ICD. FIG. 5A. Calreticulin expression levels as assessed by % of positive cells in Mel1007 30 h after transfection with M8 (500 ng/ml); mitoxantrone (1 pM) was used as positive control; FIG. 5B. Calreticulin expression levels as assessed by % of positive cells in HCT1 16 cells (left) and PC3 cells (right) 24 or 18 h, respectively, after transfection with M8 (500 ng/ml), mitoxantrone (1 pM) was used as positive control; FIG. 5C. HMGB1 levels assessed by ELISA on supernatants of Mel1007 cells transfected with M8 (500 ng/ml) for 48 h; mitoxantrone (1 pM) was used as positive control; FIG. 5D. HMGB1 levels assessed by ELISA on supernatants of HCT116 and PC3 cells transfected with M8 (500 ng/ml) for 48 h, mitoxantrone (1 pM) was used as positive control; FIG. 5E. ATP release by Mel1007 cells left untransfected (Ut) or transfected with either lipofectamine RNAiMAX alone (lipo) or in combination with 500 ng/ml M8 for 48h. ATP levels in culture supernatants were quantified by a luciferase-based test. * P < 0.05; ** P < 0.01 .
[0033] FIG. 6A-6E. M8 triggering of RIG-I represses NK cell-mediated cancer cell killing and activates antigen processing machinery. FIG. 6A. Relative expression levels of NK activating ligands on Mel1007 transfected with M8 (10-100 ng/ml) for 48 h. FIG. 6B. Degranulation of NK from healthy donors co-cultured with Mel1007 cells transfected with M8 (10-100 ng/ml) for 48 h. FIG. 6C.
Cytotoxicity assay of NKL cell line against Mel1007 cells transfected with M8 (10-100 ng/ml) for 48 h. Both in FIG. 6B and FIG. 6C, K562 were used as positive control of NK activation. FIG. 6D. MFI of HLA-ABC expression levels of Mel1007 transfected for 24 h with different doses of M8 (1 -500 ng/ml) and IFNAR1 blocking Ab (1 pg/ml) over control cells; FIG. 6E. Expression levels of the indicated APM genes in Mel1007 cells 24 h after transfection with different doses of M8 (1 -500 ng/ml) and IFNAR1 blocking Ab (1 pg/ml) over control cells. * P < 0.05; ** P < 0.01 .
[0034] FIG. 7A-7E. M8 treatment in cancer cells induces phagocytosis and pro-inflammatory phenotype in DC. FIG. 7A and FIG. 7B. Mel1007 cells were stained with CTFR and then transfected with M8 (500 ng/ml). After 48 h, Mo-DC were added to the cell culture at a 1 :1 ratio. After 4 h phagocytosis of DC was analyzed by flow cytometry analyzing the % of DC (gated on CD209 expression) that incorporated CTFR. FIG. 7A. Representative plots of phagocytosis assay. FIG. 7B Percentage of DC phagocytosis as in FIG. 7A. FIGs. 7C-7E. Effects of supernatants of transfected Mel1007 cells on DC. Mel1007 were transfected for 48 h with different doses of M8 (1 -500 ng/ml), supernatants were then used to stimulate DC. FIG. 7C. Cell surface expression levels expressed as relative MFI of costimulatory markers CD80 and CD86 and HLA-DR in DC treated for 24 h with supernatants of Mel1007 transfected with different doses of M8. FIG. 7D and FIG. 7E. Expression levels of IL-12A, IL-10 and CXCL10 genes at in DC treated as in c). * P< 0.05; ** P<0.01 ; *** P<0.001 .
[0035] FIG. 8 is a drawing of the secondary structure of WT (SEQ ID NO: 5), M5 (SEQ ID NO: 10), and M8 (SEQ ID NO: 13) 5'pppRNA oligonucleotides.
[0036] FIG. 9 is a schematic representation of 5'pppRNA sequences that include variations of the wild type (WT; SEQ ID NO: 5) VSV-derived 5’pppRNA (M1 -M8; SEQ ID NOs: 6-13).
[0037] FIG. 10 is a schematic representation of modifications to the M8 5'pppRNA (SEQ ID NO: 13). Sequence changes were made to the poly AU base-pair stretch (M8A, SEQ ID NO: 14; M8C, SEQ ID NO: 15), the WT-derived blunt-end (M8D, SEQ ID NO: 16), and the entire sequence (M8B, SEQ ID NO: 17) while keeping the structure intact.
SEQUENCE LISTING
[0038] The nucleic acid sequences described herein are shown using standard letter abbreviations for nucleotide bases, as defined in 37 C.F.R. §1 .822. Only one strand of each nucleic acid sequence is shown, but the complementary strand is understood as included in embodiments where it would be appropriate.
[0039] A computer readable text file, entitled“l081 -0003PCT_ST25.txt” created on or about May 7, 2020, with a file size of ~16 KB, contains the sequence listing for this application and is hereby incorporated by reference in its entirety.
[0040] Table 1 : Sequences in Sequence Listing
[0041] Disclosed herein are methods of treating cancer, using composition(s) that contain at least one synthetic RIG-I agonist oligoribonucleotide, synthesized with a triphosphate group at its 5' end. In various embodiments, the oligoribonucleotide includes: a first polynucleotide having the sequence shown in SEQ ID NO: 1 , a second polynucleotide having the sequence shown in SEQ ID NO: 2 and a third polynucleotide having the sequence shown in SEQ ID NO: 3 with SEQ ID NO: 3 located between SEQ ID NO: 1 and SEQ ID NO: 2. SEQ ID NO: 1 can be 5' of SEQ ID NO: 2 or SEQ ID NO: 1 can be 3' of SEQ ID NO: 2. The oligoribonucleotides can comprise any additional sequence.
[0042] In examples where SEQ ID NO: 1 is 5' of SEQ ID NO: 2, the RIG-I agonist oligoribonucleotides include the structure:
GACGAAGACCACAAAACCAGAU(A)nUAA(U)nAUCUGGUUUUGUGGUCUUCGUC (SEQ ID NO: 49) or GACGAAGACCACAAAACCAGAU(U)nUAA(A)nAUCUGGUUUUGUGGUCUUCGUC (SEQ ID NO: 50); wherein n is any integer greater than 1. This structure indicates that the nucleotide in parentheses is repeated the number of times equal to n. For example, n can equal 2, 3, 6, 1 1 , 16, 26, or more than 26 repeats of the nucleotide indicated in parentheses.
[0043] The oligoribonucleotides can also include the structure:
GACGAAGACCACAAAACCAGAU(AAU)xU(AUU)yAUCUGGUUUUGUGGUCUUCGUC (SEQ ID NO: 51 ) or
GACGAAGACCACAAAACCAGAU(AUU)xU(AAU)yAUCUGGUUUUGUGGUCUUCGUC (SEQ ID NO: 52); wherein x and y are any integer greater than 2. In this embodiment, the tripeptide in parentheses is repeated a number of times equal to x or y. In this example, x and y can be different numbers. For example, x can equal 10 while y can equal 8.
[0044] In examples where SEQ ID NO: 1 is 3' of SEQ ID NO: 2, the oligoribonucleotides can have the structure:
AUCUGGUUUUGUGGUCUUCGUC(A)nUAA(U)nGACGAAGACCACAAAACCAGAU (SEQ ID NO:
53); or
AUCUGGUUUUGUGGUCUUCGUC(U)nUAA(A)nGACGAAGACCACAAAACCAGAU (SEQ ID NO:
54), wherein n is an integer greater than 1 .
[0045] Alternatively, the therapeutic synthetic oligoribonucleotide can be an oligoribonucleotide of at least 59 nucleotides in length that can form a hairpin structure comprising at least 29 base pairs, the synthetic oligonucleotide further comprising a triphosphate group at the 5' end of the oligoribonucleotide. In examples of these aspects, the oligoribonucleotides are at least 99 nucleotides in length that can form a hairpin structure comprising at least 49 base pairs.
[0046] Synthetic Oligonucleotide RIG-1 Agonists
[0047] The synthetic oligoribonucleotides described herein can be expressed from a DNA plasmid. Such a DNA plasmid comprises the DNA sequence that encodes the described oligoribonucleotides. The oligoribonucleotides can be transcribed as an RNA molecule that automatically folds into duplexes with hairpin loops. Typically, a transcriptional unit or cassette will contain an RNA transcript promoter sequence, such as a T7 promoter operably linked to the sequence encoding the oligoribonucleotide.
[0048] The synthetic oligoribonucleotides described herein comprise a 5'-triphosphate group. These may collectively be referred to as 5'pppRNA or individually as 5'ppp-SEQ ID NO: XX herein. Alternatively, individual compounds may be referred to herein by names such as WT, M5, or M8 as indicated in the Sequence Listing (including, for instance, SEQ ID NOs: 5-17). See also FIGs. 7, 8, and 9, as well as U.S. Patent Publication No. 2017-0268007 and U.S. Patent No. 10,167,476.
[0049] Methods of isolating RNA, synthesizing RNA, hybridizing nucleic acids, making and screening cDNA libraries, and performing PCR are well known in the art (see, e.g., Gubler & Hoffman, Gene 25:263-269, 1983; Sambrook & Russell, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor NY, 2001 ) as are PCR methods (see, U.S. Pat. Nos. 4,683,195 and 4,683,202; PCR Protocols: A Guide to Methods and Applications, Innis et ai, Eds, 1990). Expression libraries are also well known to those of skill in the art. Additional basic texts disclosing the general methods of use in this invention include Sambrook and Russell (2001 ) supra ; Kriegler, Gene Transfer and Expression: A Laboratory Manual (1990); and Current Protocols in Molecular Biology (Ausubel et ai, eds., 1994).
[0050] An oligoribonucleotide can also be chemically synthesized. Synthesis of the single- stranded nucleic acid makes use of common nucleic acid protecting and coupling groups, such as dimethoxytrityl at the 5'-end and phosphoramidites at the 3'-end. As a non-limiting example, small scale syntheses can be conducted on an Applied Biosystems synthesizer using a 0.2 micromolar scale protocol with a 2.5 min coupling step for 2'-0-methylated nucleotides. Alternatively, syntheses at the 0.2 micromolar scale can be performed on a 96-well plate synthesizer from Protogene. However, a larger or smaller scale of synthesis is encompassed by the invention, including any method of synthesis now known or yet to be disclosed. Suitable reagents for synthesis of the single-stranded oligonucleotides, methods of RNA deprotection, methods of RNA purification, and methods of adding phosphate groups to an oligoribonucleotide are known to those of skill in the art.
[0051] An oligoribonucleotide can be synthesized via a tandem synthesis technique, wherein both strands are synthesized as a single continuous fragment or strand separated by a linker that is subsequently cleaved to provide separate fragments or strands that hybridize to form an RNA duplex. The linker can be any linker, including a polynucleotide linker or a non-nucleotide linker. The linker can comprise any sequence of one or more ribonucleotides. The tandem synthesis of RNA can be
readily adapted to both multiwell/multiplate synthesis platforms as well as large scale synthesis platforms employing batch reactors, synthesis columns, and the like.
[0052] Alternatively, the oligoribonucleotide can be assembled from two distinct single-stranded molecules, wherein one strand includes the sense strand and the other includes the antisense strand of the RNA. For example, each strand can be synthesized separately and joined together by hybridization or ligation following synthesis and/or deprotection. Either the sense or the antisense strand can contain additional nucleotides that are not complementary to one another and do not form a double stranded RNA molecule. In certain other instances, the oligoribonucleotide can be synthesized as a single continuous fragment, where the self- complementary sense and antisense regions hybridize to form an RNA duplex having a hairpin or panhandle secondary structure.
[0053] An oligoribonucleotide can comprise a duplex having two complementary strands that form a double-stranded region with least one modified nucleotide in the double-stranded region. The modified nucleotide may be on one strand or both. If the modified nucleotide is present on both strands, it may be in the same or different positions on each strand. Examples of modified nucleotides suitable for use in the present invention include, but are not limited to, ribonucleotides having a 2'-0-methyl (2'OMe), 2'-deoxy-2'-fluoro (2'F), 2'-deoxy, 5-C-methyl, 2'-0-(2-methoxyethyl) (MOE), 4'-thio, 2'-amino, or 2'-C-allyl group. Modified nucleotides having a conformation such as those described in, for example in Sanger ( Principles of Nucleic Acid Structure, Springer-Verlag Ed., 1984), are also suitable for use in oligoribonucleotides. Other modified nucleotides include, without limitation: locked nucleic acid (LNA) nucleotides, G-clamp nucleotides, or nucleotide base analogs. LNA nucleotides include but need not be limited to 2'-0, 4'-C-methylene-(D-ribofuranosyl)nucleotides), 2'-0-(2-methoxyethyl) (MOE) nucleotides, 2'-methyl-thio-ethyl nucleotides, 2'-deoxy-2'-fluoro (2'F) nucleotides, 2'-deoxy-2'- chloro (20) nucleotides, and 2'-azido nucleotides. A G-clamp nucleotide refers to a modified cytosine analog wherein the modifications confer the ability to hydrogen bond both Watson-Crick and Hoogsteen faces of a complementary guanine nucleotide within a duplex (Lin et ai, J Am Chem Soc, 120:8531 -8532, 1998). Nucleotide base analogs include for example, C-phenyl, C- naphthyl, other aromatic derivatives, inosine, azole carboxamides, and nitroazole derivatives such as 3-nitropyrrole, 4-nitroindole, 5-nitroindole, and 6-nitroindole (Loakes, Nucl Acids Res, 29:2437-2447, 2001 ).
[0054] An oligoribonucleotide can comprise one or more chemical modifications such as terminal cap moieties, phosphate backbone modifications, and the like. Examples of classes of terminal cap moieties include, without limitation, inverted deoxy abasic residues, glyceryl modifications, 4', 5'- methylene nucleotides, l -(P-D-erythrofuranosyl) nucleotides, 4'-thio nucleotides, carbocyclic nucleotides, 1 ,5-anhydrohexitol nucleotides, L-nucleotides, a- nucleotides, modified base nucleotides, threo pentofuranosyl nucleotides, acyclic 3',4'-seco nucleotides, acyclic 3,4-dihydroxybutyl nucleotides, acyclic 3,5-dihydroxypentyl nucleotides, 3'- 3'-inverted nucleotide moieties, 3'-3'-inverted abasic moieties, 3'-2'-inverted nucleotide moieties, 3'-2'-inverted abasic moieties, 5'-5'-inverted
nucleotide moieties, 5'-5'-inverted abasic moieties, 3'-5'-inverted deoxy abasic moieties, S'-amino-alkyl phosphate, 1 ,3-diamino-2-propyl phosphate, 3 aminopropyl phosphate, 6-aminohexyl phosphate, 1 ,2- aminododecyl phosphate, hydroxypropyl phosphate, 1 ,4-butanediol phosphate, 3'-phosphoramidate, 5' phosphoramidate, hexylphosphate, aminohexyl phosphate, 3'-phosphate, 5'-amino, 3'- phosphorothioate, 5'-phosphorothioate, phosphorodithioate, and bridging or non-bridging methylphosphonate or 5'-mercapto moieties (see, e.g., U.S. Pat. No. 5,998,203; Beaucage et al., Tetrahedron 49:1925, 1993). Non-limiting examples of phosphate backbone modifications (i.e., resulting in modified internucleotide linkages) include phosphorothioate, phosphorodithioate, methylphosphonate, phosphotriester, morpholino, amidate, carbamate, carboxymethyl, acetamidate, polyamide, sulfonate, sulfonamide, sulfamate, formacetal, thioformacetal, and alkylsilyl substitutions (see, e.g., Hunziker et at., Modern Synthetic Methods, VCH, 331 -417, 1995; Mesmaeker et al., Antisense Research, ACS, 24-39, 1994). Such chemical modifications can occur at the 5'-end and/or 3'-end of the sense strand, antisense strand, or both strands of the oligoribonucleotide.
[0055] The sense and/or antisense strand of an oligoribonucleotide may comprise a 3'-terminal overhang having 1 to 4 or more 2'-deoxyribonucleotides and/or any combination of modified and unmodified nucleotides. Additional examples of modified nucleotides and types of chemical modifications that can be introduced into the modified oligoribonucleotides of the present invention are described, e.g., in Patent No. GB 2,397,818 B and U.S. Patent Publications No. 2004/0192626 and 2005/0282188.
[0056] An oligoribonucleotide may comprise one or more non-nucleotides in one or both strands of the siRNA. A non-nucleotide can be any subunit, functional group, or other molecular entity capable of being incorporated into a nucleic acid chain in the place of one or more nucleotide units that is not or does not comprise a commonly recognized nucleotide base such as adenosine, guanine, cytosine, uracil, or thymine, such as a sugar or phosphate.
[0057] Chemical modification of the disclosed oligoribonucleotides may also comprise attaching a conjugate to the oligoribonucleotide molecule. The conjugate can be attached at the 5'- and/or the 3'- end of the sense and/or the antisense strand of the oligoribonucleotide via a covalent attachment such as a nucleic acid or non-nucleic acid linker. The conjugate can also be attached to the oligoribonucleotide through a carbamate group or other linking group (see, e.g., U.S. Patent Publications No. 2005/0074771 , 2005/0043219, and 2005/0158727). A conjugate may be added to the oligoribonucleotide for any of a number of purposes. For example, the conjugate may be a molecular entity that facilitates the delivery of the oligoribonucleotide into a cell or the conjugate a molecule that comprises a drug or label.
[0058] Examples of conjugate molecules suitable for attachment to the disclosed oligoribonucleotides include, without limitation, steroids such as cholesterol, glycols such as polyethylene glycol (PEG), human serum albumin (FISA), fatty acids, carotenoids, terpenes, bile acids, folates (e.g., folic acid,
folate analogs and derivatives thereof), sugars {e.g., galactose, galactosamine, N-acetyl galactosamine, glucose, mannose, fructose, fucose, etc.), phospholipids, peptides, ligands for cellular receptors capable of mediating cellular uptake, and combinations thereof (see, e.g., U.S. Patent Publications No. 2003/0130186, 2004/01 10296, and 2004/0249178; U.S. Pat. No. 6,753,423). Other examples include the lipophilic moiety, vitamin, polymer, peptide, protein, nucleic acid, small molecule, oligosaccharide, carbohydrate cluster, intercalator, minor groove binder, cleaving agent, and cross- linking agent conjugate molecules described in U.S. Patent Publication Nos. 200501 19470 and 20050107325. Other examples include the 2'-0-alkyl amine, 2'-0-alkoxyalkyl amine, polyamine, C5- cationic modified pyrimidine, cationic peptide, guanidinium group, amidininium group, cationic amino acid conjugate molecules described in U.S. Patent Publication No. 2005/0153337. Additional examples of conjugate molecules include a hydrophobic group, a membrane active compound, a cell penetrating compound, a cell targeting signal, an interaction modifier, or a steric stabilizer as described in U.S. Patent Publication No. 2004/0167090. Further examples include the conjugate molecules described in U.S. Patent Publication No. 2005/0239739.
[0059] The type of conjugate used and the extent of conjugation to the disclosed oligoribonucleotides can be evaluated for improved pharmacokinetic profiles, bioavailability, and/or stability of the oligoribonucleotide while retaining activity. As such, one skilled in the art can screen oligoribonucleotides having various conjugates attached thereto to identify oligonucleotide conjugates having improved properties using any of a variety of well-known in vitro cell culture or in vivo animal models.
[0060] Pharmaceutical Compositions
[0061] The therapeutic compounds provided herein can be formulated as pharmaceutical compositions and administered to a mammalian host, such as a human patient in a variety of forms adapted to the chosen route of administration, i.e., orally or parenterally, by intravenous, intramuscular, topical or subcutaneous routes.
[0062] The therapeutic compounds provided herein can be formulated as an adjuvant in a cancer vaccine composition. A cancer vaccine is a biological preparation that improves immunity to a particular cancerous disease. Vaccine compositions can affect the course of a cancerous disease by causing an effect on cells of the adaptive immune response, namely, B cells and/or T cells. The effect of vaccines can include, for example, induction of cell-mediated immunity or alteration of the response of a T cell to its antigen. A vaccine typically contains an agent (e.g., immunogen) that stimulates the body's immune system to recognize the agent as foreign, destroy it, and“remember” it, so that the immune system can more easily recognize and destroy the agent at subsequent encounters. A successful immune response is characterized by, e.g., eradication of pathogens, tissue repair, eradication of tumors, and/or short and long term immune memory. The agent can include molecules
derived from a cancerous disease-causing pathogen or can be inactivated cancer cells, tumor cell lysates, or tumor-specific antigens. Vaccines can be prophylactic or therapeutic.
[0063] A tumor (i.e. cancer) antigen is presented on the surface of cancer cells and may be specific, associated, or over-expressed on such cancer cells. Tumor antigens can be obtained by conventional techniques, such as by preparation of tumor cell lysates by repeatedly freezing and thawing tumor cells/tissues obtained from either fresh tumor biopsy tissues or from tumor cells generated in vitro by tissue culture. The tumor lysate can be obtained by centrifugation and harvesting the supernatant fluid. The tumor cell lysates can be used immediately or frozen and stored until ready for use. The tumor antigen can be used in a purified form or in partially purified or unpurified form as cell lysate. Alternatively, the tumor antigen may be expressed by recombinant DNA techniques in any of a wide variety of expression systems. In particular embodiments, a tumor antigen is derived from tumors found in melanoma, skin cancer, prostate cancer, lung cancer, pancreatic cancer, or breast cancer. In particular embodiments, a tumor antigen includes a tumor cell lysate. In particular embodiments, the tumor antigen is included in a population of cells including antigen presenting cells (APC). APC include cells that express MHC Class I and/or Class II molecules that present antigens to T cells. Examples of APCs include, e.g., professional or non-professional antigen processing and presenting cells. Examples of APC include dendritic cells, B cells, spleen cells, lymph node cells, bone-marrow derived cells, monocytes, macrophages, or non-fractionated peripheral blood mononuclear cells (PMBC). Examples of hematopoietic APC include dendritic cells, B cells, and macrophages.
[0064] A vaccine often contains, or is administered with, an adjuvant. A vaccine adjuvant is an agent that stimulates the immune system and increases the immune system's response to a vaccine. In particular embodiments, RIG-1 agonists of the disclosure can increase immunogenicity of a vaccine for an infectious disease or cancer. In particular embodiments, RIG-1 agonists can activate interferon- Y (IFN-g) producing type 1 T helper cells (Th1 ) and cytotoxic T lymphocytes (CTLs). In particular embodiments, the vaccine is a cancer vaccine. The cancer vaccine can include a tumor antigen against which an immune response is desired and a RIG-I agonist of the present disclosure. In particular embodiments, the tumor antigen and the adjuvant are formulated together. In particular embodiments, the tumor antigen and the adjuvant are not formulated together.
[0065] A RIG-I agonist functioning as an adjuvant may be formulated with buffers, carriers, preservatives, and/or excipients as described below. A RIG-I agonist may also be delivered with other PAMPs such as CpG, lipopolysaccharide (LPS), flagellin, or monophosphoryl lipid A (MPLA).
[0066] An adjuvant including a RIG-I agonist can also include a pharmaceutically acceptable excipient, and optionally other adjuvant ingredients. For example, the adjuvant may include mineral oil, certain bacterial toxins, aluminum salts such as aluminum hydroxide and aluminum phosphate, squalene, virosomes, mineral oil in water emulsions (e.g., MF59, AS3, and
montanide), CpG, LPS, MPLA, QS21 or AS02, flagellin, peptidoglycans, and/or whole killed or otherwise inactivated bacterial pathogens. An adjuvant may also include agents that help stabilize the antigen and/or the RNA component, e.g., RNAse inhibitors.
[0067] An oligoribonucleotide may be incorporated into a composition including a pharmaceutically acceptable carrier or transfection reagent, including the oligoribonucleotides described herein. The carrier system may be a lipid-based carrier system such as a stabilized nucleic acid-lipid particle (e.g., SNALP or SPLP), cationic lipid or liposome nucleic acid complexes (i.e., lipoplexes), a liposome, a micelle, a virosome, or a mixture thereof. In other embodiments, the carrier system is a polymer-based carrier system such as a cationic polymer-nucleic acid complex (i.e., polyplex). In additional embodiments, the carrier system is a cyclodextrin-based carrier system such as a cyclodextrin polymer-nucleic acid complex (see US Patent Publication 2007/0218122). In further embodiments, the carrier system is a protein-based carrier system such as a cationic peptide-nucleic acid complex. An oligoribonucleotide molecule may also be delivered as naked RNA.
[0068] A pharmaceutical composition can be any combination of active and/or inert materials that can be administered to a subject for the purpose of treating a disease. A pharmaceutically acceptable carrier/vehicle can be any material or molecular entity that facilitates the administration or other delivery of the pharmaceutical composition. In general, the nature of the carrier will depend on the particular mode of administration being employed. For instance, parenteral formulations usually comprise injectable fluids that include pharmaceutically and physiologically acceptable fluids such as water, physiological saline, balanced salt solutions, aqueous dextrose, glycerol or the like as a vehicle.
[0069] Exemplary generally used pharmaceutically acceptable carriers include any and all bulking agents or fillers, solvents or co-solvents, dispersion media, coatings, surfactants, antioxidants (e.g., ascorbic acid, methionine, vitamin E), preservatives, isotonic agents, absorption delaying agents, salts, stabilizers, buffering agents, gels, binders, disintegration agents, and/or lubricants.
[0070] Exemplary buffering agents include citrate buffers, succinate buffers, tartrate buffers, fumarate buffers, gluconate buffers, oxalate buffers, lactate buffers, acetate buffers, phosphate buffers, histidine buffers and trimethylamine salts.
[0071] Exemplary preservatives include phenol, benzyl alcohol, meta-cresol, methyl paraben, propyl paraben, octadecyldimethylbenzyl ammonium chloride, benzalkonium halides, hexamethonium chloride, alkyl parabens such as methyl or propyl paraben, catechol, resorcinol, cyclohexanol and 3- pentanol.
[0072] Exemplary isotonic agents include polyhydric sugar alcohols including trihydric or higher sugar alcohols, such as glycerin, erythritol, arabitol, xylitol, sorbitol and mannitol.
[0073] Exemplary stabilizers include organic sugars, polyhydric sugar alcohols, polyethylene glycol; sulfur-containing reducing agents, amino acids, low molecular weight polypeptides, proteins, immunoglobulins, hydrophilic polymers and polysaccharides.
[0074] For injection, compositions can be made as aqueous solutions, such as in buffers such as Flanks' solution, Ringer's solution, or physiological saline. The solutions can contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the composition can be in lyophilized and/or powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
[0075] In particular embodiments, compositions can include liposomes. Liposomes are self assembling phospholipid bilayer structures that can be prepared from natural or synthetic phospholipid sources. These vesicles can encapsulate water soluble molecules in the aqueous volume while water insoluble molecules can be embedded in the hydrophobic region of the lipid bilayer. The simplest and the most widely used method for preparing liposomes is the thin lipid film hydration method introduced by Bangham et at. (J Mol Biol, 13:238, 1965). The constituents of a liposomal delivery system are the primary determinants of the preparation method to be employed. For instance, hydrophobic molecules can be included during the lipid film formation process (passive loading), whereas water soluble molecules can be introduced during the hydration step (passive loading) or incorporated later by active loading procedures using ion gradients. The phospholipid backbone of the liposomes includes saturated or unsaturated phospholipids with acyl chain length of 14 to 20 carbons. Surface modification by hydrophilic polymers is a commonly used method in liposomal delivery systems. The main goals of surface modification are prevention of particle aggregation and reduction of the capture of the liposomes by cells of the reticuloendothelial system. Due to their low degree of immunogenicity and antigenicity, polyethylene ethylene glycol (PEG) molecules of various chain lengths can be used to provide a protective shield over the phospholipid bilayer. PEG is a linear polyether diol that has a chemically inert backbone and hydroxyl groups available for derivatization. There are commercially available PEG derivatives that are covalently bound to phospholipids, functional groups, proteins, and even fluorescent probes. In certain embodiments, the liposomes contain at least one metal ion donor, such as MnC and/or MgC ; for instance, specific liposome embodiments contain 1 mM MnC and/or 10 mM MgCh.
[0076] The therapeutic compounds described herein may be systemically administered, e.g., orally, in combination with a pharmaceutically acceptable vehicle such as an inert diluent or an assimilable, edible carrier. They may be enclosed in hard or soft shell gelatin capsules, may be compressed into tablets, or may be incorporated directly with the food of the patient's diet. For oral therapeutic administration, the active compound may be combined with one or more excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. Such compositions and preparations should contain at least 0.1% of active compound. The percentage of the compositions and preparations may, of course, be varied and may conveniently be between about 2 to about 60% of the weight of a given unit dosage form. The amount of active
compound in such therapeutically useful compositions is such that an effective dosage level will be obtained.
[0077] The tablets, troches, pills, capsules, and the like may also contain the following: binders such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, fructose, lactose or aspartame or a flavoring agent such as peppermint, oil of wintergreen, or cherry flavoring may be added. When the unit dosage form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier, such as a vegetable oil or a polyethylene glycol. Various other materials may be present as coatings or to otherwise modify the physical form of the solid unit dosage form. For instance, tablets, pills, or capsules may be coated with gelatin, wax, shellac or sugar and the like. A syrup or elixir may contain the active compound, sucrose or fructose as a sweetening agent, methyl and propylparabens as preservatives, a dye and flavoring such as cherry or orange flavor. Of course, any material used in preparing any unit dosage form should be pharmaceutically acceptable and substantially non-toxic in the amounts employed. In addition, the active compound may be incorporated into sustained-release preparations and devices.
[0078] The active compound may also be administered intravenously or intraperitoneally by infusion or injection. Solutions of the active compound or its salts can be prepared in water, optionally mixed with a nontoxic surfactant. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, triacetin, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
[0079] The pharmaceutical dosage forms suitable for injection or infusion can include sterile aqueous solutions or dispersions or sterile powders comprising the active ingredient which are adapted for the extemporaneous preparation of sterile injectable or infusible solutions or dispersions, optionally encapsulated in liposomes. In all cases, the ultimate dosage form should be sterile, fluid and stable under the conditions of manufacture and storage. The liquid carrier or vehicle can be a solvent or liquid dispersion medium comprising, for example, water, ethanol, a polyol (for example, glycerol, propylene glycol, liquid polyethylene glycols, and the like), vegetable oils, nontoxic glyceryl esters, and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the formation of liposomes, by the maintenance of the required particle size in the case of dispersions or by the use of surfactants. The prevention of the action of (contaminating) microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, buffers or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.
[0080] Sterile injectable solutions are prepared by incorporating the active compound in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filter sterilization. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and the freeze-drying techniques, which yield a powder of the active ingredient plus any additional desired ingredient present in the previously sterile-filtered solutions.
[0081] For topical administration, the present compounds may be applied in pure form, i.e., when they are liquids. However, it will generally be desirable to administer them to the skin as compositions or formulations, in combination with a dermatologically acceptable carrier, which may be a solid or a liquid.
[0082] Useful solid carriers include finely divided solids such as talc, clay, microcrystalline cellulose, silica, alumina and the like. Useful liquid carriers include water, alcohols or glycols or water- alcohol/glycol blends, in which the present compounds can be dissolved or dispersed at effective levels, optionally with the aid of non-toxic surfactants. Adjuvants such as fragrances and additional antimicrobial agents can be added to optimize the properties for a given use. The resultant liquid compositions can be applied from absorbent pads, used to impregnate bandages and other dressings, or sprayed onto the affected area using pump-type or aerosol sprayers.
[0083] Thickeners such as synthetic polymers, fatty acids, fatty acid salts and esters, fatty alcohols, modified celluloses or modified mineral materials can also be employed with liquid carriers to form spreadable pastes, gels, ointments, soaps, and the like, for application directly to the skin of the user.
[0084] In particular embodiments, for topical administration, the formulation can further include a penetration enhancer. The penetration enhancer can be a skin penetration enhancer. A skin penetration enhancer is a molecule that promotes the diffusion of polypeptides through the skin. A variety of compounds have been shown to be effective skin penetration enhancers. See, Percutaneous Penetration Enhancers (Smith et al., CRC Press, Inc., Boca Raton, F.L. 1995). Exemplary skin penetration enhancers include sulfoxides such as dimethylsulfoxide (DMSO) and decylmethylsulfoxide (CioMSO; DeMS); ethers such as diethylene glycol monoethyl ether and diethylene glycol monomethyl ether; surfactants such as sodium laurate, sodium lauryl sulfate, cetyltrimethylammonium bromide, benzalkonium chloride, Poloxamer (231 , 182, 184), Tween (20, 40, 60, 80), and lecithin; the 1 - substituted azacycloheptan-2-ones, particularly l-n-dodecylcyclazacycloheptan-2-one; alcohols such as ethanol, propanol, octanol, benzyl alcohol, etc.; fatty acids such as lauric acid, oleic acid and valeric acid; fatty acid esters such as isopropyl myristate, isopropyl palmitate, methylpropionate, and ethyl oleate; polyols and esters thereof such as propylene glycol, ethylene glycol, glycerol, butanediol, polyethylene glycol, and polyethylene glycol monolaurate; amides and other nitrogenous compounds such as urea, dimethylacetamide (DMA), dimethylformamide (DMF), 2-pyrrolidone, l-methyl-2- pyrrolidone, ethanolamine, diethanolamine and triethanolamine; terpenes; alkanones; organic acids,
particularly salicylic acid and salicylates, citric acid, and succinic acid; polyacrylic acids such as a carbomer (CARBOPOL™, B. F. Goodrich Company) and copolymers of C10 to C30 alkyl acrylates and one or more monomers of acrylic acid, methacrylic acid or one of their simple esters crosslinked with an allyl ether of sucrose or an allyl ether of pentaerythritol (PERMULEN™, B.F. Goodrich Company); galactomannan gums such as guar gum or locust bean gum; polysaccharide gum such as agar gum, alginate, carob gum, carrageen gum, ghatti gum, guar gum, karaya gum, kadaya gum, locust bean gum, rhamsan gum, xanthan gum, or a mixture thereof; and cellulose derivatives such as ethyl cellulose, methyl cellulose, hyrdoxypropyl cellulose, and mixtures thereof.
[0085] In particular embodiments, the compositions can be in the form of, e.g., gels, ointments, pastes, lotions, creams, sprays, foams, liquids, aerosol, suspension, emulsion, hydrogels, or powders. It is particularly contemplated that the compositions may be formulated as shampoos, soaps, body washes, and the like. A gel is a substantially dilute cross-linked system, which exhibits no flow when in the steady-state. Most gels are liquid; however, they behave more like solids due to the three- dimensional cross-linked network within the liquid. Gels can have properties ranging from soft and weak to hard and tough. An ointment is a homogeneous, viscous, semi-solid preparation, most commonly a greasy, thick oil (oil 80% - water 20%) with a high viscosity. Ointments have a water number, which is the maximum quantity of water that 100 g of a base can contain at 20°C. A paste includes three agents - oil, water, and powder, one of which includes a therapeutic agent. Pastes can be an ointment in which a powder is suspended. A lotion also includes oil, water, and powder, but can have additional components (e.g., alcohol to hold the emulsion together) and often has a lower viscosity than a paste. A cream is an emulsion of oil and water in equal proportions. Creams are thicker than lotions and maintain their shape when removed from a container.
[0086] Topical formulations disclosed herein can include components, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc, titanium oxide, and zinc oxide, or mixtures thereof. In particular embodiments, topical formulations may include thickening agents, surfactants, organic solvents, and/or tonicity modifiers. Optionally, in certain embodiments the topical formulations include one or more of retinol, tretinoin, vitamin A, vitamin C, hydroquinones, alpha hydroxy acids (AHAs), and/or beta hydroxy acids (BHAs).
[0087] Examples of useful dermatological compositions which can be used to deliver the therapeutic compounds provided herein to the skin are known to the art; for example, see Jacquet et al. (U.S. Pat. No. 4,608,392), Geria (U.S. Pat. No. 4,992,478), Smith et al. (U.S. Pat. No. 4,559,157) and Wortzman (U.S. Pat. No. 4,820,508).
[0088] In particular embodiments, the compositions may be in the form of emulsions. An emulsion is a dispersed system containing at least two immiscible liquid phases, one of which is dispersed in the form of small droplets throughout the other, and an emulsifying agent in order to improve the stability
of the system. There are two types of emulsions depending on the droplet size of the liquids present in the emulsions: macroemulsions and microemulsions. Light does not pass through macroemulsions because the droplets have average diameters of 10 to 1000 pm. These emulsions typically appear milky white. Microemulsions are stable systems having droplets which are significantly smaller, being 500 nm or smaller in diameter on the average. As such, microemulsions are translucent, and routinely transparent, in appearance. Microemulsions are an extraordinary type of emulsion that form spontaneously. Products having these systems are valued for their stability and small particle size, thus affording microemulsions a special consideration in the marketplace.
[0089] Compositions can also be depot preparations. Such long acting compositions may be administered by, for example, implantation (for example, subcutaneously). Thus, for example, compounds can be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as sparingly soluble salts. Optionally, such preparations may include one or more injectable fillers.
[0090] Additionally, compositions can be delivered using sustained-release systems, such as semipermeable matrices of solid polymers containing at least one compound disclosed herein. Various sustained-release materials have been established and are well known by those of ordinary skill in the art. Sustained-release capsules may, depending on their chemical nature, release the compound following administration for a few weeks up to over 100 days.
[0091] Useful dosages of the therapeutic compounds provided herein can be determined by comparing their in vitro activity, and in vivo activity in animal models. Methods for the extrapolation of effective dosages in mice, and other animals, to humans are known to the art; for example, see U.S. Pat. No. 4,938,949.
[0092] The amount of the compound useful or required for use in treatment will vary not only with the particular compound selected but also with the route of administration, the nature of the condition being treated and the age and condition of the patient and will be ultimately at the discretion of the attendant physician or clinician.
[0093] The desired dose may conveniently be presented in a single dose or as divided doses administered at appropriate intervals, for example, as two, three, four or more sub-doses per day. The sub-dose itself may be further divided, e.g., into a number of discrete loosely spaced administrations.
[0094] Methods of Use:
[0095] Methods disclosed herein include treating subjects (humans, veterinary animals (dogs, cats, reptiles, birds, etc.) livestock (horses, cattle, goats, pigs, chickens, etc.) and research animals (monkeys, rats, mice, fish, etc.) with one or more therapeutic compositions disclosed herein. Treating subjects includes delivering one or more therapeutically effective amount(s). Therapeutically effective
amounts include those that provide effective amounts, prophylactic treatments and/or therapeutic treatments.
[0096] Further types of subjects to which the pharmaceutical composition may be properly administered include subjects known to have cancer or any neoplastic disease (identified through, for example, a molecular diagnostic test or clinical diagnosis), subjects having a predisposition to developing cancer, or subjects displaying one or more symptoms of cancer.
[0097] Cancer (neoplasia) is characterized by deregulated cell growth and cell division. There are numerous types of cancers. Examples of cancers include acoustic neuroma, adenocarcinoma, astrocytoma, basal cell cancer, bile duct cancer, bladder cancer, brain cancer, breast cancer, bronchogenic cancer, central nervous system cancer, cervical cancer, colon cancer, lung cancer, prostate cancer, ovarian cancer, pancreatic cancer, thyroid cancer, and leukemia. Examples of cancers include acoustic neuroma, adenocarcinoma, astrocytoma, basal cell cancer, bile duct cancer, bladder cancer, brain cancer, breast cancer, bronchogenic cancer, central nervous system cancer, cervical cancer, chondrosarcoma, choriocarcinoma, chronic lymphocytic leukemia, colon cancer, craniopharyngioma, ependymoma, Ewing's tumor, fibrosarcoma, glandular cancer, glioma, hairy cell leukemia, hemangioblastoma, hepatocellular carcinoma, hepatoma, kidney cancer, leiomyosarcoma, liver cancer, liposarcoma, lung cancer, melanoma, medulloblastoma, medullary cancer, medullary thyroid cancer, menangioma, mesothelioma, multiple myeloma (MM), myxosarcoma, neuroblastoma, non-Flodgkin's lymphoma, oligodendroglioma, osteogenic sarcoma, ovarian cancer, papillary adenocarcinomas, papillary thyroid cancer, pancreatic cancer, pheochromocytomas papillary cancer, pineal cancer, prolymphocytic leukemia, prostate cancer (including castration-resistant prostate cancer), renal cell cancer, retinoblastoma, rhabdomyosarcoma, sarcoma, sebaceous gland cancer, seminoma, skin cancer, squamous cell cancer, sweat gland cancer, synovioma, testicular cancer, and/or Wilms' tumor.
[0098] In some embodiments, it is believed that certain types of cancers may be less susceptible to the therapeutic treatments described herein. For instance, because RIG-1 agonist mediated cancer cell death is mediated in part by IFN release, cells that have a poor IFN response may be more resistant to cell death induction. However, the other (IFN-independent) mechanisms described herein would nevertheless become activated to kill these cells. Alternatively, some tumor cells may be resistant to uptake of the therapeutic RNA oligonucleotide (e.g., M8), such that the amount delivered to the cells might be limited, which would then limit cell death. This issue can be corrected by delivering the therapeutic RIG-1 agonist RNA as a formulation, such as a nanoparticle that 'protects' the RNA. Similarly, tumor cells that are rich in RNAase activity could destroy the therapeutic RNA oligonucleotide before it has an opportunity to bind RIG-1 and activate the cell death cascade.
[0099] Cancer (sometimes referred to medically as malignant neoplasm) refers to a class of diseases in which a group of cells display uncontrolled growth (division beyond the normal limits), invasion
(intrusion on and destruction of adjacent tissues), and sometimes metastasis.“Metastasis” refers to the spread of cancer cells from their original site of proliferation to another part of the body. For solid tumors, the formation of metastasis is a very complex process and depends on detachment of malignant cells from the primary tumor, invasion of the extracellular matrix, penetration of the endothelial basement membranes to enter the body cavity and vessels, and then, after being transported by the blood or lymph, infiltration of target organs. Finally, the growth of a new tumor, i.e. a secondary tumor or metastatic tumor, at the target site depends on angiogenesis. Tumor metastasis often occurs even after the removal of the primary tumor because tumor cells or components may remain and develop metastatic potential.
[0100] Treating subjects includes delivering therapeutically effective amounts. Therapeutically effective amounts include those that provide effective amounts, prophylactic treatments and/or therapeutic treatments.
[0101] An“effective amount” is the amount of active agent(s) or composition(s) necessary to result in a desired physiological change in vivoor in vitro. Effective amounts are often administered for research purposes. In particular embodiments, effective amounts disclosed herein can cause a statistically- significant effect in an animal model or in vitro assay relevant to the assessment of: number of cancer cells; number of tumors, size of tumors and/or total tumor burden; level or speed of metastasis; frequency of or time to onset of cancer; and risk of death (hazard ratios) and/or increase in survival in subjects exposed to a cancer-causing agent.
[0102] A“prophylactic treatment” includes a treatment administered to a subject who does not display signs or symptoms of cancer, cancer relapse, or metastasis or displays only early signs or symptoms of cancer, cancer relapse, or metastasis such that treatment is administered for the purpose of diminishing, preventing, or decreasing the risk of developing cancer relapse or metastasis further. Thus, a prophylactic treatment functions as a preventative treatment against cancer, cancer relapse, or metastasis. In particular embodiments, prophylactic treatments prevent, reduce, or delay cancer, cancer relapse, or metastasis from a primary tumor site from occurring.
[0103] A “therapeutic treatment” includes a treatment administered to a subject who displays symptoms or signs of cancer (initial, relapsed, or metastasis) and is administered to the subject for the purpose of diminishing or eliminating further signs or symptoms of cancer or metastasis. The therapeutic treatment can reduce, control, or eliminate the presence or activity of cancer or metastasis and/or reduce control or eliminate side effects of cancer or metastasis. In particular embodiments, therapeutic treatments prevent, reduce, or delay further cancer or metastasis from occurring.
[0104] In particular embodiments, therapeutically effective amounts provide an anti-cancer effect, through providing an effective amount, a prophylactic treatment and/or a therapeutic treatment. As used herein, an anti-cancer effect refers to a biological effect, which can be manifested by a decrease in tumor volume, a decrease in the number of cancer cells, a decrease in the number of metastases,
an increase in life expectancy, and/or a decrease of various physiological symptoms associated with the cancerous condition. An anti-cancer effect can also be manifested by a decrease in recurrence or an increase in the time before recurrence.
[0105] In particular embodiments, an anti-cancer effect includes death of cancerous cells in a subject in need thereof administered a RIG-I agonist of the present disclosure. Death of the cancerous cells can be indicated or measured in a number of ways. In particular embodiments, death of the cancerous cells is associated with an increase in expression of chemokines CCL2, CXCL1 , CXCL10, and/or IFNp in the cancerous cells. In particular embodiments, chemokines CCL2, CXCL1 , CXCL10, and/or IFNp in the cancerous cells increase by 2 fold, 3 fold, 4 fold, 5 fold, or more, as compared to the corresponding chemokine expression in cancerous cells in the subject prior to the administering. In particular embodiments, death of the cancerous cells is associated with an increase in surface exposure of calreticulin on the cancerous cells. In particular embodiments, the percentage of cancerous cells that express calreticulin increases 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, or more as compared to the percentage of cancerous cells that express calreticulin in the subject prior to the administering. In particular embodiments, death of the cancerous cells is associated with an increase in secretion of High Mobility Group Box 1 (HMGB1 ) from the cancerous cells. In particular embodiments, HMGB1 secretion from the cancerous cells is increased 1.5 fold, 2 fold, 3 fold, 4 fold, 5 fold, or more, as compared to secretion of HMGB1 from cancerous cells in the subject prior to the administering. In particular embodiments, death of the cancerous cells is associated with an increase in release of ATP. In particular embodiments, ATP release from the cancerous cells increases 5 fold, 10 fold, 20 fold, 50 fold, 100 fold, 1000 fold, or more, as compared to ATP release from cancerous cells in the subject prior to the administering.
[0106] In particular embodiments, an anti-cancer effect includes immune reactivation in a subject in need thereof administered a RIG-I agonist of the present disclosure. Immune reactivation can be indicated or measured in a number of ways. In particular embodiments, immune reactivation is associated with an increase in NK activating ligands on the cancerous cells. In particular embodiments, the NK activating ligands include MICA, MICB, ULBP1 , ULBP3, Nectin-2, PVR, and/or B7-H6. In particular embodiments, the amount of NK activating ligands on the cancerous cells increase 1 .1 fold, 1.2 fold, 1 .3 fold, 1 .4 fold, 1 .5 fold, 1 .6 fold, 1 .7 fold, 1.8 fold, 1 .9 fold, 2 fold, or more as compared to the amount of corresponding NK activating ligands on cancerous cells in the subject prior to the administering. In particular embodiments, immune reactivation is associated with induction of expression of an NK inhibiting marker on the cancerous cells. In particular embodiments, the NK inhibiting marker is HLA-ABC. In particular embodiments, NK inhibiting marker expression is induced 2 fold, 3 fold, 4 fold, 5 fold, 6 fold, or more, as compared to NK inhibiting marker expression in cancerous cells in the subject prior to the administering. In particular embodiments, immune reactivation is associated with induction of antigen processing machinery (APM) genes in the
cancerous cells. In particular embodiments, the APM genes include: immunoproteasome subunits PSMB8, PSMB9, and PSMB10; transporters associated with antigen processing TAP1 and TAP2; and the endoplasmic reticulum chaperone Tapasin (TAPBP). In particular embodiments, APM genes are induced 15 fold, 20 fold, 30 fold, 40 fold, 50 fold, 60 fold, 70 fold, 80 fold, 90 fold, 100 fold, 200 fold, 300 fold, 400 fold, 500 fold, or more, as compared to the corresponding APM gene levels in cancerous cells in the subject prior to the administering. In particular embodiments, immune reactivation is associated with an increase in expression of CD80, CD86, and/or HLA-DR on dendritic cells from the subject. In particular embodiments, expression of CD80, CD86, and/or HLA-DR on dendritic cells increase 2 fold, 3 fold, 4 fold, 5 fold, or more, as compared to the corresponding markers on dendritic cells from the subject prior to the administering. In particular embodiments, immune reactivation is associated with an increase in IL-12 expression in dendritic cells from the subject. In particular embodiments, IL-12 expression increases 5 fold, 10 fold, 15 fold, 20 fold, or more, as compared to IL- 12 expression in dendritic cells from the subject prior to the administering.
[0107] In particular embodiments, methods of the disclosure include using a RIG-I agonist of the disclosure as an adjuvant for a cancer vaccine to stimulate an immune response against a tumor antigen in a subject at risk of having or having a cancer comprising the tumor antigen. Effectiveness of a RIG-I agonist as an adjuvant can be measured by a number of parameters including: tumor growth; early and late apoptosis of tumor cells by T cells using annexin V-FITC and propidium idodide, respectively; effector function of T cells isolated from tumors can be assessed for activation, proliferation, and lytic function by examining the levels of ICOS, Ki-67, and Granzyme B, respectively; tumor infiltrating cells can be identified and quantified by flow cytometry as follows: 1 ) cells of the innate immune compartment including NK cells (NK1 1 hi, CD3 NK1 1 hi, or CD3 DX5+) and NKT cells (NK1 .1 hi(or DX5+)CD3ehiCD1 dhiCD60hi), and 2) cells of the adaptive compartment including CD8+ T cells, CD8+ subpopulations (IFNg+ Th1 , IL4+ Th2, IL-17+, Th17), CD4+ T cells, and CD4+ subpopulations (FoxP3+CD127 CD25hi Treg) ; identification and quantification of immunosuppressive regulatory T cells (CD4hiCD25hiFoxP3hi) and myeloid-derived suppressor cells (CD1 1 bhiGr1 hi) by flow cytometry; memory status of CD8+ cells can be characterized by CCR7/CD45RO/CD62L/CD45RA expression levels; identification and quantification of granulocytic (CD1 1 b+Ly6G+Ly6C'°) and monocytic (CD1 1 b+Ly6G Ly6Chi) myeloid-derived suppressor cells; and/or macrophage M1 /M2 polarization status.
[0108] In particular embodiments, methods to stimulate an immune response against a tumor antigen in a subject at risk of having or having a cancer comprising the tumor antigen can further include administering a second anti-cancer agent to the subject. In particular embodiments, the second anti cancer agent is low dose chemotherapy. In particular embodiments, the second anti-cancer agent is an immune checkpoint inhibitor drug that blocks an immune checkpoint protein selected from
programmed cell death protein 1 (PD-1 ), programmed death-ligand 1 (PD-L1 ), and cytotoxic T- lymphocyte-associated protein 4 (CTLA-4).
[0109] A“tumor” is a swelling or lesion formed by an abnormal growth of cells (called neoplastic cells or tumor cells). A“tumor cell” is an abnormal cell that divides by a rapid, uncontrolled cellular proliferation and continues to divide after the stimuli that initiated the new division cease. Tumors show partial or complete lack of structural organization and functional coordination with the normal tissue, and usually form a distinct mass of tissue, which may be either benign, pre-malignant or malignant.
[0110] For administration, therapeutically effective amounts (also referred to herein as doses) can be initially estimated based on results from in vitro assays and/or animal model studies. The actual dose amount administered to a particular subject can be determined by a physician, veterinarian or researcher taking into account parameters such as physical and physiological factors including target, body weight, severity of cancer, type of cancer, stage of cancer, previous or concurrent therapeutic interventions, idiopathy of the subject and route of administration.
[0111] A therapeutically effective amount or concentration of a compound such as the disclosed oligoribonucleotides may be any amount of a composition that alone, or together with one or more additional therapeutic agents (such as another anti-cancer agent), is sufficient to achieve a desired effect in a subject. The effective amount of the agent will be dependent on several factors, including, but not limited to, the subject being treated and the manner of administration of the therapeutic composition. In one example, a therapeutically effective amount or concentration is one that is sufficient to prevent advancement, delay progression, or to cause regression of a disease, or which is capable of reducing symptoms caused by any disease, including cancer or any neoplasia.
[0112] In one example, a desired effect is to reduce or inhibit one or more symptoms associated with cancer. The one or more symptoms do not have to be completely eliminated for the composition to be effective. For example, a composition can decrease the sign or symptom by a desired amount, for example by at least 20%, at least 50%, at least 80%, at least 90%, at least 95%, at least 98%, or even at least 100%, as compared to the sign or symptom in the absence of the composition.
[0113] A therapeutically effective amount of a pharmaceutical composition can be administered in a single dose, or in several doses, for example daily, during a course of treatment. Flowever, the therapeutically effective amount can depend on the subject being treated, the severity and type of the condition being treated, and the manner of administration. For example, a therapeutically effective amount of such agent can vary from about 100 pg -10 mg per kg body weight if administered intravenously.
[0114] The actual dosages will vary according to factors such as the type of cancer to be treated and the particular status of the subject (for example, the subject’s age, size, fitness, extent of symptoms, susceptibility factors, and the like) time and route of administration, other drugs or treatments being administered concurrently, as well as the specific pharmacology of treatments for cancer for eliciting
the desired activity or biological response in the subject. Dosage regimens can be adjusted to provide an optimum prophylactic or therapeutic response.
[0115] Dosage can be varied by the attending clinician to maintain a desired concentration. Higher or lower concentrations can be selected based on the mode of delivery, for example, trans-epidermal, rectal, oral, pulmonary, intranasal delivery, intravenous or subcutaneous delivery.
[0116] Determination of effective amount is in some instances based on animal model studies followed up by human clinical trials and can be guided by administration protocols that significantly reduce the occurrence or severity of targeted disease symptoms or conditions in the subject. Suitable models in this regard include, for example, murine, rat, porcine, feline, non-human primate, and other accepted animal model subjects known in the art. Alternatively, effective dosages can be determined using in vitro models (for example, cell culture assays). Using such models, only ordinary calculations and adjustments are required to determine an appropriate concentration and dose to administer a therapeutically effective amount of the treatments for cancer treatment (for example, amounts that are effective to alleviate one or more symptoms of a cancer).
[0117] A therapeutically effective amount is also one in which any toxic or detrimental side effects of the compound and/or other biologically active agent is outweighed in clinical terms by therapeutically beneficial effects. A non-limiting range for a therapeutically effective amount of treatments for cancer within the methods and formulations of the disclosure is about 0.0001 pg/kg body weight to about 10 mg/kg body weight per dose, such as about 0.0001 pg/kg body weight to about 0.001 pg/kg body weight per dose, about 0.001 pg/kg body weight to about 0.01 pg/kg body weight per dose, about 0.01 pg/kg body weight to about 0.1 pg/kg body weight per dose, about 0.1 pg/kg body weight to about 10 pg/kg body weight per dose, about 1 pg/kg body weight to about 100 pg/kg body weight per dose, about 100 pg/kg body weight to about 500 pg/kg body weight per dose, about 500 pg/kg body weight per dose to about 1000 pg/kg body weight per dose, or about 1 .0 mg/kg body weight to about 10 mg/kg body weight per dose.
[0118] By way of specific example, the compound herein referred to as M8 was administered at a rate of 2-25 pg per mouse (the average weight of which was 0.01 kg). This is equivalent to 15.5 nM/kg - 77.5 nM/kg, which provides useful doses for treatment in other subjects, including human subjects.
[0119] Useful doses of a therapeutic compounds, such as the oligonucleotides described herein, can range from 0.1 to 5 pg or from 0.5 to 1 pg. In other examples, a dose can include 1 pg, 5 pg, 10 pg, 15 pg, 20 pg, 25 pg, 30 pg, 35 pg, 40 pg, 45 pg, 50 pg, 55 pg, 60 pg, 65 pg, 70 pg, 75 pg, 80 pg, 85 pg, 90 pg, 95 pg, 100 pg, 150 pg, 200 pg, 250 pg, 350 pg, 400 pg, 450 pg, 500 pg, 550 pg, 600 pg, 650 pg, 700 pg, 750 pg, 800 pg, 850 pg, 900 pg, 950 pg, 1000 pg, 0.1 to 5 mg or from 0.5 to 1 mg. In other examples, a dose can include 1 mg, 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, 100 mg, 150 mg, 200 mg, 250 mg, 350 mg, 400 mg, 450 mg, 500 mg, 550 mg, 600 mg, 650 mg, 700 mg, 750 mg, 800
mg, 850 mg, 900 mg, 950 mg, 1000 mg, or more. In one particular example, doses can be administered QD or BID to a subject with, e.g., total daily doses of 1 .5 mg/kg, 3.0 mg/kg, or 4.0 mg/kg of a composition with up to 92-98% wt/v of the compounds disclosed herein.
[0120] In particular embodiments, a therapeutic compound may be present from 0.1 wt. % to 10 wt. %, 0.1 wt. % to 9 wt. %, 0.1 wt. % to 8 wt. %, 0.1 wt. % to 7 wt. %, 0.1 wt. % to 6 wt. %, 0.1 wt. % to 5 wt. %, 0.1 wt. % to 4 wt. %, 0.1 wt. % to 3 wt. %, 0.1 wt. % to 2 wt. %, or 0.1 wt. % to 1 wt. %. Specific examples include 0.1 wt. %, 0.5 wt. %, 1 wt. %, 2 wt. %, 5 wt. %, 10 wt. %, and ranges between any two of these values. The weight percentages disclosed herein may be weight-to-weight or weight-to- volume percentages with respect to the total amount of the composition.
[0121] Therapeutically effective amounts can be achieved by administering single or multiple doses during the course of a treatment regimen (e.g., hourly, every 2 hours, every 3 hours, every 4 hours, every 6 hours, every 9 hours, every 12 hours, every 18 hours, daily, every other day, every 3 days, every 4 days, every 5 days, every 6 days, weekly, every 2 weeks, every 3 weeks, or monthly).
[0122] Administration of a pharmaceutical composition may be any method of providing or give a subject a pharmaceutical composition comprising the disclosed oligoribonucleotides, by any effective route. Exemplary routes of administration include, but are not limited to, injection (such as subcutaneous, intramuscular, intradermal, intraperitoneal, and intravenous), oral, sublingual, rectal, transdermal, intranasal, vaginal and inhalation routes.
[0123] In particular embodiments, administration of the therapeutic compound is by topical application, transdermal, percutaneous, or microneedle injection. Administration can also be, for example, parenteral, subcutaneous, intravenous, intramuscular, intraperitoneal, transdermal, oral, buccal, or ocular routes, or intravaginally, by inhalation, by depot injections, or by implants.
[0124] In particular embodiments, therapeutic compositions are administered percutaneously, and the compound reaches epidermal and dermal layer through percutaneous absorption. In some embodiments, the percutaneous application of the anhydrous composition does not result in systemic absorption. In some embodiments, percutaneous delivery is aided by the use of ultrasound technology. The ultrasound energy is applied to percutaneous delivery composition over the tissue and assists the diffusion of the composition past the tissue. Also contemplated are delivery methods involving iontophoresis, electroporation, magnetophoresis, laser assisted peptide delivery, and so forth.
[0125] In particular embodiments, the compositions disclosed herein can be used in conjunction with other cancer treatments. For example, the composition disclosed herein can be administered in combination with other active ingredients, for example, a gonadotropin-releasing hormone agonist or antagonist (e.g., Lupron, Zoladex (Goserelin), Degarelix, Ozarelix, ABT-620 (Elagolix), TAK-385 (Relugolix), EP-100 or KLH-2109); a phosphoinositide 3-kinase (PI3K) inhibitor, a TORC inhibitor, or a dual PI3K/TORC inhibitor (e.g., BEZ-235, BKM120, BGT226, BYL-719, GDC0068, GDC-0980, GDC0941 , GDC0032, MK-2206, OSI-027, CC-223, AZD8055, SAR245408, SAR245409,
PF04691502, WYE125132, GSK2126458, GSK-2636771 , BAY806946, PF-05212384, SF1 126, PX866, AMG319, ZSTK474, Call 01 , PWT33597, LY-317615 (enzastaurin hydrochloride), CU-906, or CUDC-907); a CYP17 inhibitor in addition to Galeterone ( e.g ., abiraterone acetate (Zytiga), TAK-700 (orteronel), or VT-464); prednisone; an osteoprotective agent; a radiation therapy; a kinase inhibitor (e.g. MET, VEGFR, EGFR, MEK, SRC, AKT, RAF, FGFR, CDK4/6); Provenge, Prostvac, Ipilimumab, a PD-1 inhibitor; a taxane or tubulin inhibitor; an anti-STEAP-1 antibody; a heat shock protein 90 (HSP90) or heat shock protein 27 (HSP27) pathway modulator; an anti-androgen (e.g., bicalutamide); and/or immunotherapy.
[0126] Kits.
[0127] Active component(s), including particularly at least one described RIG agonist, can be provided as kits. Kits can include one or more containers including (containing) one or more or more compounds as described herein, optionally along with one or more agents for use in therapy. For instance, some kits will include an amount of at least one additional anti-cancer composition. In particular embodiments a kit can include an immunization kit including a vaccine composition described herein (for instance, a cancer vaccine composition). In particular embodiments, a vaccine composition includes: a tumor antigen; and an adjuvant including at least one described RIG agonist of the disclosure. In particular embodiments, the tumor antigen and the adjuvant are in separate containers. In particular embodiments, the tumor antigen and the adjuvant are in the same container.
[0128] Any active component in a kit may be provided in premeasured dosages, though this is not required; and it is anticipated that certain kits will include more than one dose.
[0129] Kits can also include a notice in the form prescribed by a governmental agency regulating the manufacture, use, or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use, or sale for human administration. The notice may state that the provided active ingredients can be administered to a subject. The kits can include further instructions for using the kit, for example, instructions regarding administration; proper disposal of related waste; and the like. The instructions can be in the form of printed instructions provided within the kit or the instructions can be printed on a portion of the kit itself. Instructions may be in the form of a sheet, pamphlet, brochure, CD-ROM, or computer-readable device, or can provide directions to instructions at a remote location, such as a website. In particular embodiments, kits can also include some or all of the necessary medical supplies needed to use the kit effectively, such as applicators, ampules, sponges, sterile adhesive strips, Chloraprep, gloves, and the like. Variations in contents of any of the kits described herein can be made. The instructions of the kit will direct use of the active ingredient(s) included in that kit to effectuate a clinical and/or therapeutic use described herein.
[0130] Suitable methods, materials, and examples used in the practice and/or testing of embodiments of the disclosed invention are described herein. Such methods and materials are illustrative only and
are not intended to be limiting. Other methods, materials, and examples similar or equivalent to those described herein can be used.
[0131] Exemplary Embodiments.
1. A method of treating cancer in a subject in need thereof including: administering to the subject a therapeutically effective amount of a synthetic oligoribonucleotide including: a 5' end triphosphate group, and the sequence shown in M8 (SEQ ID NO: 13) or M5 (SEQ ID NO: 10), thereby treating the cancer in the subject.
2. A method of treating cancer in a subject in need thereof including: administering to the subject a therapeutically effective amount of a synthetic oligoribonucleotide including: a 5' end triphosphate group, and the sequence shown in SEQ ID NO: 1 1 , SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, or SEQ ID NO: 17, thereby treating the cancer in the subject.
3. The method of embodiment 1 or embodiment 2, wherein the cancer includes melanoma, adenocarcinoma, carcinoma, or a metastatic cancer.
4. The method of embodiment 1 or embodiment 2, wherein the cancer includes lung cancer, colon cancer, or prostate cancer.
5. The method of embodiment 1 or embodiment 2, wherein the sequence of the synthetic oligonucleotide consists of the sequence shown in M8 (SEQ ID NO: 13) or M5 (SEQ ID NO: 10).
6. The method of embodiment 1 or embodiment 2 , further administering at least one second anti-cancer agent.
7. A method of inducing death of cancerous cells in a subject, including: administering to the subject a therapeutically effective amount of a synthetic oligoribonucleotide including: a 5' end triphosphate group, and the sequence shown in M8 (SEQ ID NO: 13), r M5 (SEQ ID NO: 10), SEQ ID NO: 1 1 , SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, or SEQ ID NO: 17, thereby inducing death of cancerous cells in the subject.
8. The method of embodiment 7, wherein the cancerous cells include melanoma cells, adenocarcinoma cells, carcinoma cells, or metastatic cells.
9. The method of embodiment 7, wherein the cell death is dependent on caspase 3.
10. The method of embodiment 7, wherein the cell death is dependent on type I interferon (IFN-I).
11 . The method of embodiment 7, wherein death of cancerous cells includes: an increase in expression of chemokines CCL2, CXCL1 , CXCL10, and/or IFNp in the cancerous cells; an increase in surface exposure of calreticulin on the cancerous cells; an increase in secretion of High Mobility Group Box 1 (HMGB1 ) from the cancerous cells; and/or an increase in release of ATP from the cancerous cells, as compared to the corresponding parameter in cancerous cells from the subject prior to the administering.
12. The method of embodiment 7, wherein administering further elicits immune reactivation in the subject.
13. The method of embodiment 12, wherein the immune reactivation includes: an increase in NK activating ligands on the cancerous cells; induction of expression of an NK inhibiting marker on the cancerous cells; induction of antigen processing machinery (APM) genes in the cancerous cells; an increase in expression of CD80, CD86, and/or HLA-DR on dendritic cells from the subject; and/or an increase in IL-12 expression in dendritic cells from the subject, as compared to the corresponding parameter in cancerous cells or dendritic cells from the subject prior to the administering.
14. The method of embodiment 7, wherein the sequence of the synthetic oligonucleotide consists of the sequence shown in M8 (SEQ ID NO: 13) or M5 (SEQ ID NO: 10).
15. The method of embodiment 7, further administering at least one second anti-cancer agent.
16. The method of any one of embodiments 1 , 2, or 6, wherein the therapeutically effective amount includes at least 0.2 milligrams to at least 5 milligrams of the synthetic oligoribonucleotide per kilogram of the subject's body weight per week (0.2-5 mg/kg/wk).
17. The method of any one of embodiments 1 , 2, or 6, wherein the therapeutically effective amount includes at least 0.5 milligrams to at least 2.5 milligrams of the synthetic oligoribonucleotide per kilogram of the subject's body weight per week (0.5-2.5 mg/kg/wk).
18. The method of any one of embodiments 1 , 2, or 6, wherein the synthetic oligoribonucleotide is administered to the subject for at least 1 -52 weeks.
19. The method of any one of embodiments 1 , 2, or 6, wherein the synthetic oligoribonucleotide is administered to the subject 1 -6 times per week.
20. The method of any one of embodiments 1 , 2, or 6, wherein the synthetic oligoribonucleotide is administered 1 -6 times during the first week and 1 time each subsequent week.
21 . The method of any one of embodiments 1 , 2, or 6, wherein the synthetic oligoribonucleotide is administered in a total weekly dose of any of 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, 125 mg, 150 mg, 175 mg, 200 mg, 225 mg, 250 mg, 275 mg, 300 mg, 325 mg, 350 mg, 375 mg, 400 mg, 425 mg, 450 mg, 475 mg, 500 mg, 525 mg, 550 mg, 575 mg, 600 mg, 625 mg, 650 mg, 675 mg, 700 mg, 725 mg, or 750 mg.
22. The method of any one of embodiments 1 , 2, or 6, wherein the effective amount is administered at a rate of 5 nM/kg to 100 nM/kg of the synthetic oligoribonucleotide per kilogram of the subject's body.
23. The method of embodiment 22, wherein the therapeutically effective amount includes 15.5 nM/kg to 77.5 nM/kg of the synthetic oligoribonucleotide per kilogram of the subject's body.
24. A cancer vaccine composition including a tumor antigen; an adjuvant; and a pharmaceutically acceptable carrier,
wherein the adjuvant includes a synthetic oligoribonucleotide including: a 5' end triphosphate group, and the sequence shown in M8 (SEQ ID NO: 13), M5 (SEQ ID NO: 10), SEQ ID NO: 1 1 , SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, or SEQ ID NO: 17
25. The cancer vaccine composition of embodiment 24, wherein the tumor antigen is derived from tumors found in melanoma, skin cancer, prostate cancer, lung cancer, pancreatic cancer, or breast cancer.
26. The cancer vaccine composition of embodiment 24, wherein the tumor antigen is part of a tumor cell lysate.
27. The cancer vaccine composition of embodiment 24, wherein the tumor antigen is part of an inactivated cancer cell population.
28. The cancer vaccine composition of embodiment 24, wherein the tumor antigen is part of an antigen presenting cell (APC) population.
29. The cancer vaccine composition of embodiment 28, wherein the APC population includes dendritic cells.
30. The cancer vaccine composition of embodiment 24, wherein the adjuvant further includes mineral oil, bacterial toxins, aluminum salts, squalene, virosomes, mineral oil in water emulsions, CpG, lipopolysaccharide (LPS), monophosphoryl lipid A (MPLA), QS21 or AS02, flagellin, peptidoglycans, inactivated bacterial pathogens, and/or RNAse inhibitors.
31 . The cancer vaccine composition of embodiment 24, wherein the synthetic oligoribonucleotide is in a nanoparticle formulation.
32. The cancer vaccine composition of embodiment 24, wherein the tumor antigen and the adjuvant are formulated together.
33. The cancer vaccine composition of embodiment 24, wherein the tumor antigen and the adjuvant are not formulated together.
34. A method for stimulating an immune response against a tumor antigen in a subject at risk of having or having a cancer including the tumor antigen, including administering to the subject a therapeutically effective amount of the cancer vaccine composition of embodiment 24.
35. The method of embodiment 34, further administering at least one second anti-cancer agent.
36. The method of embodiment 35, wherein the second anti-cancer agent is low dose chemotherapy.
37. The method of embodiment 36, wherein the second anti-cancer agent is an immune checkpoint inhibitor that blocks programmed cell death protein 1 (PD-1 ).
38. A method of activating antigen presenting cells (APC) ex vivo including contacting the APC with the cancer vaccine composition of embodiment 24.
39. The method of embodiment 38, further administering the contacted APC to a subject at risk of having or having a cancer including the tumor antigen.
40. An immunization kit including the cancer vaccine composition of embodiment 24.
[0132] EXAMPLES
[0133] The following examples are illustrative of disclosed methods. In light of this disclosure, those of skill in the art will recognize that variations of these examples and other examples of the disclosed method would be possible without undue experimentation. At least some of the material described in Example 1 was published as Castiello et al. {Cancer Immunol. Immunother. 68(9) :1479-1492, August 28, 2019).
[0134] Example 1 : Sequence-optimized RIG-I agonist M8 induces immunogenic cell death of cancer cells and dendritic cell activation
[0135] This Example demonstrates that activation of the cytosolic innate immune sensor RIG-I using a sequence-optimized RIG-I agonist M8 induces type-l-IFN/caspase 3-dependent cell death in cancer cells characterized by induction of multiple markers of immunogenic cell death (ICD). Also, M8 activates antigen processing machinery and mature dendritic cells to a pro-inflammatory phenotype.
[0136] RIG-I is a cytosolic RNA sensor that recognizes short 5' triphosphate RNA, commonly generated during virus infection. Upon activation, RIG-I initiates antiviral immunity, and in some circumstances, induces cell death. Because of this dual capacity, RIG-I has emerged as a promising target for cancer immunotherapy.
[0137] In previous studies, a sequence-optimized RIG-I agonist (termed M8) was identified for its ability to stimulate a robust innate immune response capable of blocking viral infection and functioning as an adjuvant in vaccination strategies of influenza antigens. In this example, the potential of M8 as an anti-cancer agent is further investigated by analyzing its ability to both induce cell death and activate the immune response.
[0138] In multiple cancer cell lines, M8 treatment strongly activated caspase 3-dependent apoptosis. Apoptosis relied on an intrinsic NOXA and PUMA-driven pathway that was largely dependent on IFN- I signaling. Additionally, cell death induced by M8 was characterized by the expression of the immunogenic cell death markers - calreticulin and HMGB1 - as well as high levels of CXCL10, a marker of inflammation. Additionally, cell death induced by M8 was characterized by the expression of the immunogenic cell death related DAMP (ICD-DAMP) - calreticulin, HMGB1 and ATP - as well as high levels of CCL2, CXCL1 , CXCL10, and IFNp, cytokine markers of ICD and inflammation. Moreover, M8 increased the levels of HLA-ABC expression on the tumor cell surface, as well as up-regulation of genes involved in antigen processing and presentation. M8 induction of the RIG-I pathway in cancer cells favored dendritic cell phagocytosis and induction of co-stimulatory molecules CD80 and CD86, together with increased expression of IL12 and CXCL10. Altogether, these results highlight the potential of RIG-I agonist M8 for cancer immunotherapy, by inducing immunogenic cell death and activating immunostimulatory signals that can synergize with current therapies.
[0139] Introduction: Upon progression, tumors adopt multiple strategies to escape immune surveillance and to generate an immunosuppressive and protumorigenic microenvironment (Schreiber et al., Science 331 :1565-1570, 201 1 ). During this“immunoediting escape phase”, cancer cells become less visible to cells of the immune system by: 1 ) downregulation of HLA-ABC, co-stimulatory molecules and NK ligands; 2) expression or secretion of immunosuppressing molecules (such as PD- L1 , Galectin 9, ID01 ); and/or 3) chemoattraction of immunosuppressive cells such as regulatory T cells, myeloid derived suppressor cells or tumor activated macrophage cells (Treg, MDSC and TAM, respectively) (Mittal et al., Curr Opin Immunol 27:16-25, 2014). Several strategies are currently being investigated to overcome the limitations of the immunosuppressive microenvironment and induce tumor cell death. Among these approaches, the use of compounds that mimic viral infection represent a promising strategy to pair cell death signals with immune activation events (lurescia et al., Front Immunol 9:71 1 , 2018). During viral infection, in fact, cells sense pathogen-associated molecular patterns (PAMP) and damage-associated molecular patterns (DAMP) through a family of sensors, collectively named pattern recognition receptors (PRR) that activate multiple immune response pathways, and in some cases, lead to death of infected cells.
[0140] The retinoic acid inducible gene-l (RIG-I) is a cytosolic PRR for short 5' triphosphate double strand RNA, that has a crucial role in activating immune response against viral infection (Hornung et al., Science 314:994-997, 2006). Upon recognition of viral RNA, RIG-I activates through caspase recruitment domain (CARD)-mediated interactions the adaptor mitochondrial antiviral signaling protein (MAVS), which in turn activates TANK-binding kinase 1 (TBK1 ) and the IKB kinase (IKK) complex (Kawai et al., Nat Immunol 6:981-988, 2005). TBK1 and IKK, then, lead to the activation of IRF3 and NF-KB, respectively, thus inducing interferon (IFN), antiviral and inflammatory response (Goulet et al., PLoS Pathog 9:e1003298, 2013; Zevini et al., Trends Immunol. 38(3):194-205, 2017). Additionally, RIG-I signaling can also trigger suicide of infected cells as an ultimate mechanism of protection to limit viral spread through at least three different mechanisms: IRF3-dependent induction of apoptotic genes (Heylbroeck et al., J Virol 74:3781-92, 2000); IRF3-mediated induction of BAX-dependent mitochondrial apoptosis (Chattopadhyay et al., Immunity 44:1 151-1161 , 2016); and, direct RIG-I induction of necroptosis (Schock et al., Cell Death Differ 24:615-625, 2017). Such dual effects (i.e., induction of cell death and immune activation) render RIG-I agonists as a promising therapeutic approach for cancer treatment. Indeed, preliminary results have already shown that RIG-I agonists can induce cell death in different tumor types and activate both innate and adaptive immunity against tumors in mouse models (Poeck et al., Nat Med 14:1256-1263, 2008; Besch et al., J Clin Invest 119:2399-41 1 , 2009; Glas et al., Stem Cells 31 :1064-1074, 2013; Ellermeier et al., Cancer Res 73:1709-1720, 2013; Duewell et al., Cell Death Differ 21 :1825-1837, 2014).
[0141] By modifying the length, structure and sequence of the 5’ end of Vesicular Stomatitis Virus (VSV) RNA, a RIG-I agonist (named M8) was developed that was 10-100 fold more potent in
stimulating an antiviral response compared to other agonists (Chiang et al., J Virol 89:801 1 -25, 2015; U.S. Patents No. 9,790,509 and No. 10,167,476). M8 potently blocked a variety of viral infections in vitro and in vivo, in part due to the activation of an innate immune response with great breadth and intensity. Furthermore, M8 acted as a potent vaccine adjuvant against influenza, leading to high antibody titers and Th1 -shift in immune responses (Beljanski et ai, J Virol 89:10612-24, 2015).
[0142] In the current example, M8 was tested for cancer therapeutic effects, by taking advantage of its dual ability to induce cell death and activate innate immunity. The results described herein demonstrate that stimulation of the RIG-I pathway by M8 induced an IFN-dependent intrinsic apoptosis in different cancer cells, characterized by many immunogenic cell death features and it was paired by increased antigen processing activity and strong activation of dendritic cells (DC).
Synthetic
[0143] MATERIALS AND METHODS
[0144] Cell lines and cultures: Primary Mel1007 and metastatic melanoma Mel120 cells were a kind gift of Dr. G. Parmiani (Milan, Italy), A549, HCT1 16 and PC3 were all from ATCC. Mel1007, Mel120, and PC3 cells were grown in RPMI supplemented with 10% Fetal Bovine Serum (FBS, Thermo Fisher Scientific) and 1 % of Penicillin-Streptomycin solution (P/S, 10000 U/ml Penicillin and 10 mg/ml Streptomycin sulfate, Euroclone). A549 cells were grown in Ham's F-12K (Kaighn's) Medium (Thermo Fisher Scientific) supplemented with 10% FBS and 1 % of P/S. HCT1 16 cells were grown in McCoy's 5A (Modified) Medium (Thermo Fisher Scientific) supplemented with 10% FBS and 1 % of P/S.
[0145] Generation of RIG-I agonists and transfection: M8, RIG-I agonists #1 and #2 (RA#1 and RA#2) (Poeck et al., Nat Med. 14(1 1 ) :1256-1263, 2008; Duewell & Latz, Methods Mol Biol. 1040:19- 27, 2013) were synthesized using Megascript T7 Transcription Kit (Thermo Fisher Scientific) on synthetic oligonucleotides (Eurofins Genomics) and following manufacturer instruction. Templates used were:
[0146] For RA#1 and RA#2, the two templates were used separately to generate complementary RNAs that were annealed before transfection. Synthesized RNA was then purified using Nucleospin
MiRNA Kit (Mackerey-Nagel) and concentration assessed using Nanodrop 2000 (Thermo Fisher Scientific).
[0147] For transfection of all RA, Lipofectamine RNA/iMax (Thermo Fischer Scientific) was used following manufacturer instructions. The amount of lipofectamine was optimized for each cell type in order to reduce toxicity: 1.5 mI/ml were used for Mel 1007 cells, 2 mI/ml for HCT1 16, 3 mI/ml for PC3, Mel120 and A549. Both RNAiMAX and RA were diluted in Opti-Mem (Thermo Fisher Scientific). To remove the 5’ triphosphate group of M8, Calf Intestinal Alkaline Phosphatase (Thermo Fischer Scientific) was used following manufacturer instruction and RNA was then purified as before.
[0148] Reagents: LDH cytotoxicity assay (Thermo Fischer Scientific) was used following manufacturer instructions. For cell death inhibition Z-VAD-FMK (Santa Cruz Biotechnology) was used at a final concentration of 100 mM, Ac-YVAD-CMK (Sigma Aldrich) was used at a final concentration of 100 pg/ml (-180 mM), Necrostatin-1 (Cayman Chemical) was used at a final concentration of 50 mM; all the reagents were added to the culture immediately after transfection. For RIG-I silencing by siRNA, Mel1007 plated in 6-well plates were transfected with 80 pmol of RIG-I siRNA or Control- siRNA-A (Santa Cruz Biotechnology) using Lipofectamine RNA/iMax. After 24 h, cells were transfected with M8 and viability assessed after 48 h. To block IFN-I signaling Anti-lnterferon-a/b Receptor Chain 2 Antibody (clone MMHAR-2, Merck Millipore) was added to culture media immediately after M8-transfection at a final concentration of 1 pg/ml.
[0149] PBMC and DC differentiation: PBMC were isolated starting from healthy donor buffy coat by standard stratification with Ficoll® Paque PLUS density gradient (GE Healthcare) following manufacturer instructions and cultured in RPMI supplemented with 10% Certified FBS (Thermo Fisher Scientific) and 1 % of P/S. For DC differentiation, monocytes were isolated from fresh PBMC by magnetic selection using CD14 MicroBeads (Miltenyi Biotec) and cultured in RPMI supplemented with 10% Certified FBS (Thermo Fisher Scientific), 1 % of P/S, 50 ng/ml of GMCSF (Miltenyi) and 25 ng/ml of IL-4 (Miltenyi). After 5 days of culture, DC were used for phagocytosis assay or stimulated for 24 h with supernatants of transfected Mel1007 cells.
[0150] NK CD107 degranulation and cytotoxicity assay: As the source of effector cells, PBMCs were isolated from two healthy donors by Lymphoprep (Nycomed, Oslo, Norway) gradient centrifugation and co-cultured for 10d with the irradiated (30 Gy) EBV-transformed B cell line RPMI 8866 at 37°C in a humidified 5% CO2 atmosphere, as previously described (Zingoni et al., Eur J Immunol 30:644-651 , 2000). On day 10, the cell population was routinely >95% CD56+CD16+CD3-, as assessed by immunofluorescence and flow cytometry analysis. M8-transfected Mel1007 cells and K562 cells were then incubated with the effector cells at 37°C for 2 h. Thereafter, cells were washed and incubated for 45’ at 4°C with the lysosomal marker CD107a-APC and anti-CD3-APC-H7 and anti- CD56-PE to gate on NK cells. At the end of incubation cells were washed and analyzed by flow cytometry for percentage of CD107a+ cells among the gated CD3-/CD56+ cells.
[0151] The effector NKL cells were labeled with CFSE and co-cultured for 4 h with target Mel 1007 transfected or not with M8 for 48 h or K562 cells at different Effector to Target ratios for 4 h at 37°C. Cells were then washed and cytotoxicity assessed at flow cytometer analyzing viable cells using 7- AAD among the CFSE- cells.
[0152] Phagocytosis assay: Mel 1007 cells were labeled with Cell Trace Far Red (CTFR) (Thermo Fischer Scientific) and transfected with M8 for 48 h. Cells were then cocultured at a 1 :1 ratio with DC for 4 h. Cells were then washed and labeled with anti-CD209-PE and 7-AAD, and analyzed by flow cytometer assessing CTFR+ cells among live CD209+ cells.
[0153] Flow cytometry: Viability was assessed by gating 7-AAD exclusion over FSC-A plots on FSC- A vs FSC-H gated single cell suspensions. To evaluate early and late apoptosis, cells were labeled with Annexin-V-APC (Biolegend) and 7-AAD in a solution of HEPES 0.01 M (Sigma Aldrich), NaCI 140 mM (Sigma Aldrich), CaC 2.5 mM (Sigma Aldrich) following manufacturer instructions. To stain for calreticulin, cells were washed twice with cold PBS, fixed for 5’ in 0.25% paraformaldehyde, washed twice in cold PBS and incubated for 20’ with anti-calreticulin Ab (PA3900, Thermo Fischer Scientific). Labeled cells were then washed twice and incubated with AlexaFluor488-labeled secondary Ab for 30’ on ice (ab150077, Abeam). At the end of incubation, cells were washed twice and resuspended in a PBS solution containing 7-AAD. Cells treated with 1 mM Mitoxantrone (Sigma Aldrich) were used as a positive control.
[0154] Staining for other cell surface markers was performed using standard incubation protocols and staining with anti-HLA-ABC-PE, anti-HLA-DR-APC (21388996) (both from Immunotools), anti-CD86- Brilliant Violet 421 (305426) and anti-CD209-PE (330106) (both from Biolegend), anti-CD80-FITC (557226), anti-CD3-APC-H7 (clone SK7), anti-CD56-PE (clone NCAM16.2), anti-CD107a-APC (clone H4A3) (all from BD Biosciences) antibodies. All the experiments were performed on BD FacsCanto II (BD Biosciences).
[0155] Quantitative PCR: RNA were isolated by column separation using RNeasy Kit (Qiagen) and following manufacturer instructions and measured with Nanodrop 2000 (Thermo Fischer Scientific). 350 ng of RNA were used for cDNA synthesis using High-Capacity cDNA Reverse Transcription Kit (Thermo Fischer Scientific). Quantitative PCR was then performed using Taqman Fast Advanced MasterMix with Taqman probes or Universal ProbeLibrary Probes (Roche) with specific primers designed using Roche Lifescience Assay Design Center (available online at lifescience.roche.eom/en_it/brands/universal-probe-library.html#assay-design-center) on a StepOnePlus Real-Time PCR System (Thermo Fischer Scientific). Relative quantification method was used with GAPDH as housekeeper gene.
[0156] Magnetic Luminex Assay: Supernatants of M8-transfected Mel 1007 cells were analyzed on a 96-well plate for the presence of the following analytes: CCL2, CXCL1 , CXCL10, and IFNp. The fluorescence responses and concentrations of cytokines were obtained using a Human Premixed
Multi-Analyte kit (R&D systems, Minneapolis, Minnesota, USA), and analyzed with a MAGPIX system and the accompanying xPONENT Software. All reagents were provided with the kit and were prepared according to the manufacturer’s recommendations: reconstituted standards were serially diluted 1 to 3 in calibrator diluent, which was used as background. Concentrated wash buffer was diluted in a 25- fold volume of deionized water. Microparticle cocktail, biotin-antibody cocktail, and Streptavidin-PE were diluted in their specific buffers immediately before the assay. The protocol outlined in the Luminex manual was followed exactly. Briefly, all supernatants were diluted 2-fold with calibrator diluent prior to data acquisition. 50 mI of samples and standards were incubated for 2 hours with 50 mI of microplate cocktail, then the plate was washed and 50 mI of biotin antibody cocktail was added. After a 1 -hour incubation, plate was washed and 50 mI of streptavidin-PE were added for 30-min, followed by a final wash and resuspension in 100 mI of wash buffer. All incubations were done at room temperature on a microplate shaker at 800 rpm. Both standards and samples were tested in duplicate. The concentration values and detection limits were determined from standard curves generated from each kit’s standards using the weighted 5PL curve fitting procedure. To maximize the number of concentration values available for analysis the extrapolated values were included.
[0157] HMGB1 Elisa: Supernatants of Mel1007, HCT1 16 and PC3 cells transfected or not with M8 for 48 h were analyzed for HMGB1 levels using HMGB1 Elisa kit (ST51001 , IBL international) following manufacturer instructions and absorbance measured with iMark™ Microplate Absorbance Reader (Bio-Rad). As positive control, cells treated with Mitoxantrone 1 mM (Sigma Aldrich) were used.
[0158] ATP release: Extracellular ATP levels were measured by the luciferin-based ENLITEN ATP Assay (Promega, Madison, Wl, USA), following the manufacturer’s instructions, and light intensity was measured by Glomax luminometer. Briefly, 100 mI of not diluted supernatant were dispensed, in duplicate, in an opaque-walled 96 well plate; in each well an equal volume of rL/L reagent was added by an injection system and a 2-second delay time after injection, 10-second RLU signal integration time were used to record the light signals resulting from the luciferase reactions.
[0159] Statistical Analysis: Graphs and statistical analysis were performed using GraphPad Prism 6. Depending on the type of data analyzed ordinary one-way ANOVA or two-way ANOVA were used correcting multiple comparisons with Tukey’s test, or standard t-test using Sidak correction for multiple comparisons.
[0160] RESULTS
[0161] Sequence-optimized RIG-I agonist M8 potently induced cell death in cancer cells. To assess the potential of M8 as an anti-cancer agent, its ability to induce cell death in the melanoma cell line Mel1007 was analyzed. Significant levels of cell death were observed with concentrations of M8 higher than 100 ng/ml (FIGs. 1A, B). To determine the specificity of M8 to induce RIG-l-directed cell killing, the 5’ triphosphate group of M8 was removed by calf intestinal phosphatase, resulting in a dramatic reduction of cell death (50% vs 3.7%) (FIG. 1 C). A similar result was observed when the
expression of RIG-1 was silenced by transfecting cells with siRNA against RIG-1 for 24h prior to M8 treatment. Indeed, M8-directed cell death was reduced to control levels in RIG-1 silenced cells (from 30 % to 9.5. %) (FIG. 1 D), thus supporting the observation that 5’ triphosphate containing M8 maintained specificity for the RIG-I sensor, as observed in other models (Goulet et al., PLoS Pathog 9:e1003298, 2013; Chiang et al., J Virol 89:801 1-25, 2015).
[0162] Next, the capacity of M8 to induce cell death was compared to other RIG-I agonists previously shown to induce cell death in cancer cells (Poeck et al., Nat Med 14:1256-1263, 2008; Duewell et al., Cell Death Differ 21 :1825-1837, 2014). Among the compounds tested, M8 proved to be the strongest inducer of cell death in Mel1007 (>58% vs 1 1 and 8%) (FIG. 1 E). Moreover, M8 was effective in inducing cell death in a variety of cancer cell lines, including metastatic melanoma Mel120, lung adenocarcinoma A549, colon carcinoma HCT1 16, prostate carcinoma PC3 (FIG. 1 F) (40%, 75%, 45%, and 33%, respectively), indicating that cell death pathways activated by M8 were intact among several cancer cell types.
[0163] The toxicity of M8 was also evaluated in PBMC. Interestingly, at 48h after transfection into PBMC, M8 led to minimal levels of cell death, even at the highest dose (FIG. 1 G), thus indicating that M8 toxicity was selective for cancer cells rather than normal cells, as previously described (Besch et al., J Clin Invest 1 19:2399-41 1 , 2009). These results indicate that M8 activation of RIG-I is able to induce cell death in different cancer cell types, while displaying limited toxicity in non-cancerous cells.
[0164] M8 induced RIG-I-, IFN-I-, NOXA-dependent apoptotic pathway. Next, the kinetics of induction of apoptosis was analyzed at different times after M8 treatment by annexin V staining. As shown in FIG. 2A, Mel1007 treated with M8 began showing apoptotic features as early as 16h post transfection with high percentages of early apoptotic cells between 24 and 30h, while by 48h most of the cells were already dead, thus indicating that the mechanisms leading to cell death start within the first 24h. Several pharmacological inhibitors of cell death pathways were used to explore the specificity of M8-mediated cell death. The pan-caspase inhibitor Z-VAD significantly reduced M8-induced cell death (19% vs 44%), suggesting caspase involvement, whereas involvement of caspase 1 -dependent pyroptosis or necroptosis through the RIP1 kinase were ruled out, based on the use of the caspase 1 inhibitor YVAD or the necroptosis inhibitor necrostatin 1 (FIG. 2B). Cleavage of caspases 3 and 9 was detected by immunoblot 24h post M8 treatment (FIG. 2C), indicating that M8-induced cell death involved the intrinsic apoptotic pathway. This observation was further confirmed by analyzing mitochondria depolarization by JC1 staining at 24h post treatment; as shown in FIG. 2D, M8 treatment of mel1007 cells increased the percentage of cells exhibiting disrupted mitochondria.
[0165] Next, to understand the proapoptotic factors involved in M8-induced cell death, gene expression levels of proapoptotic genes Noxa and Puma was analyzed. Notably, both genes were significantly induced upon M8 transfection (FIGs. 2E, 2F), however while Puma expression levels were induced only 3 fold, Noxa gene expression was induced approximately 100 fold.
[0166] To evaluate whether the apoptosis induced by M8 was modulated by type I IFN (IFN-I), cell death levels were evaluated in M8-treated Mel1007 cells in the presence of IFNAR1 blocking antibodies. As shown in FIG. 3A, cell death induced by M8 was inhibited by IFNAR1 blocking antibodies (21 % vs 57%), thus demonstrating the requirement for IFN-I production and indicating that secreted IFN-I contributed to apoptosis. Consistent with this observation, the blockade of IFN-I signaling with IFNAR1 blocking antibodies inhibited proapoptotic genes and reduced the expression levels of PUMA and NOXA in M8 treated cells (1 .4 vs 2.6 fold for PUMA, 45 vs 1 10 fold for NOXA) (FIGs. 3B, 3C). These results indicate that in Mel1007 cells M8 induced an intrinsic apoptotic pathway that relied on IFN-l-dependent induction of Puma and Noxa.
[0167] M8 induced ICD-DAMP. Given its ability to mimic virus infection, M8 induced a RIG-I- dependent innate response. IFNp transcriptional levels increased proportionally with the tested concentration of M8 (10, 100, 500 ng/ml), and the downstream chemokine CXCL10 underwent an even more dramatic induction that was significantly reduced by blocking IFNAR1 signaling (FIGs. 4A, B). Given that IFNp and CXCL10 are two critical factors required for ICD [19] the potential of M8 to induce the complete chemokine signature of ICD (i.e. CCL2, CXCL1 , CXCL10 and IFNP) was investigated next by a multiplex ELISA assay. All tested cytokines displayed an M8-dose-dependent, and statistically significant increase in chemokine production, as measured in the supernatant of MS- treated Mel1007 versus control (FIG. 4C).
[0168] Apoptosis of cancer cells induced by M8 displayed several other features of ICD. By flow cytometry, it was found that M8 in Mel1007 cells induced surface exposure of calreticulin at levels comparable to the ICD inducer mitoxantrone (FIG. 5A). Similar results were also observed in other cell lines (FIG. 5B). As an additional marker of ICD, the release of the High Mobility Group Box 1 (HMGB1 ) was measured; after 48h of M8 treatment, secretion of HMGB1 was significantly increased in a panel of cancer cells (FIG. 5C, 5D). Finally, the release of ATP in the extracellular supernatants of Mel1007 cell cultures was measured using a luciferase-based assay, and demonstrated high level ATP release after M8 treatment (FIG. 5E). Altogether, these results indicated that M8 induces a caspase 3- dependent cell death characterized by stimulation of multiple immunogenic cell death associated molecular patterns (ICD-DAMP).
[0169] M8 triggering of RIG-I represses NK activity and upregulates antigen processing machinery (APM). Having observed the activation of many ICD markers in cancer cells stimulated by M8, whether pathways downstream of RIG-I activation also generated signals crucial for immune cell recognition was studied next. The induction of NK cell activating signals on Mel1007 was evaluated using mid-range doses of M8 to ensure strong RIG-I activation and minimize cell death. As shown in FIG. 6A, most activating NK ligands were increased on the Mel1007 cell surface after M8 treatment, although not to a statistically relevant level. However, when NK degranulation and cytotoxic activities were measured, a clear inhibition of NK activity was observed. In fact, both CD107 exposure on the
NK surface and the percentage of dead target cells after co-culture NK / M8-Mel1007 cells indicated that M8 treatment resulted in reduced NK activity when compared to negative or positive control cells (FIGs. 6B,6C), thus suggesting the involvement of inhibitory markers. In fact, a consistent induction of the NK inhibiting marker HLA-ABC expression was observed after M8 treatment (FIG. 6D) and associated with a general increase in the activity of the antigen processing machinery (APM).
[0170] The expression of numerous APM genes - immunoproteasome subunits PSMB8, PSMB9, and PSMB10, transporters associated with antigen processing TAP1 and TAP2, and the endoplasmic reticulum chaperone Tapasin (TAPBP) - displayed a dose dependent increase in M8-Mel1007 cells, peaking at a concentration of 100 ng/ml M8, with inductions ranging from 15-500 fold over untreated cells (FIG. 6E). In line with previous studies (Leone et at., JNCI J Natl Cancer Inst 105:1 172-1187, 2013), the expression levels of APM factors were strongly dependent on IFN-I, since IFNAR1 signaling blockade resulted in a reduction on the expression levels of both HLA-ABC protein (to basal levels) and APM genes (~3-6 fold) (FIGs. 6D, 6E). Similar results on reduced NK activity and induction of APM were also observed in HCT1 16 cells. Taken together, these results indicated that the antigen processing machinery was activated in an IFN-dependent manner in cancer cells treated with M8, whereas anti-tumoral NK activity was inhibited.
[0171] Activation of monocyte-derived dendritic cells is skewed to a Th1 phenotype. Based on the induction of ICD and APM activation in M8-Mel1007, the modulation of DC activity was next analyzed to determine whether the immunogenic signals induced by M8 enhanced DC phagocytosis of M8-Mel1007. Monocyte-derived DC (MoDC) co-cultured with labeled Mel1007 or M8-Mel1007 were evaluated for their ability to incorporate the membrane dye by phagocytosis. Interestingly, MoDC phagocytized more M8-Mel1007 cells compared to control Mel 1007, based on membrane dye inclusion (9.5% vs 2.2%) (FIGs. 7A, 7B).
[0172] Next, whether immunogenic signals induced in M8-Mel1007 cells affected DC phenotype, specifically expression of co-stimulatory markers and cytokine production, was evaluated. Cytometric analyses showed that supernatants of M8-Mel1007 administered to DC increased the expression levels of costimulatory markers CD80 and CD86, and of HLA-DR of ~ 2.2, 4.7, and 2 fold respectively, thus indicating an increased ability to stimulate T cell activation (FIG. 7C). Moreover, expression of the pro-Th1 cytokine IL-12 was stimulated in DC, whereas levels of the pro-Treg cytokine IL-10 remained unchanged (FIG. 7D). The proinflammatory cytokine CXCL10 was stimulated by M8- Mel1007 in a dose dependent manner (FIG. 7E), further evidence that M8 treatment of Mel1007 affected DC function, by stimulating their phagocytic potential and also driving them towards a pro- inflammatory Th1 biased phenotype.
[0173] DISCUSSION
[0174] Immune mechanisms against viral infection rely on recognition of viral components (including for instance unusual RNA structures) to initiate a complex and multifaceted array of processes that includes the secretion of IFN-I and chemokines to mobilize immune effector cells, the activation of the APM for immune recognition of non-self antigens, and in the last instance, cell death. All these processes are critical for the development of an efficient cancer immunotherapy. Within this setting, tumor cells develop multiple strategies to escape immune recognition and thereby evade immune control.
[0175] Here, the sequence optimized RIG agonist M8 (Chiang et al., J Virol 89:8011-8025, 2015; Beljanski et al., J Virol 89:10612-10624, 2015) was assessed for its potential effectiveness in cancer immunotherapy and its capacity to induce immunogenic cell death in several cancer cell lines that rely on secretion of IFN-I and induction of intrinsic apoptotic pathways is described. Moreover, M8 boosted HLA-ABC and APM expression, and activated proinflammatory phagocytic DC, thus illustrating its potential to trigger many propitious anti-cancer effects by inducing death of tumor cells and eliciting immune reactivation.
[0176] Cancer immunotherapy has recently emerged as a powerful tool against cancer, and many approaches mimicking viral infections have been tested or are in early phase clinical trials. Most of the RIG-1 agonists (RAs) developed for cancer immunotherapy has coupled RA activity with specific silencing of oncogenes or immunosuppressive factors (Poeck et al., Nat Med 14:1256-1263, 2008; Besch et al., J Clin Invest 1 19:2399-2411 , 2009; Ellermeier et al., Cancer Res 73:1709-1720, 2013), thus illustrating the potential of RIG-I signaling as an anti-cancer immunotherapeutic strategy. Here, a sequence optimized RA (i.e., M8) was used that strongly outperforms other RA in the induction of antiviral signaling (Chiang et al., J Virol 89:801 1-8025, 2015), as well as in the triggering and potentiation of immune response (Beljanski et al., J Virol 89:10612-10624, 2015), but whose efficacy entirely relies on functional RIG-I signaling pathway. Depending on the tumor setting, RIG-I exerts both pro- and anti-tumorigenic roles and therefore its functional activity and expression level are widely affected (Xu et al., Protein Cell 9:246-253, 2018). M8 induced cell death in several cancer cell lines together with the expression of ICD markers and activated direct and indirect immune processes. Therefore, the results presented herein highlight M8 as a promising broad-acting RA for cancer immunotherapy against multiple tumor types. More detailed studies may be helpful to dissect settings in which RIG-I activation is most preferable.
[0177] IFN-I play a critical role in tumor development and in response to therapy (Dunn et al., Nat Immunol 6:722-9, 2005; Katlinskaya et al., Cell Rep 15:171-180, 2016; Katlinski et al., Cancer Cell 31 :194-207, 2017; Castiello et al., Cancer Immunol Res 6:658-670, 2018; Rizza et al., Cytokine Growth Factor Rev 26:195-201 , 2015; Gajewski et al., Cancer Immunol Immunother 61 :1343-1347, 2012). As a large body of literature has highlighted, IFN-I are the cornerstone for the development of
anti-tumor response thanks to the activity on tumor cells and ICD (Galluzzi et al., Nat Rev Immunol 17:97-1 1 1 , 2017), and to the activation of anti-tumor immune cells (Snell et al., Trends Immunol 38:542-557, 2017).
[0178] Tumor cells often develop resistance to IFN-I signaling by downregulating IFNAR1 or altering downstream factors (Katlinskaya et al., Cell Rep 15:171-180, 2016; Katlinski et al., Cancer Cell 31 :194-207, 2017; FluangFu et al., Oncogene 31 :161-172, 2012; Bhattacharya et al., Oncogene 32:4214-21 , 2013), even though some IFN-I signals are minimally affected by IFNAR1 levels (Levin et al., Mol Cell Biol 31 :3252-66, 201 1 ). Cell death pathway induced by M8 strongly relies on IFN-I; in fact, by blocking IFNAR1 activation, cell death strongly diminished and was reasonably due to an IFN- I dependent induction of the pro-apoptotic NOXA.
[0179] Other RA have shown similar effects (Poeck et al., Nat Med 14:1256-1263, 2008), whereas others seem to induce cell death in an IFN-I independent manner (Besch etal., J Clin Invest 1 19: 2399- 241 1 , 2009). This may depend on the different ability of M8 - and other RAs - to preferentially activate antiviral response over other downstream pathways. Whether M8 effects would be limited by tumor deregulated IFN-I signaling can be explored more in depth, and strategies, such as oncolytic virotherapy, that specifically take advantage of defective IFN-I signaling may be more suited in such settings (Stojdl etal., Cancer Cell 4:263-75, 2003; Nguyen etal., Proc Natl Acad Sci 105:14981 -14986, 2008; Olagnier et al., Mol Ther 25:1900-1916, 2017).
[0180] NK cells exert a crucial role in controlling and modulating therapy response in several settings (Sanchez-Correa et al., Cancer Immunol Immunother 60:1 195-1205, 2011 ; Zingoni et al., Front Immunol 8 :1 194, 2017). However, contrasting results have been reported on the relevance of NK cells in RA-based immunotherapy (Poeck et al., Nat Med 14:1256-1263, 2008; Glas et al., Stem Cells 31 :1064-1074, 2013; Ellermeier et al., Cancer Res 73:1709-1720, 2013; Barsoum et al., Cancer Immunol Res 5:B44-B44, 2017). Differently from other groups that analyzed systemic NK activation (Poeck et al., Nat Med 14:1256-1263, 2008) or the activating effect of cell supernatants (Glas et al., Stem Cells 31 :1064-1074, 2013), the herein presented results with M8 showed an overall inhibition of NK cell activity against M8-transfected cells, despite the increased expression of several NK activating ligands. It is believed that this may be due to the strong overexpression of the inhibitory ligand HLA-ABC, but additional factors could also be involved. Whether such reduced NK activity can affect M8-based immunotherapy will be more clearly evaluated in future in vivo studies together with a more detailed understanding of mechanisms regulating NK activity upon RA immunotherapy.
[0181] The generation and/or strengthening of anti-tumor antigen specific immune responses are thought to be the foundation for successful cancer immunotherapy, particularly given the progress with immune checkpoint inhibitor therapies (Ribas & Wolchok, Science 359:1350-1355, 2018; Rizvi et al., Science 348:124-128, 2015; Van Allen et al., Science 350:207-21 1 , 2015). Because of their ability in actively uptake and process tumor antigens, DC play a pivotal role in inducing and maintaining tumor-
specific T cell responses (Zong et al., Cancer Immunol Immunother 65:821-833, 2016) and combination therapies directed towards increasing the pool of tumor antigens recognized by T cells are highly sought after strategies (Schumacher & Schreiber, Science 348:69-74, 2015). In light of this, the observations described herein that M8 treated cells are highly phagocytized by DC and that DC stimulated with supernatants of M8 treated cells increase the expression of HLA-DR and of costimulatory molecules, and switch towards a Th1 biasing cytokine production, strongly indicate that M8 immunotherapy could broaden the anti-tumor antigenic repertoire. Also, the upregulation of the APM in cancer cells induced by M8 should increase the recognition of cancer cells by the tumor infiltrating lymphocytes and thus additionally favor a strong antigen-specific T cell mediated immune response.
[0182] During the final preparation of this study, an excellent study that evaluate a distinct engineered RIG-I agonist in a breast cancer cell panel that represented each of three major clinical breast cancer subtypes was published (Elion et al., Cancer Res. 78(21 ):6183-6195, 2018). Notably, in this setting the RIG-I agonist triggered the extrinsic apoptosis pathway and pyroptosis, and also induced expression of lymphocyte-recruiting chemokines and type I IFN. Importantly, RIG-I activation in breast tumors increased tumor lymphocytes and decreased tumor growth and metastasis, thus illustrating the successful therapeutic delivery of a synthetic RIG-I agonist to induce breast tumor cell killing and to modulate the tumor microenvironment in vivo.
[0183] In conclusion, the research described herein demonstrates that the sequence-optimized RA M8 was capable of inducing an IFN-I dependent ICD in several tumor cell lines, together with the activation of APM and DC. The results described here strongly suggest that M8 triggering of RIG-I can activate multiple processes within the tumor microenvironment that favor the induction and strength of antigen-specific responses and that could strongly synergize with checkpoint inhibitors.
[0184] Example 2: Triggering M8 Induced Cell Death using Natural Killer (NK) Cells
[0185] The effect of M8 on melanoma (Mel1007) tumor cells and other tumor cell types, in terms of the induction of NK cell activity, is being examined, with the hypothesis that M8 will increase receptor expression on Mel cells. Results demonstrate that treatment of Mel1007 with M8 sensitizes the tumor cells to killing by NK cells.
[0186] The effect of M8 directly on NK cell function is also being examined. It is expected that M8 treatment of NK cells will stimulate their death effector functions and increase granzyme B release. As the name implies NK cells, can be stimulated to attack and kill tumor cells. This may be an important addition in terms of mechanism of cell death by M8.
[0187] Example 3: Cancer Immunotherapy Mediated by RIG-I Pathway Activation
[0188] This example describes translational studies that build upon mechanistic knowledge of RIG-I signaling described herein. These studies apply this knowledge to the discovery, evaluation, and development of potent immunotherapeutics based on RIG-I agonists. Use of multiple tumor models, including metastatic and poorly immunogenic models will define the therapeutic potential of RIG-I agonists in cancer immunotherapy.
[0189] Cancer vaccines represent an attractive strategy to activate the immune system against tumor cells, despite the many pitfalls to be overcome to generate a successful vaccine. On the one hand, tumour antigens are usually self-proteins, and therefore poorly immunogenic; while on the other hand, tumours develop several escape mechanisms, including loss of MHC class I molecules and secretion of suppressive cytokines. Additionally, cancer patients are frequently immune suppressed because of treatments; therefore, a therapeutic cancer vaccine requires a strong adjuvant to increase its immunogenicity. An ideal cancer immunotherapy should induce such a strong immune activation that overcomes tumour escape strategies, with acceptable profiles of toxicity and safety. The desired immune response in cancer therapy involves the activation of interferon-y (IFN-g) producing type 1 T helper cells (Th1 ) and cytotoxic T lymphocytes (CTLs). However, despite many attempts, an ideal adjuvant remains to be identified. While Alum has been widely used in prophylactic vaccines that promote type 2 helper T cells (Th2)-dependent immunity, Alum has not been effective for the induction of strong Th1 -dependent immunity. Because the immune system is tuned to recognize pathogen- associated molecular patterns (PAMPs) by means of pathogen-recognition receptors (PRRs), molecules that mimic PAMP strongly stimulate innate immunity and may therefore be ideally suited to augment cancer immunotherapy.
[0190] Using the discoveries described herein, immunostimulatory therapies can now be developed based on the provided first-in-class RNA molecules against a novel target with a well-understood mode of action. The translation of these approaches toward clinical use is an important end goal for which the proposed studies will provide the foundation. It is believed that stimulation of multiple innate antiviral and inflammatory pathways by RIG-I agonist M8 will enhance antiviral and protective immunity against infectious diseases and cancer.
[0191] Assess immunotherapeutic potential of M8 in cancer vaccine formulations. The ability of M8 to increase antitumor immune response in different tumor antigen formulations will be evaluated using metastatic and/or poorly immunogenic mouse tumor models. Nanoparticle formulated M8 will be incubated with 1 ) granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing cellular cancer vaccines, 2) tumor cell lysates, or 3) single tumor antigens. Subcutaneously growing MC38 colon carcinoma, B16-F10 metastatic melanoma, and poorly immunogenic TC-2 prostate cells, KPC pancreatic adenocarcinoma, CT26 colon carcinoma cells, and breast carcinoma transgenic Neu+/_
mice will be used as tumor models. Tumor antigens will be derived from both matched and un-matched tumor cell lysates; unmatched lysates will be used for comparison.
[0192] Determine the adjuvant potential of M8 in melanoma bearing mice. To determine whether M8 can break T cell tolerance to a naturally expressed tumor-antigen, we will utilize B16 and B16-F10 melanoma mouse model and stimulate antitumor immune responses using a single antigen, either Mart-1 or gp100, which are tumor associated antigens expressed by B16 cells. Also, to test a broader source of tumor antigen to be adjuvanted, M8 will be combined with B16 cell lysate or irradiated, GM- CSF expressing B16 cells. Mice with subcutaneously growing B16 cells will be vaccinated subcutaneously with the above antitumor vaccines formulated with or without M8 and compared to standard adjuvants Alum and AddaVax™ squalene-based oil-in-water adjuvant (InvivoGen). Subcutaneous tumor growth will be measured, and splenic cytotoxic T cell responses will be evaluated as described herein. In addition, T cell killing activity of B16 cells will be evaluated by flow cytometry. B16 cells will be labeled with PKH26 and then cocultured with T cells for 4 hours. Early and late apoptosis will be measured among PKFI26+ target cells by using Annexin-FITC and PI, respectively. Identical experiments will be performed with B16-F10 metastatic melanoma.
[0193] Activity of M8 adjuvant in other aggressive and poorly immunogenic tumor settings. T o confirm M8 adjuvant properties for cancer vaccines, M8 adjuvanted vaccines will be tested against other aggressive, poorly immunogenic and transgenic tumor models. MC38 and CT26 colon carcinoma (derived from BALB/c mice) and TC-2 prostate carcinoma (derived from C57BL6/J mice) and the KPC adenocarcinoma model of pancreatic cancer. Tumor bearing mice will be vaccinated with tumor cell lysate or irradiated, GM-CSF expressing tumor cells with or without M8. Tumor growth and immune activation will be monitored as above.
[0194] Characterize M8 stimulation of DC ex vivo for cell immunotherapy. To test the ability of M8 to activate and polarize dendritic cells (DC) ex vivo for tumor cell-based immunotherapy, femur bone collected DC of therapy-naive animals will be expanded in primary cell media. DC will be then pulsed ex-vivo with B16 tumor cell lysates or single Mart-1 or gp100 tumor antigens alone, in combination with the standard activation signal LPS, or in combination with M8. Pulsed DC will be then injected subcutaneously into tumor bearing mice and tumor growth and infiltration of immune cells will be assessed. Tumors will be digested to single cell levels and tumor infiltrating cells will be quantified as follows: 1 ) innate immune compartment, NK cells (NK1 .1 hi) and NKT cells (NK1 1 hiCD3ehiCD1 dhiCD60hi), and 2) the adaptive compartment will include CD8+ and conventional CD4+ T cells. Effector function of T cells isolated from tumors will be assessed for activation, proliferation, and lytic function by examining the levels of ICOS, Ki-67, and Granzyme B, respectively. Immunosuppressive regulatory T cells (CD4hiCD25hiFoxP3hi) and myeloid-derived suppressor cells (CD1 1 bhiGr1 hi) will be also quantified upon treatments with flow cytometry. Unpulsed DC or DC pulsed with an unrelated protein will be used as negative control.
[0195] Elucidation of immune cell/pathway contribution to M8-based immunotherapy. To determine cell type(s) primarily affected upon M8 vaccination, in-depth analysis of tumor cell infiltrates will be performed. Tumors will be digested to single cell levels and tumor infiltrating cells will be quantified: 1 ) innate immune compartment, NK cells (CD3 NK1 .1 hi or CD3 DX5+ depending on mouse models) and NKT cells(NK1 1 hi(or DX5+)CD3ehiCD1 dhiCD60hi), and 2) the adaptive compartment will include analysis of both CD4+ and CD8+ and their subpopulations (IFNg+ Th1 , IL4+ Th2, IL-17+ Th17, and FoxP3+CD127 CD25hi Treg for CD4+ cells; CD8+ cells will be characterized for their memory status by CCR7/CD45RO/CD62L/CD45RA expression levels). Effector function of T cells isolated from tumors will be assessed for activation, proliferation, and lytic function by examining the levels of ICOS, Ki-67, and Granzyme B, respectively. We will also quantify granulocytic (CD1 1 b+Ly6G+Ly6C'°) and monocytic (CD1 1 b+Ly6G Ly6Chi) myeloid-derived suppressor cells, and characterize macrophages based on their M1/M2 polarization status. Lastly, to determine which cell type(s) primarily mediate therapeutic effects of M8, treatment that yielded best immune responses (as determined in the studies described above) will be repeated in mice with targeted deletions of CD4 or CD8 T cells or in mice that are severely deficient in NK cells. In a separate set of experiments, mice will be depleted for CD4+, CD8+, or NK cells using appropriate depleting antibodies. Adequate cell depletion of each cell subset upon antibody treatment will be confirmed by flow cytometry of peripheral blood. Mice deficient for CD4, CD8 or NK cells will be injected with MC38, B16-F10, or TC-2 cells, vaccinated, and therapeutic effect of M8 will be assessed by examining long-term survival.
[0196] Development of M8 vaccination with immunomodulatory strategies. In order to strengthen vaccine immune responses and overcome tumor-induced immune tolerance, the vaccination strategies described above will be combined with 1 ) low dose chemotherapy to eliminate Treg cells and to reactivate the immune system, or 2) the immunomodulatory antibodies anti-PD1 to activate tumor infiltrating T cells inhibited by tumor microenvironment. Therefore, to test the synergistic effect of chemotherapy with M8-induced vaccination, we will administer one therapeutic dose of cyclophosphamide (which depletes Treg cells) IP prior to vaccination. Then, 1 day later, mice will be vaccinated subcutaneously with the most promising immunization strategies identified above. In parallel, such immunization strategies will be combined with IP injection of anti-PD1 twice a week after vaccination. Tumor growth will be followed over time in both treated and control animals and immune responses will be examined post-vaccination as above.
[0197] Experiments described in this Example will examine whether M8 will augment an effective antitumor immune response when combined with tumor antigens. The results of these studies will also determine which tumor antigen formulation is optimal in combination with M8, and which immune cells mediate the immunostimulatory antitumor effects of M8. Several parameters may be adjusted, such as the dose of M8 and the ratio of M8/tumor antigen concentration, as well as vaccination regimen
needed for additional immunomodulatory strategies to overcome immune tolerance and/or boost immune response.
[0198] RIG-I agonists possess many intrinsic advantages over currently approved antiviral and adjuvant therapies, with the capacity to transiently stimulate antiviral, inflammatory and immune modulatory gene networks that bridge innate and adaptive immune responses. Sequence dependent optimization of the RIG-I agonist, coupled with an advanced understanding of the activation pathways, provide a solid foundation for these challenging and ambitious analyses. The discoveries provided herein enable immunostimulatory therapies based on a first-in-class RNA motif targeted against a well-defined immunomodulatory pathway. The programs and research described herein provide antiviral and adjuvant immunotherapies with improved efficacy against different immunogenic and non-immunogenic tumors. As vaccine adjuvants, RNA molecules combine simplicity, safety, and focused immunogenicity with favorable immunological properties: 1 ) an RNA adjuvant is molecularly defined and can target a specific pathway; and 2) RNA is rapidly degraded by ubiquitous RNases, leading to a precise‘hit & run’ stimulation of specific innate pathways and bypass of autoimmune responses that could result from repeated administration. Significant advances in RNA chemistry and delivery have ushered in a new era of RNA-based therapeutics, involving technologies that improve stability and delivery, including lipid-based nanovectors, polymer-mediated delivery systems, and oligonucleotide nanoparticles. Finally, the capacity of the RIG-I agonist to stimulate immune responses to antitumor vaccines is an important challenge for the development of cancer vaccines. Collectively, these studies form the basis of a novel adjuvant-vaccine approach that provides improvements in the efficacy of immunotherapy against cancer.
[0199] As will be understood by one of ordinary skill in the art, each embodiment disclosed herein can comprise, consist essentially of or consist of its particular stated element, step, ingredient or component. Thus, the terms“include” or“including” should be interpreted to recite:“comprise, consist of, or consist essentially of.” The transition term“comprise” or“comprises” means includes, but is not limited to, and allows for the inclusion of unspecified elements, steps, ingredients, or components, even in major amounts. The transitional phrase“consisting of” excludes any element, step, ingredient or component not specified. The transition phrase“consisting essentially of” limits the scope of the embodiment to the specified elements, steps, ingredients or components and to those that do not materially affect the embodiment. A material effect, in this context, results in a statistically relevant change in the effectiveness of the method of composition to treat cancer.
[0200] Unless otherwise indicated, all numbers expressing quantities of ingredients, properties such as molecular weight, reaction conditions, and so forth used in the specification and claims are to be understood as being modified in all instances by the term“about.” Accordingly, unless indicated to the contrary, the numerical parameters set forth in the specification and attached claims are
approximations that may vary depending upon the desired properties sought to be obtained by the present invention. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should at least be construed in light of the number of reported significant digits and by applying ordinary rounding techniques. When further clarity is required, the term“about” has the meaning reasonably ascribed to it by a person skilled in the art when used in conjunction with a stated numerical value or range, i.e. denoting somewhat more or somewhat less than the stated value or range, to within a range of ±20% of the stated value; ±19% of the stated value; ±18% of the stated value; ±17% of the stated value; ±16% of the stated value; ±15% of the stated value; ±14% of the stated value; ±13% of the stated value; ±12% of the stated value; ±1 1 % of the stated value; ±10% of the stated value; ±9% of the stated value; ±8% of the stated value; ±7% of the stated value; ±6% of the stated value; ±5% of the stated value; ±4% of the stated value; ±3% of the stated value; ±2% of the stated value; or ±1 % of the stated value.
[0201] Notwithstanding that the numerical ranges and parameters setting forth the broad scope of the invention are approximations, the numerical values set forth in the specific examples are reported as precisely as possible. Any numerical value, however, inherently contains certain errors necessarily resulting from the standard deviation found in their respective testing measurements.
[0202] The terms“a,”“an,”“the” and similar referents used in the context of describing the invention (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. Recitation of ranges of values herein is merely intended to serve as a shorthand method of referring individually to each separate value falling within the range. Unless otherwise indicated herein, each individual value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g.,“such as”) provided herein is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention otherwise claimed. No language in the specification should be construed as indicating any non-claimed element essential to the practice of the invention.
[0203] Groupings of alternative elements or embodiments of the invention disclosed herein are not to be construed as limitations. Each group member may be referred to and claimed individually or in any combination with other members of the group or other elements found herein. It is anticipated that one or more members of a group may be included in, or deleted from, a group for reasons of convenience and/or patentability. When any such inclusion or deletion occurs, the specification is deemed to contain the group as modified thus fulfilling the written description of all Markush groups used in the appended claims.
[0204] Certain embodiments of this invention are described herein, including the best mode known to the inventors for carrying out the invention. Of course, variations on these described embodiments will
become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventor expects skilled artisans to employ such variations as appropriate, and the inventors intend for the invention to be practiced otherwise than specifically described herein. Accordingly, this invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context.
[0205] Furthermore, numerous references have been made to patents, printed publications, journal articles and other written text throughout this specification (referenced materials herein). Each of the referenced materials are individually incorporated herein by reference in their entirety for their referenced teaching.
[0206] It is to be understood that the embodiments of the invention disclosed herein are illustrative of the principles of the present invention. Other modifications that may be employed are within the scope of the invention. Thus, by way of example, but not of limitation, alternative configurations of the present invention may be utilized in accordance with the teachings herein. Accordingly, the present invention is not limited to that precisely as shown and described.
[0207] The particulars shown herein are by way of example and for purposes of illustrative discussion of the preferred embodiments of the present invention only and are presented in the cause of providing what is believed to be the most useful and readily understood description of the principles and conceptual aspects of various embodiments of the invention. In this regard, no attempt is made to show structural details of the invention in more detail than is necessary for the fundamental understanding of the invention, the description taken with the drawings and/or examples making apparent to those skilled in the art how the several forms of the invention may be embodied in practice.
[0208] Definitions and explanations used in the present disclosure are meant and intended to be controlling in any future construction unless clearly and unambiguously modified in the examples or when application of the meaning renders any construction meaningless or essentially meaningless. In cases where the construction of the term would render it meaningless or essentially meaningless, the definition should be taken from Webster's Dictionary, 3rd Edition or a dictionary known to those of ordinary skill in the art, such as the Oxford Dictionary of Biochemistry and Molecular Biology (Ed. Anthony Smith, Oxford University Press, Oxford, 2004).
Claims
1. A method of treating cancer in a subject in need thereof comprising:
administering to the subject a therapeutically effective amount of a synthetic oligoribonucleotide comprising:
a 5' end triphosphate group, and
the sequence shown in M8 (SEQ ID NO: 13) or M5 (SEQ ID NO: 10), thereby treating the cancer in the subject.
2. A method of treating cancer in a subject in need thereof comprising:
administering to the subject a therapeutically effective amount of a synthetic oligoribonucleotide comprising:
a 5' end triphosphate group, and
the sequence shown in SEQ ID NO: 1 1 , SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, or SEQ ID NO: 17,
thereby treating the cancer in the subject.
3. The method of claim 1 or claim 2, wherein the cancer comprises melanoma, adenocarcinoma, carcinoma, or a metastatic cancer.
4. The method of claim 1 or claim 2, wherein the cancer comprises lung cancer, colon cancer, or prostate cancer.
5. The method of claim 1 or claim 2, wherein the sequence of the synthetic oligonucleotide consists of the sequence shown in M8 (SEQ ID NO: 13) or M5 (SEQ ID NO: 10).
6. The method of claim 1 or claim 2 , further administering at least one second anti-cancer agent.
7. A method of inducing death of cancerous cells in a subject, comprising:
administering to the subject a therapeutically effective amount of a synthetic oligoribonucleotide comprising:
a 5' end triphosphate group, and
the sequence shown in M8 (SEQ ID NO: 13), r M5 (SEQ ID NO: 10), SEQ ID NO: 11 , SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, or SEQ ID NO: 17,
thereby inducing death of cancerous cells in the subject.
8. The method of claim 7, wherein the cancerous cells comprise melanoma cells, adenocarcinoma cells, carcinoma cells, or metastatic cells.
9. The method of claim 7, wherein the cell death is dependent on caspase 3.
10. The method of claim 7, wherein the cell death is dependent on type I interferon (IFN-I).
11 . The method of claim 7, wherein death of cancerous cells comprises: an increase in expression of chemokines CCL2, CXCL1 , CXCL10, and/or IFNp in the cancerous cells; an increase in surface exposure of calreticulin on the cancerous cells; an increase in secretion of High Mobility Group Box 1 (HMGB1 ) from the cancerous cells; and/or an increase in release of ATP from the cancerous cells, as compared to the corresponding parameter in cancerous cells from the subject prior to the administering.
12. The method of claim 7, wherein administering further elicits immune reactivation in the subject.
13. The method of claim 12, wherein the immune reactivation comprises: an increase in NK activating ligands on the cancerous cells; induction of expression of an NK inhibiting marker on the cancerous cells; induction of antigen processing machinery (APM) genes in the cancerous cells; an increase in expression of CD80, CD86, and/or HLA-DR on dendritic cells from the subject; and/or an increase in IL-12 expression in dendritic cells from the subject, as compared to the corresponding parameter in cancerous cells or dendritic cells from the subject prior to the administering.
14. The method of claim 7, wherein the sequence of the synthetic oligonucleotide consists of the sequence shown in M8 (SEQ ID NO: 13) or M5 (SEQ ID NO: 10).
15. The method of claim 7, further administering at least one second anti-cancer agent.
16. The method of any one of claims 1 , 2, or 6, wherein the therapeutically effective amount comprises at least 0.2 milligrams to at least 5 milligrams of the synthetic oligoribonucleotide per kilogram of the subject's body weight per week (0.2-5 mg/kg/wk).
17. The method of any one of claims 1 , 2, or 6, wherein the therapeutically effective amount comprises at least 0.5 milligrams to at least 2.5 milligrams of the synthetic oligoribonucleotide per kilogram of the subject's body weight per week (0.5-2.5 mg/kg/wk).
18. The method of any one of claims 1 , 2, or 6, wherein the synthetic oligoribonucleotide is administered to the subject for at least 1 -52 weeks.
19. The method of any one of claims 1 , 2, or 6, wherein the synthetic oligoribonucleotide is administered to the subject 1 -6 times per week.
20. The method of any one of claims 1 , 2, or 6, wherein the synthetic oligoribonucleotide is administered 1 -6 times during the first week and 1 time each subsequent week.
21 . The method of any one of claims 1 , 2, or 6, wherein the synthetic oligoribonucleotide is administered in a total weekly dose of any of 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, 125 mg, 150 mg, 175 mg, 200 mg, 225 mg, 250 mg, 275 mg, 300 mg, 325 mg, 350 mg, 375 mg, 400 mg, 425 mg, 450 mg, 475 mg, 500 mg, 525 mg, 550 mg, 575 mg, 600 mg, 625 mg, 650 mg, 675 mg, 700 mg, 725 mg, or 750 mg.
22. The method of any one of claims 1 , 2, or 6, wherein the effective amount is administered at a rate of 5 nM/kg to 100 nM/kg of the synthetic oligoribonucleotide per kilogram of the subject's body.
23. The method of claim 22, wherein the therapeutically effective amount comprises 15.5 nM/kg to 77.5 nM/kg of the synthetic oligoribonucleotide per kilogram of the subject's body.
24. A cancer vaccine composition comprising
a tumor antigen;
an adjuvant; and
a pharmaceutically acceptable carrier,
wherein the adjuvant comprises a synthetic oligoribonucleotide comprising:
a 5' end triphosphate group, and
the sequence shown in M8 (SEQ ID NO: 13), M5 (SEQ ID NO: 10), SEQ ID NO: 11 , SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, or SEQ ID NO: 17
25. The cancer vaccine composition of claim 24, wherein the tumor antigen is derived from tumors found in melanoma, skin cancer, prostate cancer, lung cancer, pancreatic cancer, or breast cancer.
26. The cancer vaccine composition of claim 24, wherein the tumor antigen is part of a tumor cell lysate.
27. The cancer vaccine composition of claim 24, wherein the tumor antigen is part of an inactivated cancer cell population.
28. The cancer vaccine composition of claim 24, wherein the tumor antigen is part of an antigen presenting cell (APC) population.
29. The cancer vaccine composition of claim 28, wherein the APC population comprises dendritic cells.
30. The cancer vaccine composition of claim 24, wherein the adjuvant further comprises mineral oil, bacterial toxins, aluminum salts, squalene, virosomes, mineral oil in water emulsions, CpG, lipopolysaccharide (LPS), monophosphoryl lipid A (MPLA), QS21 or AS02, flagellin, peptidoglycans, inactivated bacterial pathogens, and/or RNAse inhibitors.
31 . The cancer vaccine composition of claim 24, wherein the synthetic oligoribonucleotide is in a nanoparticle formulation.
32. The cancer vaccine composition of claim 24, wherein the tumor antigen and the adjuvant are formulated together.
33. The cancer vaccine composition of claim 24, wherein the tumor antigen and the adjuvant are not formulated together.
34. A method for stimulating an immune response against a tumor antigen in a subject at risk of having or having a cancer comprising the tumor antigen, comprising administering to the subject a therapeutically effective amount of the cancer vaccine composition of claim 24.
35. The method of claim 34, further administering at least one second anti-cancer agent.
36. The method of claim 35, wherein the second anti-cancer agent is low dose chemotherapy.
37. The method of claim 36, wherein the second anti-cancer agent is an immune checkpoint inhibitor that blocks programmed cell death protein 1 (PD-1 ).
38. A method of activating antigen presenting cells (APC) ex vivo comprising contacting the APC with the cancer vaccine composition of claim 24.
39. The method of claim 38, further administering the contacted APC to a subject at risk of having or having a cancer comprising the tumor antigen.
40. An immunization kit comprising the cancer vaccine composition of claim 24.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962845783P | 2019-05-09 | 2019-05-09 | |
US62/845,783 | 2019-05-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020225779A1 true WO2020225779A1 (en) | 2020-11-12 |
Family
ID=70804854
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2020/054361 WO2020225779A1 (en) | 2019-05-09 | 2020-05-08 | Rig-i agonists for cancer treatment and immunotherapy |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2020225779A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021097347A1 (en) * | 2019-11-15 | 2021-05-20 | Infectious Disease Research Institute | Rig-i agonist and adjuvant formulation for tumor treatment |
WO2024006362A1 (en) * | 2022-06-28 | 2024-01-04 | Transcode Therapeutics, Inc. | Nanoparticles and template directed rig-i agonist precursor compositions and uses thereof for cancer therapy |
Citations (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4559157A (en) | 1983-04-21 | 1985-12-17 | Creative Products Resource Associates, Ltd. | Cosmetic applicator useful for skin moisturizing |
US4608392A (en) | 1983-08-30 | 1986-08-26 | Societe Anonyme Dite: L'oreal | Method for producing a non greasy protective and emollient film on the skin |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4820508A (en) | 1987-06-23 | 1989-04-11 | Neutrogena Corporation | Skin protective composition |
US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
US4992478A (en) | 1988-04-04 | 1991-02-12 | Warner-Lambert Company | Antiinflammatory skin moisturizing composition and method of preparing same |
US5998203A (en) | 1996-04-16 | 1999-12-07 | Ribozyme Pharmaceuticals, Inc. | Enzymatic nucleic acids containing 5'-and/or 3'-cap structures |
US20030130186A1 (en) | 2001-07-20 | 2003-07-10 | Chandra Vargeese | Conjugates and compositions for cellular delivery |
US20040110296A1 (en) | 2001-05-18 | 2004-06-10 | Ribozyme Pharmaceuticals, Inc. | Conjugates and compositions for cellular delivery |
US6753423B1 (en) | 1990-01-11 | 2004-06-22 | Isis Pharmaceuticals, Inc. | Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals |
US20040167090A1 (en) | 2003-02-21 | 2004-08-26 | Monahan Sean D. | Covalent modification of RNA for in vitro and in vivo delivery |
US20040192626A1 (en) | 2002-02-20 | 2004-09-30 | Mcswiggen James | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US20040249178A1 (en) | 2001-05-18 | 2004-12-09 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
US20050043219A1 (en) | 1991-10-24 | 2005-02-24 | Isis Pharmaceuticals, Inc. | Derivatized oligonucleotides having improved uptake and other properties |
GB2397818B (en) | 2002-02-20 | 2005-03-09 | Sirna Therapeutics Inc | Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US20050074771A1 (en) | 1996-09-13 | 2005-04-07 | Isis Pharmaceuticals, Inc. | Carbamate-derivatized nucleosides and oligonucleosides |
US20050107325A1 (en) | 2003-04-17 | 2005-05-19 | Muthiah Manoharan | Modified iRNA agents |
US20050119470A1 (en) | 1996-06-06 | 2005-06-02 | Muthiah Manoharan | Conjugated oligomeric compounds and their use in gene modulation |
US20050153337A1 (en) | 2003-04-03 | 2005-07-14 | Muthiah Manoharan | iRNA conjugates |
US20050239739A1 (en) | 2001-05-18 | 2005-10-27 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
US20050282188A1 (en) | 2001-05-18 | 2005-12-22 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA) |
US20070218122A1 (en) | 2005-11-18 | 2007-09-20 | Protiva Biotherapeutics, Inc. | siRNA silencing of influenza virus gene expression |
WO2008017473A2 (en) * | 2006-08-08 | 2008-02-14 | Gunther Hartmann | Structure and use of 5' phosphate oligonucleotides |
US20140287023A1 (en) | 2013-02-11 | 2014-09-25 | Mcgill University | 5'-triphosphate oligoribonucleotides |
WO2016011324A2 (en) * | 2014-07-18 | 2016-01-21 | Oregon Health & Science University | 5'-triphosphate oligoribonucleotides |
WO2016179475A1 (en) * | 2015-05-07 | 2016-11-10 | Baylor College Of Medicine | Dendritic cell immunotherapy |
US20170268001A1 (en) * | 2016-03-16 | 2017-09-21 | The University Of Chicago | Rnas with tumor radio/chemo-sensitizing and immunomodulatory properties and methods of their preparation and application |
WO2017173427A1 (en) * | 2016-04-01 | 2017-10-05 | Vycellix Inc | Novel rna construct and methods of use thereof for enhancing the therapeutic effects of cytotoxic cells and stem cells |
-
2020
- 2020-05-08 WO PCT/IB2020/054361 patent/WO2020225779A1/en active Application Filing
Patent Citations (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4559157A (en) | 1983-04-21 | 1985-12-17 | Creative Products Resource Associates, Ltd. | Cosmetic applicator useful for skin moisturizing |
US4608392A (en) | 1983-08-30 | 1986-08-26 | Societe Anonyme Dite: L'oreal | Method for producing a non greasy protective and emollient film on the skin |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4683202B1 (en) | 1985-03-28 | 1990-11-27 | Cetus Corp | |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4683195B1 (en) | 1986-01-30 | 1990-11-27 | Cetus Corp | |
US4820508A (en) | 1987-06-23 | 1989-04-11 | Neutrogena Corporation | Skin protective composition |
US4992478A (en) | 1988-04-04 | 1991-02-12 | Warner-Lambert Company | Antiinflammatory skin moisturizing composition and method of preparing same |
US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
US6753423B1 (en) | 1990-01-11 | 2004-06-22 | Isis Pharmaceuticals, Inc. | Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals |
US20050043219A1 (en) | 1991-10-24 | 2005-02-24 | Isis Pharmaceuticals, Inc. | Derivatized oligonucleotides having improved uptake and other properties |
US20050158727A1 (en) | 1992-10-23 | 2005-07-21 | Isis Pharmaceuticals, Inc. | Derivatized oligonucleotides having improved uptake and other properties |
US5998203A (en) | 1996-04-16 | 1999-12-07 | Ribozyme Pharmaceuticals, Inc. | Enzymatic nucleic acids containing 5'-and/or 3'-cap structures |
US20050119470A1 (en) | 1996-06-06 | 2005-06-02 | Muthiah Manoharan | Conjugated oligomeric compounds and their use in gene modulation |
US20050074771A1 (en) | 1996-09-13 | 2005-04-07 | Isis Pharmaceuticals, Inc. | Carbamate-derivatized nucleosides and oligonucleosides |
US20050282188A1 (en) | 2001-05-18 | 2005-12-22 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA) |
US20050239739A1 (en) | 2001-05-18 | 2005-10-27 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
US20040249178A1 (en) | 2001-05-18 | 2004-12-09 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
US20040110296A1 (en) | 2001-05-18 | 2004-06-10 | Ribozyme Pharmaceuticals, Inc. | Conjugates and compositions for cellular delivery |
US20030130186A1 (en) | 2001-07-20 | 2003-07-10 | Chandra Vargeese | Conjugates and compositions for cellular delivery |
GB2397818B (en) | 2002-02-20 | 2005-03-09 | Sirna Therapeutics Inc | Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US20040192626A1 (en) | 2002-02-20 | 2004-09-30 | Mcswiggen James | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US20040167090A1 (en) | 2003-02-21 | 2004-08-26 | Monahan Sean D. | Covalent modification of RNA for in vitro and in vivo delivery |
US20050153337A1 (en) | 2003-04-03 | 2005-07-14 | Muthiah Manoharan | iRNA conjugates |
US20050107325A1 (en) | 2003-04-17 | 2005-05-19 | Muthiah Manoharan | Modified iRNA agents |
US20070218122A1 (en) | 2005-11-18 | 2007-09-20 | Protiva Biotherapeutics, Inc. | siRNA silencing of influenza virus gene expression |
WO2008017473A2 (en) * | 2006-08-08 | 2008-02-14 | Gunther Hartmann | Structure and use of 5' phosphate oligonucleotides |
US20140287023A1 (en) | 2013-02-11 | 2014-09-25 | Mcgill University | 5'-triphosphate oligoribonucleotides |
WO2016011324A2 (en) * | 2014-07-18 | 2016-01-21 | Oregon Health & Science University | 5'-triphosphate oligoribonucleotides |
US20170268007A1 (en) | 2014-07-18 | 2017-09-21 | Oregon Health & Science University | 5'-triphosphate oligoribonucleotides |
US9790509B2 (en) | 2014-07-18 | 2017-10-17 | Oregon Health & Science University | 5′-triphosphate oligoribonucleotides |
US10167476B2 (en) | 2014-07-18 | 2019-01-01 | Oregon Health & Science University | 5′-triphosphate oligoribonucleotides |
WO2016179475A1 (en) * | 2015-05-07 | 2016-11-10 | Baylor College Of Medicine | Dendritic cell immunotherapy |
US20170268001A1 (en) * | 2016-03-16 | 2017-09-21 | The University Of Chicago | Rnas with tumor radio/chemo-sensitizing and immunomodulatory properties and methods of their preparation and application |
WO2017173427A1 (en) * | 2016-04-01 | 2017-10-05 | Vycellix Inc | Novel rna construct and methods of use thereof for enhancing the therapeutic effects of cytotoxic cells and stem cells |
Non-Patent Citations (76)
Title |
---|
"Oxford Dictionary of Biochemistry and Molecular Biology", 2004, OXFORD UNIVERSITY PRESS |
AKIRA ET AL., CELL, vol. 124, 2006, pages 783 - 801 |
BANGHAM ET AL., J MOL BIOL, vol. 13, 1965, pages 238 |
BARSOUM ET AL., CANCER IMMUNOL RES, vol. 5, 2017, pages B44 - B44 |
BAUM ET AL., PROC NATL ACAD SCI USA, vol. 107, 2010, pages 16303 - 16308 |
BEAUCAGE ET AL., TETRAHEDRON, vol. 49, 1993, pages 1925 |
BELGNAOUI ET AL., CURR OPIN IMMUNOL, vol. 23, 2011, pages 564 - 572 |
BELJANSKI ET AL., J VIROL, vol. 89, 2015, pages 10612 - 10624 |
BESCH ET AL., J CLIN INVEST, vol. 119, 2009, pages 2399 - 2411 |
BEUTLER, BLOOD, vol. 113, 2009, pages 1399 - 1407 |
BHATTACHARYA ET AL., ONCOGENE, vol. 32, 2013, pages 4214 - 21 |
BRENNANBOWIE, CURR OPIN MICROBIOL, vol. 13, 2010, pages 503 - 507 |
CASTIELLO ET AL., CANCER IMMUNOL RES, vol. 6, 2018, pages 658 - 670 |
CASTIELLO ET AL., CANCER IMMUNOL. IMMUNOTHER., vol. 68, no. 9, 28 August 2019 (2019-08-28), pages 1479 - 1492 |
CASTIELLO LUCIANO ET AL: "An optimized retinoic acid-inducible gene I agonist M8 induces immunogenic cell death markers in human cancer cells and dendritic cell activation", CANCER IMMUNOLOGY, IMMUNOTHERAPY, vol. 68, no. 9, 28 August 2019 (2019-08-28), pages 1479 - 1492, XP036895400, ISSN: 0340-7004, [retrieved on 20190828], DOI: 10.1007/S00262-019-02380-2 * |
CHATTOPADHYAY ET AL., IMMUNITY, vol. 44, 2016, pages 1151 - 1161 |
CUI ET AL., MOLECULAR CELL, vol. 29, 2008, pages 169 - 179 |
DUEWELL ET AL., CELL DEATH DIFFER, vol. 21, 2014, pages 1825 - 1837 |
DUEWELLLATZ, METHODS MOL BIOL., vol. 1040, 2013, pages 19 - 27 |
ELION DAVID L ET AL: "Therapeutically Active RIG-I Agonist Induces Immunogenic Tumor Cell Killing in Breast Cancers", CANCER RESEARCH, vol. 78, no. 21, 1 November 2018 (2018-11-01), pages 6183 - 6195, XP055714560 * |
ELION ET AL., CANCER RES., vol. 78, no. 21, 2018, pages 6183 - 6195 |
ELLERMEIER ET AL., CANCER RES, vol. 73, 2013, pages 1709 - 1720 |
FUJITA, IMMUNITY, vol. 31, 2009, pages 4 - 5 |
GAJEWSKI ET AL., CANCER IMMUNOL IMMUNOTHER, vol. 61, 2012, pages 1343 - 1347 |
GALLUZZI ET AL., NAT REV IMMUNOL, vol. 17, 2017, pages 97 - 111 |
GLAS ET AL., STEM CELLS, vol. 31, 2013, pages 1064 - 1074 |
GOULET ET AL., PLOS PATHOG, vol. 9, 2013, pages e1003298 |
GUBLERHOFFMAN, GENE, vol. 25, 1983, pages 263 - 269 |
HEYLBROECK ET AL., J VIROL, vol. 74, 2000, pages 3781 - 92 |
HUANGFU ET AL., ONCOGENE, vol. 31, 2012, pages 161 - 172 |
HUNZIKER ET AL.: "Percutaneous Penetration Enhancers", 1995, CRC PRESS, INC., pages: 331 - 417 |
JIANG ET AL., NATURE, vol. 479, 2011, pages 423 - 427 |
KATLINSKAYA ET AL., CELL REP, vol. 15, 2016, pages 171 - 180 |
KATLINSKI ET AL., CANCER CELL, vol. 31, 2017, pages 194 - 207 |
KATO ET AL., J EXP MED, vol. 205, 2008, pages 1601 - 1610 |
KAWAI ET AL., NAT IMMUNOL, vol. 6, 2005, pages 722 - 988 |
KAWAIAKIRA, IMMUNITY, vol. 34, 2011, pages 637 - 650 |
KIM ET AL., NAT BIOTECHOL, vol. 22, 2004, pages 321 - 325 |
KRIEGLER: "PCR Protocols: A Guide to Methods and Applications", 1990 |
KUMAR ET AL., INT REV IMMUNOL, vol. 30, 2011, pages 16 - 34 |
LEONE ET AL., JNCI J NATL CANCER INST, vol. 105, 2013, pages 1172 - 1187 |
LEVIN ET AL., MOL CELL BIO/, vol. 31, 2011, pages 3252 - 66 |
LIN ET AL., JAM CHEM SOC, vol. 120, 1998, pages 8531 - 8532 |
LOAKES, NUCL ACIDS RES, vol. 29, 2001, pages 2437 - 2447 |
LURESCIA ET AL., FRONT IMMUNOL, vol. 9, 2018, pages 711 |
MESMAEKER ET AL.: "Current Protocols in Molecular Biology", 1994, ACS, pages: 24 - 39 |
MEYLAN ET AL., NATURE, vol. 437, 2005, pages 1167 - 1172 |
MITTAL ET AL., CURR OPIN IMMUNOL, vol. 27, 2014, pages 16 - 25 |
MITTAL ET AL., CURROPIN IMMUNOL, vol. 27, 2014, pages 16 - 25 |
NGUYEN, PROC NATL ACAD SCI, vol. 1 05, 2008, pages 149S1 - 149S6 |
OLAGNIER ET AL., MOL THER, vol. 25, 2017, pages 1900 - 1916 |
PICHLMAIR ET AL., SCIENCE, vol. 314, 2006, pages 997 - 1001 |
POECK ET AL., NAT MED, vol. 14, 2008, pages 1256 - 1263 |
POECK ET AL., NAT MED., vol. 14, no. 11, 2008, pages 1256 - 1263 |
REHWINKEL ET AL., CELL, vol. 140, 2010, pages 397 - 408 |
REHWINKELSOUSA, SCIENCE, vol. 327, 2010, pages 284 - 286 |
RIBASWOLCHOK, SCIENCE, vol. 359, 2018, pages 1350 - 1355 |
RIZZA ET AL., CYTOKINE GROWTH FACTOR REV, vol. 26, 2015, pages 195 - 201 |
SANCHEZ-CORREA ET AL., CANCER IMMUNOL IMMUNOTHER, vol. 60, 2011, pages 1195 - 1205 |
SANGER: "Principles of Nucleic Acid Structure", 1984 |
SCHLEEHARTMANN, MOLECULAR THERAPY, vol. 18, 2010, pages 1254 - 1262 |
SCHOCK ET AL., CELL DEATH DIFFER, vol. 24, 2017, pages 615 - 625 |
SCHREIBER ET AL., SCIENCE, vol. 331, 2011, pages 1565 - 1570 |
SCHUMACHERSCHREIBER, SCIENCE, vol. 348, 2015, pages 207 - 211 |
SNELL ET AL., TRENDS IMMUNOL, vol. 38, 2017, pages 542 - 557 |
STOJDL ET AL., CANCER CELL, vol. 4, 2003, pages 263 - 75 |
TAKEUCHIAKIRA, IMMUNOL REV, vol. 227, 2009, pages 75 - 86 |
WILKINSGALE, CURR OPIN IMMUNOL, vol. 22, 2010, pages 41 - 47 |
XU ET AL., PROTEIN CELL, vol. 9, 2018, pages 246 - 253 |
YONEYAMAFUJITA, J BIOL CHEM, vol. 282, 2007, pages 15315 - 15318 |
YONEYAMAFUJITA, REV MED VIROI, vol. 20, 2010, pages 4 - 22 |
ZEVINI ALESSANDRA ET AL: "Crosstalk between Cytoplasmic RIG-I and STING Sensing Pathways", TRENDS IN IMMUNOLOGY, vol. 38, no. 3, 7 January 2017 (2017-01-07), pages 194 - 205, XP029932815, ISSN: 1471-4906, DOI: 10.1016/J.IT.2016.12.004 * |
ZEVINI ET AL., TRENDS IMMUNOL., vol. 38, no. 3, 2017, pages 194 - 205 |
ZINGONI ET AL., EUR J IMMUNOL, vol. 30, 2000, pages 644 - 651 |
ZINGONI ET AL., FRONT IMMUNOL, vol. 8, 2017, pages 1194 |
ZONG ET AL., CANCER IMMUNOL IMMUNOTHER, vol. 65, 2016, pages 821 - 833 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021097347A1 (en) * | 2019-11-15 | 2021-05-20 | Infectious Disease Research Institute | Rig-i agonist and adjuvant formulation for tumor treatment |
WO2024006362A1 (en) * | 2022-06-28 | 2024-01-04 | Transcode Therapeutics, Inc. | Nanoparticles and template directed rig-i agonist precursor compositions and uses thereof for cancer therapy |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2022519557A (en) | Method for preparing lipid nanoparticles | |
RU2487938C2 (en) | NUCLEIC ACID OF FORMULA (I): GlXmGn OR (II): GlXmGn, DESIGNED TO BE USED FIRST OF ALL AS IMMUNOGEN/ADJUVANT | |
US8853177B2 (en) | Use of inhibitors of toll-like receptors in the prevention and treatment of hypercholesterolemia and hyperlipidemia and diseases related thereto | |
de Jong et al. | Encapsulation in liposomal nanoparticles enhances the immunostimulatory, adjuvant and anti-tumor activity of subcutaneously administered CpG ODN | |
JP6406793B2 (en) | Immunoregulatory nucleotide (IRO) compounds that modulate immune responses based on toll-like receptors | |
JP7186094B2 (en) | Liposomal Spherical Nucleic Acid (SNA) Constructs Presenting Antisense Oligonucleotides (ASOs) for Specific Knockdown of Interleukin 17 Receptor mRNA | |
EP2021008B1 (en) | Stabilized immune modulatory rna (simra) compounds for tlr7 and tlr8 | |
AU2016250372A1 (en) | Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response | |
US20130121988A1 (en) | Nucleic Acid of Formula (I): GlXmGn, or (II): ClXmCn, in Particular as an Immune-Stimulating Agent/Adjuvant | |
HUE025027T2 (en) | NUCLEIC ACIDS COMPRISING FORMULA (NuGiXmGnNv)a AND DERIVATIVES THEREOF AS AN IMMUNOSTIMULATING AGENTS /ADJUVANTS | |
MXPA04010415A (en) | Oligonucleotide compositions and their use for the modulation of immune responses. | |
PT1511845E (en) | Immunostimulatory oligonucleotides and uses thereof | |
RU2718534C2 (en) | Mir-155 inhibitors for treatment of cutaneous t-cell lymphoma (ctcl) | |
US11679082B2 (en) | Therapeutic constructs for co-delivery of mitotic kinase inhibitor and immune checkpoint inhibitor | |
US10041076B2 (en) | Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response | |
WO2020225779A1 (en) | Rig-i agonists for cancer treatment and immunotherapy | |
TW201924722A (en) | Methods and compositions comprising cationic lipids for stimulating type I interferon genes | |
KR20230164124A (en) | Targeting multiple T cell types using spherical nucleic acid vaccine constructs | |
Pordanjani et al. | Extracellular vesicles in vaccine development and therapeutic approaches for viral diseases | |
US20220370490A1 (en) | Synergistic immunostimulation through the dual activation of tlr3/9 with spherical nucleic acids | |
WO2023092040A1 (en) | Spherical nucleic acids for cgas-sting and stat3 pathway modulation for the immunotherapeutic treatment of cancer | |
CN117157104A (en) | Targeting multiple T cell types using spherical nucleic acid vaccine architecture | |
CN117159492A (en) | Lipid nanoparticle containing sialic acid lipid derivative and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20727844 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 20727844 Country of ref document: EP Kind code of ref document: A1 |